PT1013661E - 2'-o,4'-c-metileno-biciclonucleósidos - Google Patents
2'-o,4'-c-metileno-biciclonucleósidos Download PDFInfo
- Publication number
- PT1013661E PT1013661E PT98905804T PT98905804T PT1013661E PT 1013661 E PT1013661 E PT 1013661E PT 98905804 T PT98905804 T PT 98905804T PT 98905804 T PT98905804 T PT 98905804T PT 1013661 E PT1013661 E PT 1013661E
- Authority
- PT
- Portugal
- Prior art keywords
- group
- compound
- nucleic acid
- pyrimidine
- derivative
- Prior art date
Links
- -1 purine nucleic acid Chemical group 0.000 claims abstract description 48
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 31
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 31
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims abstract description 24
- 125000000714 pyrimidinyl group Chemical group 0.000 claims abstract description 9
- 229940127073 nucleoside analogue Drugs 0.000 claims description 21
- 239000002777 nucleoside Substances 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 14
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 13
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 10
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 8
- 229940104302 cytosine Drugs 0.000 claims description 6
- 229940035893 uracil Drugs 0.000 claims description 6
- 229930024421 Adenine Natural products 0.000 claims description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 5
- 229960000643 adenine Drugs 0.000 claims description 5
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 4
- 229960003495 thiamine Drugs 0.000 claims description 4
- 235000019157 thiamine Nutrition 0.000 claims description 4
- 239000011721 thiamine Substances 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims description 2
- 125000001990 thiamine group Chemical group 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- 229940113082 thymine Drugs 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract description 36
- 238000001727 in vivo Methods 0.000 abstract description 5
- 108091081021 Sense strand Proteins 0.000 abstract description 4
- 108091033319 polynucleotide Proteins 0.000 abstract description 4
- 102000040430 polynucleotide Human genes 0.000 abstract description 4
- 239000002157 polynucleotide Substances 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- 239000000243 solution Substances 0.000 description 57
- 150000001875 compounds Chemical class 0.000 description 49
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 44
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 39
- 230000015572 biosynthetic process Effects 0.000 description 39
- 238000003786 synthesis reaction Methods 0.000 description 36
- 238000005481 NMR spectroscopy Methods 0.000 description 34
- 239000000203 mixture Substances 0.000 description 34
- 125000003729 nucleotide group Chemical group 0.000 description 31
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 30
- 239000002904 solvent Substances 0.000 description 30
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 28
- 229910052757 nitrogen Inorganic materials 0.000 description 28
- 239000011541 reaction mixture Substances 0.000 description 28
- 239000012043 crude product Substances 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- 238000010898 silica gel chromatography Methods 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 20
- 239000012074 organic phase Substances 0.000 description 20
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 19
- 238000004821 distillation Methods 0.000 description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 239000000843 powder Substances 0.000 description 17
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 15
- 239000012267 brine Substances 0.000 description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 description 15
- 235000011152 sodium sulphate Nutrition 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 6
- KWQCNAXZKYMWAL-DLTWYDFYSA-N 1-[(1r,4s,6r,7s)-4-(hydroxymethyl)-7-phenylmethoxy-2,5-dioxabicyclo[2.2.1]heptan-6-yl]pyrimidine-2,4-dione Chemical compound N1([C@@H]2O[C@]3(CO[C@@]2([C@@H]3OCC=2C=CC=CC=2)[H])CO)C=CC(=O)NC1=O KWQCNAXZKYMWAL-DLTWYDFYSA-N 0.000 description 6
- KNLNWXXWKDEEFW-JIOCBJNQSA-N 1-[(1r,4s,6r,7s)-7-hydroxy-4-(hydroxymethyl)-2,5-dioxabicyclo[2.2.1]heptan-6-yl]pyrimidine-2,4-dione Chemical compound N1([C@@H]2O[C@]3(CO[C@@]2([C@@H]3O)[H])CO)C=CC(=O)NC1=O KNLNWXXWKDEEFW-JIOCBJNQSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 229940126657 Compound 17 Drugs 0.000 description 6
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 229940125898 compound 5 Drugs 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 5
- 229940045145 uridine Drugs 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 4
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 4
- 108020004394 Complementary RNA Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 238000010533 azeotropic distillation Methods 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 229940126142 compound 16 Drugs 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 4
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 3
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 3
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 3
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 3
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 3
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 3
- JBWYRBLDOOOJEU-UHFFFAOYSA-N 1-[chloro-(4-methoxyphenyl)-phenylmethyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 JBWYRBLDOOOJEU-UHFFFAOYSA-N 0.000 description 3
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 3
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 3
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 229940125877 compound 31 Drugs 0.000 description 3
- 229940125878 compound 36 Drugs 0.000 description 3
- 229940125807 compound 37 Drugs 0.000 description 3
- 229940127573 compound 38 Drugs 0.000 description 3
- 229940126540 compound 41 Drugs 0.000 description 3
- 229940125936 compound 42 Drugs 0.000 description 3
- 229940125844 compound 46 Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 3
- 125000004437 phosphorous atom Chemical group 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- CILVRNHAVZSPJB-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;propan-2-one Chemical compound CC(C)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O CILVRNHAVZSPJB-BTVCFUMJSA-N 0.000 description 1
- UJJLJRQIPMGXEZ-BYPYZUCNSA-N (2s)-oxolane-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCO1 UJJLJRQIPMGXEZ-BYPYZUCNSA-N 0.000 description 1
- LENAVORGWBTPJR-UHFFFAOYSA-N (5-pyridin-3-ylfuran-2-yl)methanamine Chemical compound O1C(CN)=CC=C1C1=CC=CN=C1 LENAVORGWBTPJR-UHFFFAOYSA-N 0.000 description 1
- SBKCKZYFAIFJPV-UHFFFAOYSA-N (6-amino-7h-purin-2-yl)-phenylmethanone Chemical compound N=1C=2N=CNC=2C(N)=NC=1C(=O)C1=CC=CC=C1 SBKCKZYFAIFJPV-UHFFFAOYSA-N 0.000 description 1
- UKDOTCFNLHHKOF-FGRDZWBJSA-N (z)-1-chloroprop-1-ene;(z)-1,2-dichloroethene Chemical group C\C=C/Cl.Cl\C=C/Cl UKDOTCFNLHHKOF-FGRDZWBJSA-N 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- FAQUZFOZBPJJNK-JVOXNHGTSA-N 1-[(1r,4r,6r,7s)-4-[[tert-butyl(diphenyl)silyl]oxymethyl]-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptan-6-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@@H]([C@@H]2O)OC[C@]2(CO[Si](C=2C=CC=CC=2)(C=2C=CC=CC=2)C(C)(C)C)O1 FAQUZFOZBPJJNK-JVOXNHGTSA-N 0.000 description 1
- AVSIEIYAKRGKIJ-QPBRMJRSSA-N 1-[(1r,4r,6r,7s)-4-[[tert-butyl(diphenyl)silyl]oxymethyl]-7-phenylmethoxy-2,5-dioxabicyclo[2.2.1]heptan-6-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@@H]([C@@H]2OCC=3C=CC=CC=3)OC[C@]2(CO[Si](C=2C=CC=CC=2)(C=2C=CC=CC=2)C(C)(C)C)O1 AVSIEIYAKRGKIJ-QPBRMJRSSA-N 0.000 description 1
- INUHCZCTBOPIRO-KKBFJZEXSA-N 1-[(1r,4s,6r,7s)-4-(hydroxymethyl)-7-phenylmethoxy-2,5-dioxabicyclo[2.2.1]heptan-6-yl]-5-methylpyrimidine-2,4-dione Chemical compound N1([C@@H]2O[C@]3(CO[C@@]2([C@@H]3OCC=2C=CC=CC=2)[H])CO)C=C(C)C(=O)NC1=O INUHCZCTBOPIRO-KKBFJZEXSA-N 0.000 description 1
- TYYUAZVXLRMUMN-SZVQBCOZSA-N 1-[(1r,4s,6r,7s)-7-hydroxy-4-(hydroxymethyl)-2,5-dioxabicyclo[2.2.1]heptan-6-yl]-5-methylpyrimidine-2,4-dione Chemical compound N1([C@@H]2O[C@]3(CO[C@@]2([C@@H]3O)[H])CO)C=C(C)C(=O)NC1=O TYYUAZVXLRMUMN-SZVQBCOZSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- CFIBTBBTJWHPQV-UHFFFAOYSA-N 2-methyl-n-(6-oxo-3,7-dihydropurin-2-yl)propanamide Chemical compound N1C(NC(=O)C(C)C)=NC(=O)C2=C1N=CN2 CFIBTBBTJWHPQV-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- ZTRXFCGYDLPIDD-UHFFFAOYSA-N 4-amino-1-benzoylpyrimidin-2-one Chemical group O=C1N=C(N)C=CN1C(=O)C1=CC=CC=C1 ZTRXFCGYDLPIDD-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- WWLKLINKKRCFFR-NQGQNVDZSA-N [(2r,3r,4s,5s)-2-(6-benzamidopurin-9-yl)-5-[[tert-butyl(diphenyl)silyl]oxymethyl]-5-[(4-methylphenyl)sulfonyloxymethyl]-4-phenylmethoxyoxolan-3-yl] acetate Chemical compound C([C@@]1(COS(=O)(=O)C=2C=CC(C)=CC=2)O[C@H]([C@@H]([C@@H]1OCC=1C=CC=CC=1)OC(=O)C)N1C2=NC=NC(NC(=O)C=3C=CC=CC=3)=C2N=C1)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 WWLKLINKKRCFFR-NQGQNVDZSA-N 0.000 description 1
- JKJXALCUKHUZRA-JKCDPMEWSA-N [(2r,3r,4s,5s)-5-[[tert-butyl(diphenyl)silyl]oxymethyl]-2-(5-methyl-2,4-dioxopyrimidin-1-yl)-5-[(4-methylphenyl)sulfonyloxymethyl]-4-phenylmethoxyoxolan-3-yl] acetate Chemical compound C([C@@]1(COS(=O)(=O)C=2C=CC(C)=CC=2)O[C@H]([C@@H]([C@@H]1OCC=1C=CC=CC=1)OC(=O)C)N1C(NC(=O)C(C)=C1)=O)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 JKJXALCUKHUZRA-JKCDPMEWSA-N 0.000 description 1
- VXKCBGQWMFHOED-FTCREWOSSA-N [(2r,3r,4s,5s)-5-[[tert-butyl(diphenyl)silyl]oxymethyl]-5-[(4-methylphenyl)sulfonyloxymethyl]-2-[2-(2-methylpropanoylamino)-6-oxo-3h-purin-9-yl]-4-phenylmethoxyoxolan-3-yl] acetate Chemical compound C([C@@]1(COS(=O)(=O)C=2C=CC(C)=CC=2)O[C@H]([C@@H]([C@@H]1OCC=1C=CC=CC=1)OC(C)=O)N1C=NC=2C(=O)N=C(NC=21)NC(=O)C(C)C)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 VXKCBGQWMFHOED-FTCREWOSSA-N 0.000 description 1
- SFJPVFLWRWFTGN-JWBSPJEOSA-N [(2s,3s,4r,5r)-2-[[tert-butyl(diphenyl)silyl]oxymethyl]-4-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)-3-phenylmethoxyoxolan-2-yl]methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC[C@@]1(CO[Si](C=2C=CC=CC=2)(C=2C=CC=CC=2)C(C)(C)C)[C@@H](OCC=2C=CC=CC=2)[C@@H](O)[C@H](N2C(NC(=O)C(C)=C2)=O)O1 SFJPVFLWRWFTGN-JWBSPJEOSA-N 0.000 description 1
- XFKQDFPNJKUJNE-BFTVCZDZSA-N [(2s,3s,4r,5r)-2-[[tert-butyl(diphenyl)silyl]oxymethyl]-4-hydroxy-5-[2-(2-methylpropanoylamino)-6-oxo-3h-purin-9-yl]-3-phenylmethoxyoxolan-2-yl]methyl 4-methylbenzenesulfonate Chemical compound C([C@@]1(COS(=O)(=O)C=2C=CC(C)=CC=2)O[C@H]([C@@H]([C@@H]1OCC=1C=CC=CC=1)O)N1C=NC=2C(=O)N=C(NC=21)NC(=O)C(C)C)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 XFKQDFPNJKUJNE-BFTVCZDZSA-N 0.000 description 1
- LBMSYTKSXBUCRF-DLTWYDFYSA-N [(2s,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC[C@@]1(CO)[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LBMSYTKSXBUCRF-DLTWYDFYSA-N 0.000 description 1
- YQVISGXICTVSDQ-UHFFFAOYSA-O [c-]1nn[nH]n1.CC(C)[NH2+]C(C)C Chemical compound [c-]1nn[nH]n1.CC(C)[NH2+]C(C)C YQVISGXICTVSDQ-UHFFFAOYSA-O 0.000 description 1
- CDXSJGDDABYYJV-UHFFFAOYSA-N acetic acid;ethanol Chemical compound CCO.CC(O)=O CDXSJGDDABYYJV-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000031016 anaphase Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 238000006480 benzoylation reaction Methods 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000005828 desilylation reaction Methods 0.000 description 1
- ZLRAAUUPULJGTL-UHFFFAOYSA-N diaminophosphinous acid Chemical compound NP(N)O ZLRAAUUPULJGTL-UHFFFAOYSA-N 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- KQZLWYOPMVFLBN-HRSBRNJNSA-N n-[9-[(1r,4s,6r,7s)-4-(hydroxymethyl)-7-phenylmethoxy-2,5-dioxabicyclo[2.2.1]heptan-6-yl]-6-oxo-3h-purin-2-yl]-2-methylpropanamide Chemical compound O([C@@H]1[C@]2(CO)CO[C@]1([C@@H](O2)N1C2=C(C(NC(NC(=O)C(C)C)=N2)=O)N=C1)[H])CC1=CC=CC=C1 KQZLWYOPMVFLBN-HRSBRNJNSA-N 0.000 description 1
- NGDXJHPVLLOECO-GRADPPADSA-N n-[9-[(1r,4s,6r,7s)-4-(hydroxymethyl)-7-phenylmethoxy-2,5-dioxabicyclo[2.2.1]heptan-6-yl]purin-6-yl]benzamide Chemical compound N1=CN=C2N([C@H]3[C@@H]4OC[C@](O3)([C@H]4OCC=3C=CC=CC=3)CO)C=NC2=C1NC(=O)C1=CC=CC=C1 NGDXJHPVLLOECO-GRADPPADSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
ΡΕ1013661 1
DESCRIÇÃO "2'-Ο,4'-C-METILENO-BICICLONUCLEOSIDOS"
Esta invenção diz respeito a análogos de nucleó-sidos inovadores e à sua utilização em análogos de nucleótidos e, mais especificamente, em análogos de nucleó-tidos apropriados para serem utilizados como moléculas de sentido reverso.
TÉCNICA ANTERIOR
Em 1978, relatou-se pela primeira vez que uma molécula de sentido reverso inibia infecções provocadas pelo vírus da grupe. Desde então, emitiram-se relatórios que defendiam que as moléculas de sentido reverso inibiam a expressão de oncogenes e a infecção com SIDA. Nos últimos anos, oligonucleótidos de sentido reverso têm-se tornado nuns dos produtos farmacêuticos mais promissores, uma vez que controlam especificamente a expressão de genes indesej áveis. 0 método de sentido reverso encontra-se baseado na ideia de controlar uma corrente unidireccional sendo designado por dogma central, i.e., ADN ARN -► proteína, por intermédio da utilização de um oligonucleótido de sentido reverso. 2 ΡΕ1013661
No entanto, ao aplicar-se um oligonucleótido disponível na natureza a este método, como molécula de sentido reverso, este decompôs-se com várias nucleases em vivo, ou a sua permeação através da membrana celular não foi elevada. Para se resolverem estes problemas, sintetizaram-se vários derivados e análogos de ácido nucleico, e levaram-se a cabo os seus respectivos estudos. Os exemplos de produtos sintetizados incluem um fosforotioato, tendo um átomo de enxofre em substituição de um átomo de oxigénio no átomo de fósforo, e um metilfosfonato tendo um grupo de metilo de substituição. Recentemente, sintetizaram-se produtos em que o átomo de fósforo também tem sido substituído por um átomo de carbono, ou em que a estrutura da porção se modificou, ou em que a base de ácido nucleico se modificou. No entanto, quaisquer derivados ou análogos resultantes não têm sido plenamente satisfatórios em termos da estabilidade em vivo, da facilidade de síntese, e da especificidade da sequência (a propriedade em que se controla selectivamente a expressão de um gene específico isoladamente).
Obika et al. ("Properties of Novel Oligonucleo-tide Analogues Containing an Acyclic Nucleoside and a Carbamate Linkage", Bioorganic & Medicinal Chemistry Letters, 6(12) (1996) p.1357-1360) descrevem heterodímeros contendo um nucleósido acíclico e uma ligação de carbamato na posição 3' incorporada em oligonucleótidos. Estudaram-se as temperaturas de fusão dos dímeros de ADN-ADN e ADN-ARN 3 ΡΕ1013661 bem como a resistência da nuclease dos oligonucleótidos modificados.
Nestas circunstâncias, tem surgido procura para a criação de uma molécula de sentido reverso que se decomponha minimamente com uma nuclease em vivo, se ligue ao mensageiro-alvo do ARN com afinidade elevada, tenha especificidade elevada e que, assim, possa controlar eficientemente a expressão de um gene especifico.
DESCRIÇÃO DA INVENÇÃO
Os inventores da invenção presente conceberam um análogo de ácido nucleico com configuração imobilizada da porção de açúcar presente num ácido nucleico, que teria utilidade no método de sentido reverso. Sintetizaram um análogo de nucleósido que irá, portanto, ser uma estrutura unitária, e confirmaram que um análogo de oligonucleótido preparado com a sua utilização provou ser muito útil como molécula de sentido reverso.
BREVE DESCRIÇÃO DAS FIGURAS A Fig. 1 apresenta um gráfico que representa o decurso no tempo da absorção ultravioleta (260 nm) de um oligonucleótido decomposto com uma exonuclease; e A Fig. 2 apresenta um gráfico que representa o decurso no tempo da absorção ultravioleta (260 nm) de um 4 ΡΕ1013661 oligonucleótido preparado com a utilização de um análogo de nucleósido análogo ao da invenção presente (X2) decomposto com uma exonuclease.
Em seguida descrevem-se os detalhes das invenção presente. A estrutura de um análogo de nucleósido de acordo com a invenção presente é um análogo de nucleósido com a fórmula geral (I) seguinte
X—O· d) em que B seja uma base de ácido nucleico de pirimidina ou de purina, ou um seu análogo, e X e Y sejam idênticos ou diferentes, e cada um destes representa um átomo de hidrogénio, um grupo alquilo, um grupo alcenilo, um grupo alcinilo, um grupo cicloalquilo, um grupo aralquilo, um grupo arilo, um grupo acilo, ou um grupo sililo, ou um seu derivado de amidito. 0 grupo alquilo representa um grupo alquilo, de cadeia linear ou cadeia ramificada, com 1 a 20 átomos de carbono. Os seus exemplos incluem metilo, etilo, n-propilo, 5 ΡΕ1013661 i-propilo, n-butilo, t-butilo, pentilo, hexilo, heptilo, octilo, nonilo e decilo. 0 grupo alcenilo representa um grupo alcenilo, de cadeia linear ou cadeia ramificada, com 2 a 20 átomos de carbono. Os seus exemplos incluem vinilo, alilo, butenilo, pentenilo, geranilo, e farnesilo. O grupo alcinilo representa um grupo alcinilo, de cadeia linear ou cadeia ramificada, com 2 a 20 átomos de carbono. Os seus exemplos incluem etinilo, propinilo, e butinilo. 0 grupo cicloalquilo representa um grupo cicloalquilo, com 3 a 8 átomos de carbono, e inclui, por exemplo, ciclopropilo, ciclobutilo, ciclopentilo, ciclo-hexilo, ciclo-heptilo, e ciclo-octilo. Outro exemplo é um grupo heterociclico em que um ou mais grupos metileno arbitrários no anel do grupo cicloalquilo foram substituídos por um átomo de oxigénio, um átomo de enxofre, ou um átomo de azoto alquilo-substituído. Este será, por exemplo, um grupo tetra-hidropiranilo. 0 grupo arilo diz respeito a um substituinte monovalente formado pela remoção de um átomo de hidrogénio a partir de um grupo heterociclico aromático ou um grupo hidrocarboneto aromático. De preferência, este representa um substituinte monovalente formado pela remoção de um átomo de hidrogénio a partir de um grupo heterociclico 6 ΡΕ1013661 aromático ou um grupo hidrocarboneto aromático, e inclui, por exemplo, fenilo, toluilo, xililo, bifenilo, naftilo, antrilo, e fenantrilo. 0 átomo de carbono no anel do grupo arilo pode ser substituído por um ou mais de entre um átomo de halogéneo, um grupo alquilo inferior, um grupo hidroxilo, um grupo alcoxilo, um grupo amino, um grupo nitro, e um grupo trifluorometilo. Neste caso o substituinte será, por exemplo, um átomo de halogéneo, um grupo hidroxilo, um grupo amino, um grupo alcoxilo, ou um grupo ariloxilo. 0 grupo aralquilo diz respeito a um grupo alquilo ligado a um grupo arilo, e que pode ser substituído. 0 grupo aralquilo que pode ser substituído representa um grupo alquilo ligado a um grupo arilo, com um ou mais átomos de hidrogénio arbitrários do grupo arilo e do grupo alquilo a serem substituídos opcionalmente pelos substituintes seguintes: Os exemplos de substituintes são acilo, amino, arilo, alquilo, cicloalquilo, alcoxilo, hidroxilo, nitro, e halogéneo. 0 grupo amino não necessita ser substituído, embora o grupo amino uma vez substituído inclua, por exemplo, alquilamino, arilamino, e acilamino. Os exemplos de grupos alcoxilo são metoxilo, etoxilo, n-propoxilo, i-propoxilo, n-butoxilo, i-butoxilo, s-butoxilo, t-butoxilo, pentiloxilo, hexiloxilo, e fenoxilo. Os exemplos de átomos de halogéneo são flúor, cloro, bromo, e iodo. 7 ΡΕ1013661
Os exemplos preferidos do grupo aralquilo são tritilo, benzilo, fenetilo, tritilmetilo, difenilmetilo, naftilmetilo, e 4,4'-dimetoxitritilo (DMTr). 0 grupo DMTr é especialmente preferido.
Tal como os grupos acilo, acetilo, formilo, propionilo, benzoilo, e benziloxicarbonilo se podem exemplificar. Um exemplo do grupo sililo é um grupo trial-quilsililo, de preferência trimetilsililo, trietilsililo, tri-isopropilsililo, t-butildimetilsililo ou t-butildife-nilsililo, e de preferência trimetilsililo. 0 análogo de nucleótido preparado a partir dos análogos de nucleósido da invenção presente é um análogo de oligonucleótido ou de polinucleótido tendo uma ou mais estruturas com a fórmula geral (Ia)
( la) em que B seja uma base de ácido nucleico de pirimidina ou de purina, ou um seu análogo, ou um análogo de oligonucleótido ou polinucleótido com a fórmula geral (II) ΡΕ1013661
em que B1 e B sejam idênticos ou diferentes, e cada qual representa uma base de ácido nucleico de pirimidina ou de purina, ou um seu análogo, R seja um átomo de hidrogénio, um grupo hidroxilo, um átomo de halogéneo, ou um grupo alcoxilo, W1 e W2 sejam idênticos ou diferentes, e cada qual representa um átomo de hidrogénio, um grupo alquilo, um grupo alcenilo, um grupo alcinilo, um grupo cicloalquilo, um grupo aralquilo, um grupo arilo, um grupo acilo, um grupo sililo, um resíduo de ácido fosfórico, um nucleósido que ocorre na natureza ou um nucleósido sintético ligado através de uma ligação fosfodiéster, ou um oligonucleótido ou polinucleótido contendo o nucleósido, n1 ou n2 sejam idênticos ou diferentes, e cada qual indica um número inteiro de 0 a 50, desde que os n1 ou n2 não sejam zero ao mesmo tempo, e desde que nem todos os n2 sejam zero ao mesmo tempo, n3 indica um número de 1 a 50, desde que quando n1 e/ou n2 sejam ou seja 2 ou seja 2 ou mais, B1 e B não têm que ser idênticos, e os R' não têm que ser necessariamente idênticos. A base de ácido nucleico de pirimidina ou de purina da invenção presente diz respeito a tiamina, ura-cilo, citosina, adenina, guanina, ou um seu derivado. 9 ΡΕ1013661 0 análogo de nucleósido da invenção presente pode ser sintetizado do modo abaixo descrito. (1) Síntese do análogo de nucleósido
7 B
Tratou-se o Composto 1, sintetizado a partir de uridina de acordo com a literatura [1) J.A. Secrist et al., J. Am. Chem. Soc., 101, 1554 (1979); 2) G.H. Jones et al., J. Org. Chem., 44, 1309 (1979)], com cloreto de tosilo (TsCl) para ser tosilado apenas um dos dois alcoóis primários, conduzindo ao Composto 2. 0 Composto 2 foi hidrolisado com ácido para se obter um triol, Composto 3. Condensou-se o Composto 3 com benzaldeido na presença de um catalisador ácido para se formar um benzilideno, Composto 4. Levou-se a cabo a redução do Composto 4 com cianoboro-hidreto de sódio (NaBH3CN) na presença de tetracloreto de 10 ΡΕ1013661 titânio (TiCl4) para se obter o Composto 5. Fez-se reagir este composto com hexametildisilazida de sódio (NaHMDS) em tetra-hidrofurano (THF) para se obter um biciclo, Composto 6 (Composto I: B = uracilo (U) , X = Η, Y = benzilo). Quando se efectuou cataliticamente a redução do Composto 6 na presença de um catalisador de paládio sobre carbono, obteve-se um diol, Composto 7 (Composto (I): B=U, X=Y= H) . Do tratamento posterior do Composto 7 com cloreto de 4,4'-dimetoxitritilo (DMTrCl) resultou num tritilo, Composto 8 (Composto I: B = U, X = DMTr, Y = H) . Os Compostos 6, 7 e 8 poderão ser utilizados como materiais de partida para a obtenção de vários compostos I.
Os compostos (I) tendo várias bases de ácido nucleico, tanto naturais como não naturais, que não a uridina, poderão ser sintetizados recorrendo a qualquer um dos três métodos seguintes: 0 primeiro método configura a conversão a partir do Composto 8. Isto é, acetila-se o Composto 8 para se obter o Composto 9, e em seguida faz-se reagir com 1,2,4-triazole para se formar o Composto 10. A hidrólise deste composto proporciona o Composto 11 (Composto (I): B = citosina (C) , X = DMTr, Y = H) . O Composto 12 (Composto (I) : B = benzoilcitosina (CBz) , X = DMTr, Y = Η) , que se irá tornar numa matéria de partida para a síntese de oligonucleótidos, poderá obter-se facilmente pela benzoilação do Composto 11. 11 ΡΕ1013661
0 segundo método é um método que se leva a cabo através do Composto 13 que se poderá obter facilmente a partir de D-ribose de acordo com a literatura [3 ) A.G.M. Barrett et al., J. Org. Chem., 55, 3853 (1990); 4) G.H. Jones et al., ibid. , 44, 1309 ( 1979) ] . Isto é, o Composto 13 foi conduzido ao Composto 16 em três passos, e ciclizado sob condições básicas para se obter um metilglicosilo desejado, Composto 17. 0 grupo OMe na posição 1 deste composto poderá ser substituído por diversas bases naturais de ácidos nucleicos ou bases não naturais análogas às dos ácidos nucleicos seguindo um de vários métodos que já foram desenvolvidos anteriormente. Por exemplo, pode aplicar-se um método tal como se representa por um esquema que vai do Composto 17 ao Composto 20.
HO
OH
OH OH 0-ribOSe c. HO reflux. 19 hr (SO %)
MeOH, aceona
Cr03f Py CH2CI2 rt, 20 <riin
H
1) p-dioxane rt 15 hr ( 37 %. 2 steps ) HCHO aq., NaOH aq.
2) (3 °X° 12 ΡΕ1013661 12 ΤΒθΡ3θ/80Ρ3°]^ο^ΟΟΗ3 TiCUOMAP TSOPSO-|^o-^ aaN/CH,C«z JW rsJrí 2\ rt. 13 hr ( 70 %) 14 ( 38 %) X ts
TTFA-HjO TH0P3ai NaHMOS THF rt, 20 min (77%)
Jp Ts<V OH OH THF rt, 1 hr TBOPSO.. OCHj TBDPSO· 16 (35%) 17
'0 OH (43 %) >8 OCH3
OTMS N
Me.
(7
AcgO TBOPSO·» oCH3 O MAPI Py rt, 3 hr ( 86 %) 'N- OTMS TMSOTT/ 1,1-dichloroethane CHjCN rt, 18 hr (ca. 70 %) - cy mFo 15
O terceiro método tem início em acetona-D-glucose, que se obtém a partir de D-glucose num só passo e se encontra disponível no comércio. Preparou-se o Composto 31 de acordo com a referência 5) R.D. Youssefyeh, J.P.H. Verheyden e J.G. Moffatt., J. Org. Chem., 44, 1301-1309 (1979) . Em seguida, tratou-se o Composto 31 tal como se representa pelo esquema seguinte para se protegerem os dois grupos hidroxilo primários com um grupo t-butildifenil-sililo e um grupo p-toluenossulfonilo, progressivamente. Acetilou-se o composto protegido para se obter o Composto 13 ΡΕ1013661
TBDPSOk _ HGT OSn 32
TsC)/ DM AP / Et3N TBOPSCk, CH2q2 f f L TsCT 97% iBn 33
AcOH / Ac20/ conc. H^SOí rt 86% TBDPS* Ts( iriíiAc 34
Condensou-se o Composto 34, separadamente, com tiamina, benzoiladenina, e isobutirilguanina activada por trimetilsililação (referidos como 2TMS*T, 2TMS*ABz, e 3TMS*GlBu, respectivamente) , para se obterem os Compostos 35, 40 e 44 com elevados rendimentos, tal como se representa no esquema colocado abaixo. Em seguida, sujeitaram-se estes condensados à desacetilação (Compostos 36, 41, 45), formação de anéis com cinco membros (Compostos 37, 42, 46), des-sililação (Compostos 38, 43, 47), e mais desbenzilação para se formarem os Compostos 39 pretendidos.
34 2TMS · T or 2TMS · A®* or 3TMS · G®u
TMS OTI/CIC HjCH jCI TBOPS' Ts< aq. K2C03 / MeOH "7t ~ rt. (70-97%) 35: 8=T 40: 8»Aa* 44: 8*Gi0u (64-92%) 14 ΡΕ1013661
B TBDPSl
TsOr ôsn OH
NaHMOS/THF TBOPi TBAF/THF rt. 38: B=.T +1: B=ASl 45: B»QISu (44-100%) (83-100%)
37: B=T At B=ABi 48: B=G®U
Htf 20%Pd(OH)a-C HO· MeOH rl 96% 38: B=T -Μίβ-Α31 47: BbGí6m ai iSu
39a: B=>T 39b: B=A 39c: B=G (2) Síntese do análogo de oligonucleótido
Faz-se reagir o Composto 8 com 2-cianoetil-N,N, N'N'-tetraisopropilfosforamidito para se obter um amidito, Composto 21. Combina-se este composto com amidito nucleósi-do que ocorre na natureza, e sujeita-se a um sintetizador de ADN para se sintetizarem vários análogos de oligonucleó-tidos. Purificam-se os produtos impuros sintetizados uma coluna cromatográfica de fase reversa (Oligo-Pak). Analisa-se o grau de pureza do produto purificado por HPLC, altura em que se poderá confirmar quanto à formação de um análogo de oligonucleótido. jtaidfc de nadeàskkí natai
21 15 ΡΕ1013661
Pelo menos uma unidade de monómero sob a forma de Composto 8 pode ser contida no análogo de oligonucleótido. Alternativamente, as unidades de monómero podem estar presentes em duas ou mais localizações no análogo de oligonucleótido de tal forma que se separem de cada qual através de um ou mais nucleótidos que ocorrem na natureza. A invenção presente torna possível sintetizar uma molécula de sentido reverso incorporando um número necessário de análogos de nucleótido (análogos de nucleósido) da invenção (um comprimento necessário do análogo de nucleótido ou nucleósido) numa localização necessária. 0 comprimento da totalidade do análogo de oligonucleótido é de 2 a 50, 10 a 30 de preferência, unidades de nucleósido.
Um tal análogo de nucleótido (molécula de sentido reverso) é minimamente degradável por várias nucleases, e pode existir em vivo durante um longo período de tempo após a sua administração. Esta molécula de sentido reverso opera, por exemplo, na formação de uma dupla hélice estável em conjunto com um ARN mensageiro, inibindo assim a biossíntese de uma proteína potencialmente patogénica; ou forma uma tripla hélice em combinação com ADN de cadeia dupla num genoma para se inibir a transcrição para ARN mensageiro. O análogo de oligonucleótido também poderá suprimir a proliferação de um vírus que tenha provocado a infecção. À luz destas revelações, torna-se expectável que um análogo de nucleótido (molécula de sentido reverso) 16 ΡΕ1013661 utilizando um análogo de nucleósido da invenção presente tenha utilidade sob a forma de medicamentos, incluindo os antineoplásicos e os antivirais, para tratamento de doenças por inibição das acções especificas dos genes. A molécula de sentido reverso que utiliza o análogo de nucleótido (nucleósido) da invenção presente pode ser formulada sob a forma de preparações parentéricas ou preparações de lipossomas pela incorporação auxiliares habituais tais como tampões e/ou estabilizadores. Sob a forma de preparações para aplicação tópica, esta poderá ser misturada com veículos farmacêuticos utilizados habitualmente para a preparação de unguentos, cremes, líquidos ou emplastros. A síntese dos análogos de nucleósido da invenção presente e dos análogos de nucleótido da invenção presente será descrita mais detalhadamente por intermédio dos Exemplos e Exemplos de Produção seguintes. Nestes Exemplos, o uracilo é utilizado principalmente como uma base, mas à sua semelhança também se poderão utilizar outras bases de purina de ácido nucleico.
[Exemplo 1] Síntese de um análogo de nucleósido (1) Síntese de 2',3'-O-ciclo-hexilideno-4'-(p-toluenossulfoniloximetil)uridina (Composto 2)
Adicionou-se cloreto de p-toluenossulfonilo (771 17 ΡΕ1013661 mg, 4,05 mmoles) a uma solução de piridina anidra (13,5 mL) do Composto 1 (956 mg, 2,70 mmoles) conhecida na litera tura, à temperatura ambiente numa corrente de azoto, e agitou-se a mistura durante 5 horas a 60°C.
Adicionou-se uma solução de bicarbonato de sódio à mistura reaccional, extraindo-se o sistema reaccional de seguida com benzeno por 3 vezes. Lavou-se a fase orgânica uma vez com uma solução saturada de cloreto de sódio, e secou-se por sobre MgS04 anidro. Retiraram-se os solventes por destilação sob pressão reduzida, e sujeitou-se o resíduo a uma destilação azeotrópica com benzeno, por 3 vezes. Purificou-se o produto impuro resultante por croma-tografia em coluna sobre silicagel (CHCl3:MeOH = 15:1), e em seguida precipitou-se novamente a partir de benzeno-hexano para se obter um pó branco (Composto 2) (808 mg, 1,59 mmo1e s, 59%).
Composto 2: Pó branco, p.f. 104-106°C (benzeno-hexano) . IV v (KBr) : 3326, 2929, 2850, 1628, 1577, 1544, 1437, 1311, 1244 cm1. RMN de ^ (d6-acetona) : δ 1,45-1,67 (1 OH , m) , • 2,45 ( 3H, s) , 3 ,71 (2H, ABq, J = 12 H. z) , 4 ,20 (2H, ABq, J = 11 Hz) , 4 ,92 (1H, d, J’ = 6 Hz), 5, 05, 5 , 06 (1H, dd, J = 4, 6 Hz) , 5, 60 (1H, d, J = 7 Hz ), 5,75 (1H t d, J = 4 Hz) , 7,48 ( :2h, d, J = = 8 Hz), 7,77 ( 1H , d, J = 8 H z) , \—1 co (2H, , d, J = = 8 Hz) t 10,10 (1H, s,) • RMN de 13c ( d6- acetona): δ 21,5, 24, Λ, 24, 5, 25,5, 34,8, 36 i,9, 63, 5, 69 ,7, 82,5 , 84, 7, 87,8, 92 ,9, 102,9, 115 ,4, 128 ,8 , 130,8 , 133 ,9, 142, 7, 14 5,9, 151 ,3, 163 ,5. Massa ( EI): m/z 481 (M+- -h2o) 18 ΡΕ1013661
Anál. Calculado. para C23H28N2O9S · 1/3 H20: C, 53,69; H, 5,61; N, 5,44; S, 6,22. Determinado: C, 53,99;H, 5,48; N, 5, 4 2 ; S, 6,10. (2) Síntese de 4'-(p-toluenossulfoniloximetil)-uridina (Composto 3)
Agitou-se o Composto 2 acima (107 mg, 0,21 mmole) em TFA-H20 (98:2, 1 mL) durante 10 minutos à temperatura ambiente. Retirou-se a mistura reaccional por destilação sob pressão reduzida, e adicionou-se EtOH ao resíduo, seguindo-se a realização de uma destilação azeotrópica por 3 vezes. Purificou-se o produto impuro resultante por cromatografia em coluna sobre silicagel (CHCl3:MeOH = 10:1) para se obter o Composto 3 (85.0 mg, 0.20 mmole, 94%).
Composto 3: Pó branco, p.f. 119-120°C. IV v (KBr): 3227, 3060, 2932, 2837, 1709, 1508, 1464, 1252, 978, 835, 763, 556 cm-1. RMN de 1H (d6~acetona) : δ 2,31 (3H, s) , 2,84 (3H, s) , 3, 71 (2H, s) , 4, 13, 4,20 (2H, ABq, J = 11 Hz) , 4, 28, 4,31 (1H, dd, J' = 9, 6 Hz ) , 4 ,36 ( 1H, d, J’ = = 6 Hz) , 5, 54 (1H, d, J' = 8 Hz) , 5,75 ( 1H, d, J = 7 Hz), 7, , 32 (2H, d, J = 8 Hz) 7 , 67 (2H, d, J = 8 Hz ), 7, 70 (1H, d, J’ = 8 Hz ) , 10, 14 (1H, s) . RMN de 13C (d6- -acetona) : δ 21, ,5, 63,7, 70, 8, 72,7, 74, 6, 86, 8, 88, 8, 103, 1, 128,8, 130,7, 133, 9, 141,7, 145, 8, 151,8, 163, 9. Massa (EI): m/z 256 (M+- OTs) . 19 ΡΕ1013661 (3) Síntese de 2',3'-O-benzilideno-4'-(p-tolue-nossulfoniloximetil)uridina (Composto 4)
Numa corrente de azoto, adicionaram-se benzal-deído (2.4 mL, em excesso) e cloreto de zinco (670 mg, 5,0 mmoles) ao Composto 3 acima (400 mg, 0,93 mmoles), e agitou-se a mistura durante 5 horas à temperatura ambiente. Após terminada a reacção com a adição de solução saturada de bicarbonato de sódio, extraiu-se a mistura reaccional com clorofórmio, e lavou-se com uma solução saturada de bicarbonato de sódio, água, e uma solução saturada de cloreto de sódio. Secou-se a fase orgânica sobre sulfato de sódio anidro. Retiraram-se os solventes por destilação sob pressão reduzida, e purificou-se o resíduo por cromato- grafia em coluna sobre silicagel (CHCl3:MeOH = 40:1) para se obter o Composto 4 (380 mg, 0,74 mmol, 80%).
Composto 4: Pó branco, p.f. 99-102°C (CH2CI2- hexano) . [a]D23-26, 7 ° (c = 1,0, CHC13) . IV v (KBr) : 3059, 1691, 1460, 1362, 1269, 1218, 1177 cnT1. RMN de XH (CDC13) : δ 2,41 (3H, s), 3,25 (1H, lg) , 3,79 (2H, m) , 4,19 (2H, s) ,
5, 09 (1H, cr C-l II ^1 Hz) , 5,28 (1H, dd, J = 3, 7 Hz), 5 , 60 (1H, d, J = 4 Hz), 5, 73 (1H, N CO II l~D ), 5, 94 (1H, s) , 7,24 (1H, d, J = 8 Hz) , 7,38 (2H, d, J = 9 Hz) ), 7,42 ( 5H, lg), 7, 69 (2H, d, J = 9 Hz) , 9,11 (1H, lg) . RMN de 13C (CDCL3) : δ 21, 6, 63,5, 68,3, 77,2, 82,8, 84,2, 87,7, 94, 9, 102, 6, 107,5, 126, 5, 127,9, 128,5, 129, 7, 132,2, 135, 0, 143,0, 145,0, 150,4, 163,5. 20 ΡΕ1013661
Anál. Calculado. para C24H24N2O9S· 1/3 H20: C, 55,17; H, 4,76; N, 5,36; S, 6,14. Determinado: C, 55,19; H, 4,66; N, 5,29; S, 5,98. (4) Síntese de 3'-O-benzil-4'-(p-toluenossulfo-niloximetil)uridina (Composto 5)
Adicionou-se cianoboro-hidreto de sódio (92 mg, 1,5 mmoles) a uma solução de acetonitrilo (3 mL) do Composto 4 (150 mg, 0,29 mmole) à temperatura ambiente numa corrente de azoto. Em seguida, adicionou-se tetracloreto de titânio (0,16 mL, 1,5 mmoles) gota-a-gota sob arrefecimento com gelo, e agitou-se a mistura durante 15 horas à temperatura ambiente. Diluiu-se a mistura reaccional com clorofórmio, e lavou-se com uma solução saturada de bicarbonato de sódio, água, e uma solução saturada de cloreto de sódio. Em seguida, secou-se a fase orgânica sobre sulfato de sódio anidro. Após se retirarem os solventes por destilação, purificou-se o resíduo por cromatografia em coluna sobre silicagel (CHCl3:MeOH = 25:1) para se obter o Composto 5 (112 mg, 0,22 mmole, 75%).
Composto 5: Cristais incolores. P.f. 195-197°C (AcOEt-hexano) . [a]D23-14,6° (c = 1,0, CHC13) . IV v (KBr) : 3033, 2885, 2820, 1726, 1470, 1361, 1274, 1175, 1119 cm-1. RMN de ^ (CDCI3) δ: 2,40 (3H, s), 3,59-3,77 (3H, m) , 4,10, 4,24 (2H, AB, J = 11 Hz), 4,32 (1H, d, J = 6 Hz), 4,56 (2H, m) , 4,69 (1H, d, J = 11 Hz), 5,52 (1H, d, J = 6 Hz), 5,67 (1H, d, J = 8 Hz), 7,24-7,29 (7H, m) , 7,48 (1H, d, J = 8 21 ΡΕ1013661
Hz), 7,70 (2H, d, J = 9 Hz), 9,91 (1H, s). RMN de 13C (CDC13) : δ 21, 6, 63,2, 69, 2, 73, 6, 74, 6, 78, 1, 86, 6, 92,9, 102,5, 127,9, 128,2, 128,3, 128, 6, 129, 9, 132,3, 136, 9, 142,4, 145,2, 150,7, 163,8.
Anál. Calculado, para C24H26N2O9S: C, 55, 59; H, 5,05; N, 5,40; S, 6,18, Determinado: C, 55,41;H, 5,02;N, 5,32;S, 6,15. (5) Síntese de 3'-O-benzil-2'-O,4'-C-metileno-uridina (Composto 6)
Adicionou-se uma suspensão anidra de benzeno (0,7 mL) de NaHDMS (3,2 mmoles) a uma solução anidra de THF (1,5 mL) do Composto 5 (80 mg, 0.16 mmole) , à temperatura ambi ente numa corrente de azoto, e agitou-se a mistura durante 20 horas à temperatura ambiente. Adicionou-se uma solução saturada de bicarbonato de sódio à mistura reaccional, seguindo-se a extracção da mistura com CHC13. Lavou-se a fase orgânica com uma solução saturada de cloreto de sódio, e em seguida secou-se sobre sulfato de sódio anidro. Após se retirarem os solventes por destilação sob pressão reduzida, purificou-se o produto impuro resultante por cromatografia de coluna sobre silicagel (CHCl3:MeOH = 10:1), and recristalizou-se em seguida a partir de MeOH para se obter o Composto 6 (41 mg, 0,10 mmole, 61%).
Composto 6: Cristais incolores. P.f. 217-219°C (MeOH). [oí]d23° +108,4° (c = 0,3, MeOH). IV v (KBr) : 3059, 22 ΡΕ1013661 2951, 1688, 1459, : 1271, 1053 cm 1. RMN de 1H (d6-DMSO) δ: 3,75, 3,85 (2H, AB, J = 8 Hz) , 3, 77 (2H, d, J = 5 Hz) , 3, 92 (1H, s), 4,44 (1H, s) , 4, 60 (2h, s; ), 5 ,39 (1H, t, J = 5 Hz) , 5,48 (1H, s) , 7,31 (5H, m) , 7, 72 ( 1H, d, J = 8 Hz ) , 11,37 (1H, s). RMN de 13C (d6 -DMSO) δ: 56,0, 71,1, 71, 6, 75,8, 76, 5, 86, 5, 8 8,3, 100,9, 127,4 , 127, 6, 128,2, 137, 9, 139, 0 , 150, 0, 163,3 . Massa (EI ) : m/z 346 (M+, 1.1) .
Anál. Calculado para C17H18N2O6: C, 58,96; H, 5,24; N, 8,09.
Determinado: C, 58,67; H, 5,23; N, 8,05. (6) Síntese de 2'-O,4'-C-metileno-uridina (Composto 7)
Adicionou-se 10% Pd-C (25 mg) a uma solução de metanol (2,5 mL) do Composto 6 (25 mg, 0, 072 mmole) , e agitou-se a mistura reaccional durante 15 horas à pressão atmosférica numa corrente de azoto. Filtrou-se a mistura reaccional, e retirou-se o solvente por destilação. Em seguida, purificou-se o resíduo por cromatografia de coluna sobre silicagel (CHCl3:MeOH = 10:1, 5:1 em seguida) para se obter o Composto 7 (18,3 mg, quant.).
Composto 7: Cristais incolores. P.f. 239-243 °C (MeOH) . [a] d23° +92.2° ( O II 0 CO MeOH). IV v (KBr) : 3331, 3091, 3059, 2961, 1689 , 1463, 1272, 1049 cm1. RMN de 1H (CD3OD) δ: 3,76, 3,96 (2H, AB, J = 8 Hz), 3,90 (2H, s), 23 ΡΕ1013661 4,04 (1Η, s), 4,28 (1H, s), 5,55 (1H, s), 5,69 (1H, d, J = 8 Hz), 7,88 (1H, d, J = 8 Hz).
Anál. Calculado para C10H12N2O6: C, 46, 88; H, 4,72; N, 10,93.
Determinado: C, 46,74; H, 4,70; N, 10,84. (7) 5'-O-(4,4'-dimetoxitritil)-2'-O,4'-C-metile- no-uridina (Composto 8)
Adicionou-se piridina anidra ao Composto 7 (140 mg, 0,53 mmole), seguindo-se uma destilação azeotrópica da mistura por 3 vezes. Em seguida, converteu-se o produto numa solução anidra de piridina (1,5 mL), e adicionaram-se cloreto de 4,4'-dimetoxitritilo (210 mg, 0,63 mmole) e DMAP (6,5 mg, 0,053 mmole) à temperatura ambiente numa corrente de azoto. Agitou-se a mistura durante 5 horas à temperatura ambiente. Adicionou-se uma solução saturada de bicarbonato de sódio à mistura reaccional, seguindo-se a extracção com CH2CI2. Lavou-se a fase orgânica com água e com uma solução saturada de cloreto de sódio, e secou-se em seguida sobre sulfato de sódio anidro. Após se retirarem os solventes por destilação sob pressão reduzida, purificou-se o produto impuro resultante por cromatografia de coluna sobre sili-cagel (CHCl3:MeOH = 40:1) para se obter o Composto 8 (230 mg, 0,34 mmole, 66%).
Composto 8: Pó branco. P.f. 117-120°C (CHC13) . 24 ΡΕ1013661 [oí] d23° +17,2° (c = 1,0, CHC13) . IV v (KBr) : 3393, 3101, 2885, 1689, 1464, 1272, 1047 cm-1. RMN de ^ (CDC13) δ: 2,59 (1H, lg) , 3,56 (2H, q, J = 7, 11 Hz), 3,87 (1H, d, J = 7
Hz), 4,26 (1H, s), 4,47 (1H, s), 5,60 (1H, d, J = 9 Hz), 5,63 (1H, s), 5,84 (4H, d, J = 9 Hz), 7,22-7,45 (9H, m) , 7,93 (1H, d, J = 9 Hz) .
[Exemplo 2] Síntese de um análogo de nucleósido (1) Síntese de metil=5-0-(t-butildifenilsilil) -4-hidroximetil-2,3-0-isopropilideno-p-D-ribofuranosida (Composto 14)
Numa corrente de azoto, adicionaram-se EtsN (2,62 mL, 18,8 mmoles) e cloreto de t-butildifenilsililo (4,88 mL, 18,8 mmoles) a uma solução anidra de CH2CI2 (40 mL) do Composto 13 (2,00 g, 8,54 mmoles) conhecido da literatura sob arrefecimento com gelo, e agitou-se a mistura durante 13 horas à temperatura ambiente. À mistura reaccional, adicionou-se uma solução saturada de bicarbonato de sódio, e extraiu-se o sistema reaccional em seguida com AcOEt por 3 vezes. Lavou-se a fase orgânica com uma solução saturada de cloreto de sódio, e secou-se em seguida sobre Na2S04. Retiraram-se os solventes sob pressão reduzida, e purificou-se o produto impuro resultante por cromatografia de coluna sobre silicagel (hexano:AcOEt = 5:1) para se obter um material oleoso incolor (Composto 14) (2,82 g, 5,98 mmo1e s, 7 0%). 25 ΡΕ1013661 [a] 17° D -16,2° (c — 0,52, CHCI3) • IV v ( KBr) : 3510, 3061, 2938 , 2852, 1465, 1103 cm 1. RMN de Oí (CDC1 3) δ: 1,09 (9H, s) , 1, 28 ( 3H , s) , 1,49 (3H, s) , 3,22 (3H, s: ), 3, 67, 3,76 ( 2H, AB, J = 11 Hz) , co co 00 3,93 (: 2H, AB, J = 11 Hz), 4,49 (1H, d, J = 6 Hz) , 4,57 (1H, d, J = = 6 Hz) r 4, 93 (1H, s), 7,38-7, 43 ( 6H , m) , 7, 67 (4H, d, J = 7 Hz) . RMN de 13C ( CDCI3 ) δ: 19,2, 24,4, 25, 9 t 26,9, 55, 0, 62, 9, 64, 8 , 82,2 r 85 , 9, 88,7, 108, 6, 112, 6, 127,8, 129, 9, r 133,0, 135 >,7.
Anál. Calculado para C26H36O6S1 · 1/4 H20: C, 65,45; H, 7,71.
Determinado: C, 65,43; H, 7,59. (2) Síntese de metil=5-0-(t-butildifenilsilil)-2,3-0-isopropylideno-4-(p-toluenossulfoniloximetil)-β-ribofuranósido (Composto 15)
Numa corrente de azoto, adicionaram-se EtsN (3,92 g, 28,0 mmoles), cloreto de p-toluenossulfonilo (1.34 g, 7,22 mmoles), e 4-dimetilaminopiridina (90 mg, 0,72 mmole) a uma solução anidra de CH2CI2 (15 mL) do Composto 14 (2,13 g, 4,51 mmoles), e agitou-se a mistura durante 17 horas à 26 ΡΕ1013661 temperatura ambiente. Adicionou-se uma solução saturada de bicarbonato de sódio à mistura reaccional, e em seguida extraiu-se o sistema reaccional com AcOEt por 3 vezes. Lavou-se uma vez a fase orgânica com solução saturada de cloreto de sódio, e secou-se sobre Na2S04 anidro. Retiraram-se os solventes por destilação sob pressão reduzida, e purificou-se o produto impuro resultante por cromato-grafia de coluna sobre silicagel (hexano:AcOEt = 10:1) para se obter um material oleoso incolor, Composto 15 (2,76 g, 4,42 mmo1e s, 98%).
[a] d17° -3.82o (c = 0,56, CHC13) . IV v (KBr) : 2934, 2852, 1369, 1104 cm'1. RMN de 3H (CDCls) δ: 1,02 (9H, s) , 1, 20 (3H, s) , 1,32 (3H, s) , 2,41 ( :3h, s), 3, 09 (3H, s) , 3 ,51 , 3 ,77 (2H, AB, J = 1 0 Hz ), 4,34 (1H, d, J = 6 Hz) , 4 ,25, 4, 39 (2H, AB, J = 9 Hz) , 4, 47 (1H, d, J = 6 H z) , 4,77 (: 1H, s) , 7, 28, 7, 81 (4H, AB, J = 9 Hz) , 7,39 - 7,4 4 ( 6H, m) , 7, 62 - 7 , 65 (4H, m) , 7 ,81 (2H, d, J = 9 Hz) . 13c- NMR (CDCI3) δ: 19 ,2, 21, 6, 24,. 5, 25, 8, 2 6,8, 54,9 f 62, 7, 68,8, 8: 1,9, 85 , 6, 87 ,5, 108 ,7, 112,8 , 12 7,7, 127, 8 , 12 8,2, 129, 6, 129,9, 132 ,9, 135 , 6, 144 f 4 .
Anál. Calculado para C33H42O8SSÍ: C, 63,23; H, 6,75; S, 5,11.
Determinado: C, 62,99; H, 6,53; S, 5,13. 27 ΡΕ1013661 (3) Síntese de metil=5-0-(t-butildifenylsilil)-4-(p-toluenossulfoniloximetil)-β-D-ribofuranósido (Composto 16)
Adicionou-se ácido trifluoroacético (14 mL) a uma solução de THF-H20 [11 mL, 8:3 em volume] do Composto 15 (645 mg, 1,03 mmoles) à temperatura ambiente, e agitou-se a mistura durante 20 minutos à temperatura ambiente. Retiraram-se os solventes por destilação sob pressão reduzida e purificou-se o produto impuro resultante por cromatografia de coluna sobre silicagel (hexano: AcOEt = 5: 1) para se obter um material oleoso incolor, Composto 16 (464 mg, 0,79 mmole, 77%).
[a] d17° -35.8° (c=l, 90, CHC13) IV v (KBr): 3499, 3051, 2931, 2840, 1594, 1468, 1362, 1109 crrf1. RMN de ^ (CDCI3) δ: 1,02 (9H,s), 2,42 (3H,s), 3,16 (3H,s), 3,54, 3,70 (2H,AB,J=10Hz ) , 3,97 (1H,d,J=5Hz), 4,18 (1H,d,J=5Hz) , 4,26, 4,39 (2H,AB,J=10Hz) , 4,73 (lH,s), 7,30 (2H,d,J=8Hz), 7,36-7,44 (6H,m), 7,59-7,66 (4H,m), 7,78 (2H,d,J=8Hz). RMN de 13C-NMR (CDCI3) δ: 19, 2, 21, 6, 26, 7, 55, 2, 66, 5, 69, 6, 74, 0, 75, 2, 76, 5, 84, 8, 107,5, 127,7, 128,0, 129, 8, 132, 6, 132,7, 132,8, 135, 5, 135, 6, 144,9. 28 ΡΕ1013661
Anál. Calculado para C3oH38SSi08· 1/4 H20: C, 60, 94; H, 6,56.
Determinado: C, 60,94; H, 6,43. (4) Síntese de metil=5-0-(t-butildifenilsilil)-2-O,4-C-metileno-p-D-ribofuranósido (Composto 17) e metil=5-0-(t-butildifenilsilil)-3-0,4-C-metileno-p-D-ribofuranósido (Composto 18)
Numa corrente de azoto, adicionou-se uma suspensão de benzeno (1,6 mL) de NaHMDS (3,30 mmoles) a uma solução anidra de THF (4 mL) do Composto 16 (194 mg, 0,33 mmol) à temperatura ambiente, e agitou-se a mistura durante 1 hora à temperatura ambiente. Após a adição de uma solução saturada de bicarbonato de sódio à mistura reaccional, retiraram-se os solventes por destilação, e extraiu-se o resíduo com AcOEt por 3 vezes. Lavou-se a fase orgânica uma vez com uma solução saturada de cloreto de sódio, e secou-se em seguida sobre Na2S04 anidro. Retirou-se o solvente por destilação sob pressão reduzida, e purificou-se o produto impuro resultante por cromatografia de coluna sobre silicagel (hexano:AcOEt = 5:1) para se obter um material oleoso incolor, Composto 17 (48 mg, 0,116 mmole, 35%) e um material oleoso incolor, Composto 18 (59 mg, 0,142 mmole, 43%) . ΡΕ1013661 29
Composto 17: IV v (KBr) : 3438, 3064, 1103, 1036 cm 1. RMN de 1H (CDC13) δ: 1,08 (9H,s), 2,04 (1H, s lg) , 3,39 (3H,s), 3, 65, 3, 98 (2 Η, AB, J= 8 H z ) , 3,95, 4,02 (2 Η, AB, J= 12 H z ) , 4,02 (lH,s), 4,30 (lH,s), 4,79 (lH,s), 7,38-7,46 (6H,m), 7,65-7,69(4H,m). RMN de 13C (CDC13) δ: 19, 2, 26, 7, 55, 0, 60,7, 71,2, 73, 1, 79, 9, 85, 5, 104,3, 127,8, 129, 9, 130, 0, 132,9, 135, 6, 135, 7.
Anál. Calculado para C23H30O5SÍ · 1/4 H20: C, 65, 68; H, 7,34.
Determinado: C, 65,98; H, 7,23.
Composto 18: IV v (KBr): 3456, 3058, 2938, 2852, 1467, 1108crrf1. RMN de 3Η (CDC13)õ: 1,10 (9H,s), 3,26 (3H,s), 3,71 (2H,s), 4,02 (1H, d, J=6Hz ) , 4,35, 4,95 (2H, d, J=7Hz ) , 5,01 (1H,s) , 5,11 (1H, d,J=6Hz) , 7,38-7,44 (6H,m), 7,66 (4H, d, J=7Hz) . RMN de 13C (CDC13) δ: 19, 3, 26, 8, 55, 4, 63,7, 75, 1, 77,9, 84,5, 86, 3, 111,9, 127,8, 128,0, 129, 9, 132,9, 133, 0, 135, 6, 135, 8, 135, 9. 30 ΡΕ1013661
Anál. Calculado para C23H30O5S1 · 1/4 H20: C, 65,91; H, 7,34.
Determinado: C, 66,07; H, 7,14. (5) Sintese de metil=3-0-acetil-5-0-(t-butildi-fenilsilil)-2-0,4-C-metileno-p-D-ribofuranósido (Composto 19)
Numa corrente de azoto, adicionaram-se anidrido acético (0,38 mL, 4,08 mmoles) e 4-dimetilaminopiridina (21 mg, 0,170 mmoles) a uma solução em piridina anidra (10 mL) do Composto 17 (704 mg, 1,70 mmoles) à temperatura ambi ente, e agitou-se a mistura durante 3 horas à temperatura ambiente. Após a adição de uma solução saturada de bicarbonato de sódio à mistura reaccional, extraiu-se o sistema com AcOEt por 3 vezes. Lavou-se uma vez a fase orgânica com uma solução saturada de cloreto de sódio, and secou-se em seguida sobre Na2S04 anidro. Retiraram-se os solventes por destilação sob pressão reduzida, e purificou-se o produto impuro resultante por cromatografia de coluna sobre sili-cagel (hexano:AcOEt = 7:1) para se obter um material oleoso incolor, Composto 19 (665 mg, 1,46 mmoles, 86%).
[a]D17° -34.3° (c=0, 93, CHC13) IV v (KBr) : 3438, 3064, 2934, 1749, 1468, 1103, 103 6 cm-1. 31 ΡΕ1013661 RMN de 1H (CDC13) δ: 0,99 (9H,s), 1,97 (3H,s), 3,34 (3H,s), 3, 69, 3, 86 (2H, AB, J=8Hz) , 3,86 (2H,s), 4,17 (1H,s) , 4,77 (1H,s), 5,06 (lH,s), 7,28-7,39 (6H,m), 7,58- 7,63 (4H, m) . RMN de 13C (CDC13) õc: 19, 3, 20, 9, 26, 7, 55, 0, 60, 3, 72,0, 73, 6, 78,3, 85, 3, 104,4, 127,7, 129, 8, 133, 0, 135, 6, 169, 8.
Anál. Calculado para C25H3206Si· 1/4 H20: C, 65,12/ H, 7,10.
Determinado: C, 65,27; H, 7,00. (6) Síntese de 5'-O-(t-butildifenilsilil)-2'-O,4'-C-metileno-5-metiluridina (Composto 20)
Numa corrente de azoto, adicionou-se Ο,Ο'-bis-trimetilsililtimina (154 mg, 0,598 mmoles) a uma solução anidra de CH3CN (2 mL) do Composto 19 (109,2 g, 0,239 mmole) à temperatura ambiente. Em seguida, adicionou-se sob arrefecimento com gelo uma solução de 1,1-dicloroetano (0,31 mL) de trifluorometanossulfonato de trimetilsililo (0,82 mL, 8,74 mmoles), e agitou-se a mistura durante 18 horas à temperatura ambiente. Diluiu-se a mistura reacci-onal com CH2C12, e adicionou-se uma solução saturada de bicarbonato de sódio, seguindo-se a extracção do sistema com AcOEt por 3 vezes. Lavou-se a fase orgânica com uma solução saturada de cloreto de sódio, e secou-se em seguida 32 ΡΕ1013661 sobre Na2S04 anidro. Retiraram-se os solventes sob pressão reduzida, e purificou-se o produto impuro resultante por cromatografia de coluna sobre silicagel (hexano:AcOEt = 3:1) para se obter um material oleoso incolor, Composto 20 (87,7 mg, 0,173 mmole, 70%). IV v (KBr): 3048, 2935, 2852, 1749, 1466, 1369, 1234, 1108, 1040 cm1. RMN de ^ (CDC13) δ: 1,06 (9H,s), 1.94 (3H,s), 2,98 (1H,br s), 3, 63, 4, 00 (2H,AB,J=10Hz), 3,72 (1H,d,J=7Hz), 3,82-3,84 (2H,m), 4,30 (lH,s), 5,25 (lH,s), 7,40-7,46 (6H,m), 7,60 (4H, d, J=6Hz) , 7,66 (lH,s), 9,68 (1H,s lg).
[Exemplo 3] Síntese de análogo de nucleósido (método diferente) (1) Síntese de 3-0-benzil-5-0-t-butildifenilsi-lil-4-(hidroximetil)-1,2-O-isopropilideno-a-D-eritropento-furanose (Composto 32)
Sob uma corrente de azoto, adicionaram-se tri-etilamina (3,71 mL, 26,6 mmol) e cloreto de t-butildife-nilsililo (6,94 mL, 26,7 mmol), sob arrefecimento com gelo, a uma solução em cloreto de metileno (50 mL) do Composto 31 (2,50 g, 8,08 mmol) preparada consoante a referência 5) mencionada acima. Agitou-se a mistura durante 10,5 horas à temperatura ambiente. Em seguida adicionou-se uma solução 33 ΡΕ1013661 saturada de bicarbonato de sódio à mistura reaccional, extraiu-se o sistema com acetato de etilo. Lavou-se a fase orgânica com uma solução saturada de cloreto de sódio, e depois secou-se sobre sulfato de sódio. Separaram-se os solventes por destilação sob pressão reduzida, e purificou-se o produto resultante em bruto por cromatografia em coluna sobre silicagel (AcOEt-hexano: = 1:4 — 1:3) para se obter um sólido branco, Composto 32 (2,97 g, 5,41 mmol, 67%) . P.f. 98-99°C (hexano) . [oí]d20 +54,8°(c = 1,12, acetona). IV vmax (KBr) : 3553, 2936, 1463 , 137 9, 1107 cm 1. RMN de 2H (CDC13) δ: 1, 13 (9H, s) , 1,50 (: 3H, s ) , 1,78 (3H, s), 2,56 (1H, t, J = = 7 Hz) , 3, 82, 3 ,92 (2H , AB, J = 11 Hz) , 3, 94 (2H, t, J = 6 Hz) , 4 ,57 (1H, d, J = 5 Hz ) , 4, 64, 4,95 (2H, AB, J = 12 Hz) , 4, 83 (1H, dd, , J = 4, 5 Hz) , 5, 95 (1H, d, J = 4 Hz) , 7,44-7, , 55 (11H, m) , 7, 72-7, 78 (4H, m) . RMN de 13C (CDC13) 5C: 19 72, 26, 2 , 26,5, 26, 8, 63,2, 65, 4, 72,5, 77,9, 79,1 , 87,4, , 104,4, 113,7, 127, 6, 127,7 , 12 :8, 0, 128,5, 129, 5, 129,7, 132,9, 133,1, 134, 7, 135,5, 137,2.
Anál, Calculado para C32H4o06Si : C, 70, 04; H, 7,38. Determinado: C, 70,19; H, 7,35. 34 ΡΕ1013661 (2) Síntese de 3-0-benzil-5-0-(t-butildifenilsi-lil)-4-(p-toluenossulfoniloximetil)-1,2-a-D-eritropentofu-ranose (Composto 33)
Sob uma corrente de azoto, adicionaram-se tri-etilamina (395 pL, 2,83 mmol) , cloreto de p-toluenossul-fonilo (139,2 mg, 0,730 mmol), e 4-dimetilaminopiridina (8,92 mg, 0, 0730 mmol), sob arrefecimento com gelo, a uma solução em cloreto de metileno do Composto 32 (250 mg, 0,456 mmol). Agitou-se a mistura durante 15,5 horas à temperatura ambiente. Depois de se adicionar um solução saturada de bicarbonato de sódio à mistura reaccional, extraiu-se o sistema com acetato de etilo. Lavou-se a fase orgânica com uma solução saturada de cloreto de sódio, e depois secou-se sobre sulfato de sódio. Separaram-se os solventes por destilação sob pressão reduzida, e purificou-se o produto resultante em bruto por cromatografia em coluna sobre silicagel (AcOEt-hexano: = 1:6) para se obter um material oleoso amarelo claro, Composto 33 (310,6 mg, 0,442 mmol, 97%).
[a]D20 +16,0° (c = 0,44, acetona). IV vmax (KBr) : 2935, 1595, 1462, 1363, 1174, 1106 cm-1. RMN de XH (CDC13) δ co 0 \—1 (9H , s) O \—1 (3H, s ) , 1/ 46 (3H, S) , 2, 48 (3H, s) , 3 , 68, 3 , 83 (2H, AB, J = 11 Hz ) , 4, 45 (2H, dd, J = 4 , 5 Hz), 4 ,64, 4 ,81 (2H, AB, J = 12 Hz ) , 4, 68 (1H, dd, J = 4, 5 Hz) f 5, 81 (1H, d, J = 4 Hz) , 7, 32 (2H, d, J = 8 Hz) , 7,42 -7,72 (15H, m) , 7,82, (2H, d, J 8 Hz ) , 7, 66 (4H, m) , 7,72 (2H, f d, J = 8 Hz) . 35 ΡΕ1013661 RMN de 13C (CDC13) õc: 19, 1, 21,5, 26,1, 26, 4, 26,7, 64,4,70 , 0, 72,5, 78, 1, 78,9, 85,4, 104,2, 113, 6, 127,3, 127,7, 127,9, 128,0, 128,4, 129, 6, 129, 7, 129, 8, 132,7, 132,8, 135,5, 137,2, 144,4. MS (EI) m/z : 646 (M+-t-Bu) . HRMS(EI): Calculado para C35H37O8SS1 (M+-t-Bu) : 645, 1978, Determinado: 645, 1969. (3) Síntese de 1,2-di-0-acetil-3-0-benzil-5-0-t-butildifenilsilil-4-(p-toluenossulfoniloximetil)-a- e -β-D-ribofuranose (Composto 34)
Sob uma corrente de azoto, adicionou-se anidrido acético (6,0 mL, 63,6 mmol) e ácido sulfúrico concentrado (56 pL, 1,10 μπιοί) a uma solução em ácido acético (56 mL) do Composto 34 (3, 70 g, 5,27 mmol) . Agitou-se a mistura durante 2 horas à temperatura ambiente. Verteu-se a mistura reaccional sobre água gelada (300 mL), e agitou-se durante 30 minutos. Depois de se lhe adicionar uma solução saturada de cloreto de sódio, extraiu-se a mistura com acetato de etilo. Em seguida secou-se a fase orgânica sobre sulfato de magnésio. Separaram-se os solventes por destilação, e purificou-se o produto resultante em bruto por cromatografia em coluna sobre silicagel (AcOEt-hexano, a 2:1) para se obter um material oleoso amarelo, Composto 34 (3,36 g, 4,53 mmol, 86%), sob a forma de uma mistura α-β (a 1:4). ΡΕ1013661 36 IV vmax (KBr) : 2934, 2863, 1751, 1365, 1217, 1106 cm RMN de 1H (CDCI3) [configuração β] δ: 1,02 (9H, s) , 1,77 (3H, s ) , CO \—1 (3H, s), 2, 39 (3H, s ) , 3 , 61, 3,76 (2H, AB, J = 11 Hz) , 4, 21-4,58 (5H, m) , 5,26 (1H, d, J = 5 Hz) , 5, 94 (1H, s) , 7,15-7,59 (13H, m) , 7,58- 7, 66 (4H, m) , 7,72 (2H, d, J = 8 Hz) [configuração cí] δ: 1,02 (9H, s) , co \—1 (3H, s) , 2, 36 (3H, s), 3,48, 3, 58 (2H, AB, J = 11 Hz) , 4,21 -4,58 (5H , m) , 5, 12 (1H, dd, J = : 5, 6 Hz), . 6,33 (1H , d, j = 5 Hz) , 7, 15- 7,59 (13H, m) , 7,58- 7,66 (4H, m) , 7,72 (2H, d, J = 8 Hz). RMN de 13C (CDCI3) 5C: 14,2, 19,3, 20,5, 20, 8, 21, 6, 26,7, 26 ,8, 60,3, 64,8 , 69,1 , 73, 6, 74, 1, 78, 6, 85, 3, 97,4, 127,4, 127, ,6, 127,7, 127, 8, 127,9, 128, 0, 128, 2, 128,3, 128,4, 129 ,5, 129,6, 1289 , 8, 129, 9, 132,4, 132, 8, 132,9, 135,4, 135, 5, 135,6, 136, 9, 144,5, 168,7, 169, 4 . HRMS (FAB) : Calculado para C^H^OioSSiNa (M++Na) : 769,2479, Determinado: 769,2484. (4) Síntese de 2'-O-acetil-3'-O-benzil-5'-O-t-butildifenilsilil-4'-p-toluenossulfoniloximetil-5-metiluri-dina (Composto 35)
Sob uma corrente de azoto, adicionaram-se 2TMS»T (1,04 g, 4,03 mmol) e trifluorometanossulfonato de trime-tilsililo (730 pL, 4,03 mmol), sob arrefecimento com gelo, 37 ΡΕ1013661 a uma solução em 1,2-dicloroetano (26 mL) do Composto 34 (1,88 g, 2,52 mmol), e agitou-se a mistura durante 17 horas à temperatura ambiente. Adicionou-se uma solução saturada de bicarbonato de sódio à mistura reaccional, e filtrou-se o sistema através de Celite, extraindo-se as águas-mães em seguida com clorofórmio. Lavou-se a fase orgânica com uma solução saturada de cloreto de sódio, e depois secou-se sobre sulfato de sódio. Removeram-se os solventes por destilação sob pressão reduzida, e purificou-se o produto resultante em bruto por cromatografia em coluna sobre silicagel (AcOEt-hexano, a 2:3) para se obter um pó branco, Composto 35 (2,00 g, 2,44 mmol, 97%). P.f. 70-71,5°C. [a] D24 +4,58° (c = 1,25, acetona). IV vmax (KBr) : 3059, 2934, 1694, 1465, 1368, 704 cnf1. RMN de ^ (CDC13) δ: 1,11 3 (9H, s) , 1,63 (3H, d, = 1H z) , 2, 10 (3H, s ) , 2,42 (3H , s) , 3,73 , 3,8 6 (2H, AB , J : 11 H z) , 4, 12, 4,20 (2H , ab, J = 11 Hz) , 4,44, 4,57 i !2H , AB J = 11 Hz) , 4 ,45 (1H, d, J = 6 Hz) , 5, 38 (1H, t, J = = 6 Hz) 6, 02 ( 1H, d, J = 6 Hz) ', 7, 21-' 7, 60 (13H, m) , 7,62-7, 69 (7H m) , 8, 91 ( 1H, s lg) • RMN de 13 !C (CDC1 3 ) õc: 11,9, 19, 3 , 20, 6 f 21, 6 27,0 f 65, 3, 68, 6, 74 :,1, 74, 8, 1 77,2, 77,3, , 86,0, f 86, 4 111, 6, 12 7,9, 128, 0, 128, 2, 128, 5, 12 9,7, 130,1, 1 30,2 131, 8, 132,3, 132, 5, 135, 3, 135, 5, 135,6, 136,8, 1 44,9 150, 2, 163 !,4, 170,2 * 38 ΡΕ1013661 MS (FAB) m/z : 813 (M++H).
Anál, Calculado para C43H48N2O10SS1 ·2H20: C, 60,83; H, 6,17; N, 3,30. Determinado: C, 60,55; H, 5,78; N, 3,22. (5) Síntese de 3'-O-benzil-5'-O-t-butildifenil-silil-4'-p-toluenossulfoniloximetil-5-metiluridina (Composto 36)
Adicionaram-se carbonato de potássio (12,75 mg, 0,0923 mmol) e água (0,5 mL), sob arrefecimento com gelo, a uma solução em metanol (4 mL) do Composto 35 (250 mg, 0,308 mmol), e agitou-se a mistura durante 22 horas à temperatura ambiente. Sob arrefecimento com gelo, adicionou-se ácido acético à mistura reaccional para a neutralizar, e depois separou-se o solvente por destilação sob pressão reduzida. Depois de se adicionar água ao resíduo, extraiu-se a mistura com acetato de etilo. Lavou-se a fase orgânica com uma solução saturada de cloreto de sódio, e depois secou-se sobre sulfato de sódio. Separou-se o solvente por destilação sob pressão reduzida, e purificou-se o produto em bruto resultante por cromatografia em coluna sobre gel (AcOEt-hexano, a 3:2) para se obter um pó branco, Composto 36 (216,7 mg, 0,283 mmol, 92%). p. f. . 74 - 77 °C. [a] d23 + 5,15° (c = 1,23, CHC13) . IV vmax (KBr) : 3048, 2934, 1695, 1363, 1181, 1108, 977, 819, 704 cm-1. 39 ΡΕ1013661 RMN de XH (CDCI3) δ: 1,05 (9H, s), 1, 65 (3H, d, J = 1 Hz) , 2,39 (3H, s), 3,04 (1H, d lg, J = 9 Hz) , 3, 72 (2H, s) t 4, 17 (2H, s) , 4,18 (1H, d, J = 5 Hz), 4,24 -4,32 (1H, m) f 4,54, 4, 62 (2H, AB, J = 11 Hz), 5,62 (1H , d, J = 6 Hz) , 7, 19 -7, 69 (2 0H , m) , 8,46 (1H, s lg) φ RMN 13C (CDC13) õc: 12,1, 19, 4, 26, 9, 58,8, 72,0, 72.2, 75,8, 76,7, 87,4, 88,8, 110,4, 127,7, 12,79, 128,1, 128.2, 128,5, 128,7, 129,8, 130,0, 130,1, 132,2, 134,3, 135.3, 135,5, 136,8, 149,8, 163,9. MS(FAB) m/z : 771 (N++H) .
Anál. Calculado para C41H46N2O9SSÍ: C, 63,41; H, 6,16; N, 3,51; S, 3,95.
Determinado: C, 63,87; H, 6,01; N, 3,63; S, 4,16. (6) Síntese de 3'-O-benzil-5'-O-t-butildifenil-silil-2'-O,4'-C-metileno-5-metiluridina (Composto 37)
Numa corrente de azoto, adicionou-se bis(trime-tilsilil) amideto de sódio (1,0 M em THF, 8,47 mL, 8,47 mmol), sob arrefecimento com gelo, a uma solução em tetra-hidrofurano (30 mL) do Composto 36 (1,86 g, 2,42 mmol), e agitou-se a mistura durante 1 hora à temperatura ambiente. Adicionou-se uma solução saturada de bicarbonato de sódio (14 mL) à mistura reaccional, e depois destilou-se o solvente sob pressão reduzida. Adicionou-se água ao resí- 40 ΡΕ1013661 duo, extraiu-se a mistura com clorofórmio. Lavou-se a fase orgânica com uma solução saturada de cloreto de sódio, e depois secou-se sobre sulfato de sódio. Separaram-se os solventes por destilação sob pressão reduzida, e purificou-se o produto resultante em bruto por cromatografia em coluna sobre silicagel (AcOEt-hexano, 2:3) para se obter um pó branco, Composto 37 (1,42 g, 2,37 mmol, 98%). P.f. 7 0,5-72 °C. [a]D22+52.47 (c= 1,025, acetona). IV vmax (KBr) : 2936, 1694, 1465, 1275, 1106, 1055, 809, 7040101. RMN de 1H (CDC13 ) δ: 1,21 (9H, s) , 1,76 (3H 3, 88, 4,07(2H, AB, J = 8 Hz) , 4,07, 4,15 (2H, AB, J Hz) , 4,16 (1H, s), 4, 66, 4, 80 (2H, AB, J = 11 Hz), (1H, s), 7,34-7,79 (16H, m) , 10,0 (1H, s lg) . MS (FAB) m/z : 599 (M++H) .
Anál. Calculado para C34H38N206Si · 2H20: C, 64,33; H, 6,03; N, 4,41, Determinado: C, 64,58; H, 6,15; N, 4,28. (7) Sintese de 3'-O-benzil-2'-O,4'-C-metileno-5-metiluridina (Composto 38)
Em corrente de azoto, adicionou-se fluoreto de tetrabutilamónio (1,0 M em THF, 379 pL, 0,379 pmol) a uma solução em tetra-hidrofurano (1 mL) do Composto 37 (188,7 mg, 0,316 mmol), e agitou-se a mistura durante 2,5 horas à 41 ΡΕ1013661 temperatura ambiente. Destilou-se a mistura reaccional sob pressão reduzida, e purificou-se o produto resultante em bruto por cromatografia em coluna sobre silicagel (AcOEt-hexano, 1:1-+1:0) para se obter um pó branco, Composto 38 (94,6 mg, 0, 262 itimol, 83%). IV vmax (KBr) : 3424, 3183, 3063, 2950, 1691, 1463, 1273, 1057, 7340101. RMN de XH (CDC13) δ: 1,90 ( 3H, d, J = 1 Hz) , 3, 83, . 4,05 (2H, AB, J = 8 Hz) , 3,93, 4 , 02 (2H, AB, J = 12 Hz) , 3,94 (1H, s), 4 ,53 (1H, s), 4,56, 4,58 (2H, AB, J = 12 Hz) , 5, 65 (1H, s) , 7,32 (5H, s) 1, 7,44 (1H, d, J = 1 Hz) . HRMS (EI): Calculado para Ci8H2oN06 (M+) : 360, 1321,
Determinado: 360,1312. (8) Síntese de 2'-O,4'-C-metileno-5-metiluridina (Composto 39a)
Adicionou-se a uma solução em álcool metílico (4 mL) do Composto 38 (86, 5 mg, 0,240 mmol) , Pd(0H)2 a 20 % sobre C (86,5 mg), e agitou-se a mistura durante 14,5 horas à pressão atmosférica em corrente de hidrogénio. Filtrou-se a mistura reaccional, e depois separou-se o solvente por destilação sob pressão reduzida para se obterem cristais incolores, Composto 39 (62,5 mg, 0,230 mmol, 96%).
p.f. 194-195°C. [a] D20 + 53, 7° (c =1,02, EtOH) . IV vmax (KBr) : 3323, 3163, 3027, 2889, 2826, 1689, 1471, 1276, 1057 cm1. 42 ΡΕ1013661 RMN de (CD3OD) δ: 1,89 (3H, q, J = 1 3,74, 3,95 (2H, AB, J = 8 Hz ), 3,90 (1H, s) , 4,07 (1H 4,26 (1H, s), 5,53 ( 1H, s) , 7,74 (1H, d, J = 1 Hz) RMN de 13C (CD3OD) õc: 12, 6, 57, 6, 70, 3, 72, 4, 80,8, 88,3, 90,4, 110,7, 136,8, 151,8, 166,5.
[Exemplo 4] (1) Síntese de 2'-O-acetil-3'-O-benzil-5'-O-t-butildifenilsilil-4'-p-toluenossulfoniloximetil-N6-benzoíladenosina (Composto 40)
Numa corrente de azoto, adicionaram-se uma solução em 1,2-dicloroetano (5,0 mL) do Composto 34 (250 mg, 0,336 mmol) e trifluorometanossulfonato de trimetilsililo (6,7 pL, 0,0336 mmol), à temperatura ambiente, a 2TMS*ABz (128,7 mg, 0,336 mmol) preparado de acordo com a referência 6) (H. Vorbrggen, K. Krolikiewicz e B. Bennua, Chem., Ber., 114, 1234-1255 (1981)). Aqueceu-se a mistura ao refluxo durante 26 horas. Depois de se adicionar uma solução saturada de bicarbonato de sódio à mistura reaccional, extraiu-se 3 vezes o sistema com cloreto de metileno. Lavou-se a fase orgânica com uma solução saturada de cloreto de sódio, e depois secou-se sobre sulfato de sódio. Separaram-se os solventes por destilação sob pressão reduzida, e purificou-se o produto resultante em bruto por cromatografia em coluna sobre silicagel (CHCl3-MeOH, a 1:3) para se obter um pó branco, Composto 40 (234,5 mg, 0,253 mmol, 75%). 43 ΡΕ1013661 P.f. 77-7 8°C (AcOEt/hexano) . [oí]d24 - 13,2° (c = 1,00, CHC13) . IV vmax (KBr) : 3058, 2934, 1749, 1703, 1606, 1105 cm-1. RMN de 3H (CDCI3) δ: 0,99 ( 9H, s ), 2 ,04 (3H, s) , 2,38 (3H, s) , 3, 7 4, 3, 85 (2H, AB, J = 11 Hz) , 4,31, 4,43 (2H, AB, J = 11 Hz) , 4, 52, 4,58 (2H, AB, J = 11 Hz), 4,81 (1H, d, J = 6 Hz ) , 5, 94 (1H , d, J = 6 Hz) , 6, 04 (1H, d, J = 5 Hz' >, 7, 18 - 7, 61 ( 2 0H, m ), 7,69 (2H, d, J = 8 Hz) , 7,99 (1H, s), 8,01 (2H, d, J = 7 Hz), 8,56 (1H, s), 8,99 (1H, s ig) · RMN de 13C (CDCI3 ) δ: 19, 1, 2 0,5 , 21 ,5, 26 ,7, 64, 1 f 00 4,0, 74 ,6, 77, «·. to 00 σΤ 57, to co 64, 123, 4, 127 ,7, 127, 8, 127,9, 128 /1/ 128,5 , 128, 8, 129, 6, 129, 9, 132 ,0, 132, 3, 132,6, 132 ,7, 133, 5 , 135, 4, 135, 5, 136, 8, 142 ,0, 144, 7, 149, 6, 151, 2, 152,6, 164,5, 169,8. MS ( FAB) m/z : 926 (M++H) . (2) Síntese de 3'-O-benzil-5'-O-t-butildifenil-silil-4 ' -p-toluenossulfoniloximetil-N6-benzoíladenosina (Composto 41)
Adicionou-se a uma solução em metanol (3,0 mL) do Composto 40 (167,9 mg, 0,182 mmol), carbonato de potássio (15,0 mg, 0,109 mmol) à temperatura ambiente, e agitou-se a mistura durante 15 minutos à temperatura ambiente. Adicionou-se ácido clorídrico concentrado à mistura reaccional para a neutralizar, em seguida extraiu-se o sistema 3 vezes 44 ΡΕ1013661 com cloreto de metileno. Lavou-se a fase orgânica com uma solução saturada de cloreto de sódio, e depois secou-se sobre sulfato de sódio. Removeram-se os solventes sob pressão reduzida, e purificou-se o produto resultante em bruto por cromatografia em coluna sobre silicagel (CHC13-MeOH, a 30:1) para se obter um pó branco, Composto 41 (140,5 mg, 0,160 mmo1, 88%). P.f. 82-83°C (AcOEt-hexano) . [a]D25 - 6, 02° (c = 0,96, CHCI3) . IV vmax (KBr) : 3306, 3066, 2935, 2859, 1701, 1611 cm-1. RMN de XH (CDCI3) δ: 0,98 ( :9H, ; S) , 2,37 (3H, s ) , 3,76 (2H, s), 4, 39, 4,45 (1H, AB, J = 11 Hz) , 4,54 ( 1H, d, II 1~D Hz), 4,67, 4, 76 (2H, AB / J = 1 1 Hz) , 4 , 85 (1H, dd, J = 5, 6 Hz), 5 ,79 (1H, d, J = 5 Hz) , 7,20 - 7,58 (21H, m ) , 7,73 (2H, d, J = 8 Hz), 7,80 (1H, s ), 7, 96 (2H, d, J = 8 NI 8,49 (1H, s) , 9,18 (1H, s ig) . RMN de 13C (CDCI3) δ: 19, 1, 2 1, 6 , 26 ,8, 64, 4, 68,9, 74,1, 7 4, 6 , 7 9, 2, 86, 8, 89,8, 123, 127, 7, 127, 8, 128,0 , 128,2, 12 CO C\J \—1 00 128,8, 129, 7, 130, 0, 132, 1, 132,5 , 132,6, 132,8, 133,4, 135,4, 135, 5, 136, 8, 142, 1, 144,8 , 149,4, 152 ,3, 164,5. (3) Síntese de 3'-O-benzil-5'-O-t-butildifenil-silil-2 ' -0,4 ' -C-metileno-N6-benziladenosina (Composto 42)
Sob uma corrente de azoto, adicionou-se bis(tri- 45 ΡΕ1013661 metilsilil) amideto de sódio (1,0 M em THF, 0,58 mL, 0,572 mmol) a uma solução em tetra-hidrofurano (8,0 mL) do Composto 41 (210,5 mg, 0,238 mmol) à temperatura ambiente, e agitou-se a mistura durante 3 horas à temperatura ambiente. Adicionou-se uma solução saturada de bicarbonato de sódio à mistura reaccional, e depois extraiu-se o sistema 3 vezes com cloreto de metileno. Lavou-se a fase orgânica com uma solução saturada de cloreto de sódio, e depois secou-se sobre sulfato de sódio. Destilaram-se os solventes sob pressão reduzida, e purificou-se o produto resultante em bruto por cromatografia em coluna sobre silicagel (CHCI3-MeOH, a 30:1) para se obter um pó branco, Composto 42 (169,5 mg, 0,238 mmol, quant.). P .f . 80-81° C. IV ^max (KBr): 3259, 3064, 2932, 2858 , 1703, 1 607 cnf1. RMN de 1H (CDC13) δ: 1,07 (9H, s), 3,95, 4, 10 (2H, AB, J = 8 Hz) , 4, 02 (2H, d, J = 8 Hz), 4,56, 4, 64 (2H, AB, J = 12 Hz), 4,26 ( 1H, s ), 4,86 (1H, s ), 6,14 (1H, S) , 7,26 - 7, ,70 (18H , m) , 8,04 (2 H, d, J = 7 Hz) , 8,22 (1H, s) , 8, 78 (1H, s) , 9,18 (1H, s lg) . RMN de 13C (CDCI3) δ: 19,2, 26,5 , 26,8, 29, 7 59,2, 72,4, 72 , 6, 7 6, 5, 76, 8, 86,7, 88,6, 123,4, 127,7 127,8, 127,9, 128,1, 128,4, 128,8, 129, 5, 130,0, 132,4 132,5, 132,8, 133,5, 134,8, 135,2, 135,5, 135,6, 136, 8 140,4, 152,7. 46 ΡΕ1013661 (4) Síntese de 3'-O-benzil-2'-O,4'-C-metileno-N6-benzoíladenosina (Composto 43)
Adicionou-se fluoreto de tetrabutilamónio (1,0 M em THF, 1,0 mL, 1,0 mmol) , à temperatura ambiente, a uma solução em tetra-hidrofurano (7,0 mL) do Composto 42 (173,6 mg, 0,244 mmol), e agitou-se a mistura durante 25 minutos à temperatura ambiente. Destilou-se a mistura reaccional sob pressão reduzida, e purificou-se o produto resultante em bruto por cromatografia em coluna sobre silicagel (CHC13-MeOH, 15:1) para se obter um pó branco, Composto 43 (115,4 mg, 0,244 mmol, quant.). p.f. 154 - 155°C (Et20) . IV vmax (KBr) : 3339, 2944, 1701, 1611 cm-1. RMN de 1H (CDC13) δ: 3, 91, 4,13 ( 2H, AB, J = 8 Hz) , 3, 93 , 4, 01 (2H, , AB, J = 12 Hz) , 4,38 (1H , s) r 4, 64 (1H, s) t 4,85 (1H, s) , 6,08 l :ih, s) , 7,29 (1H, , s) r 7,51 (2H, d, J = 8 Hz), 7, ,58 (1H, d, j = 7 Hz), 8, , 05 (2H, d, J = 7 Hz), 8,14 (1H, s), 8,75 (1H, s), 9,50 (1H, s lg). RMN de 13C (CDC13) δ: 57,1, 72,4, 77, 0, 77, 1, 86, 9, 88, 6, 122,9, 127, 6, 128,0, 128,1, 128,4, 128,7, 132,8, 133, 5, 136, 9, 140, 5, 149, 8, 150, 5, 152, 8, 165, 0. 47 ΡΕ1013661 [Exemplo 5] (1) Síntese de 2'-0-acetil-3'-0-benzil-5'-0-t-butildifenilsilil-4'-p-toluenossulfoniloximetil-N2-isobutirilguanosina (Composto 44)
Sob uma corrente de azoto, adicionou-se uma solução em 1,2-dicloroetileno (5,0 mL) do Composto 4 (250 mg, 0,336 mmol) e trifluorometanossulfonato de trimetilsililo (6,7 pL, 0, 0336 mmol), à temperatura ambiente, a 3TMS*GlBu (146,8 mg, 0,336 mmol) preparado de acordo com a referência 6 mencionada acima). Aqueceu-se a mistura ao refluxo durante 15 horas. Em seguida adicionou uma solução saturada de bicarbonato de sódio à mistura reaccional, extraiu-se o sistema 3 vezes com cloreto de metileno. Lavou-se a fase orgânica com uma solução saturada de cloreto de sódio, e depois secou-se sobre sulfato de sódio. Separaram-se os solventes por destilação sob pressão reduzida, e purificou-se o produto resultante em bruto por cromatografia em coluna sobre silicagel (CHCl3-MeOH, a 30:1) para se obter um pó branco, Composto 44 (213,6 mg, 0,235 mmol, 70 %). P. f. 96-97°C (AcOEt-hexano). [«]d24° -11,09° (c = 0, 97, CHC13) . IV vmax (KBr) : 3152, 3065 , 2934 , 1746, 1681, 160 6 cm 1. RMN de XH (CDCI3) δ: 0,96 (9H, s), 1 .,10 (3H, d, J = 9 Hz), 1, 13 (3H, d, J = 9 Hz), 1,98 (3H, s), 2,36 (3H, s), 2,48 (1H, m), 3,65, 3, 72 (2H, AB, J = 11 Hz), 4,23, 4,43 (2H, AB, J = 11 Hz), 4 ,47 (2H, s), 4, 63 (1H, d, J = 6 48 ΡΕ1013661
Hz) , 5 ,74 (1H , t, J = 6 Hz) , 5,96 (1H, d, J = 6 Hz), 7, 14 - 7,68 ( 20H, m) , 9,15 (1H, s) , 12, 2 :o (1H, s) . RMN de 13C (CDCI3) δ: 19 ,1, 19, 3, 19,4, 20, 8, 21,9, 27,0, 27,2, 36, 5, 64,5, 68 ,9, 74, 4, 74,9, 76, 7, 86,1, 86,7, 122,0, 127,6, 12 7, 7, 127 ,9, 128,1, 128, 3, 128,4, 128,8, 130, 1, 130, 4, 132, -3, 132 ,7, 132,9, 135, 7, 135,8, 137,3, 137, 8, 145, 2, 147, -8, 148 ,5, 156,2, 170, 2, 178,8. (2) Síntese de 3'-O-benzil-5'-O-t-butildifenilsi-lil-4 ' -p-toluenossulfoniloximetil-N2-isobutirilguanosina (Composto 45)
Adicionou-se a uma solução em álcool metilico (3,0 mL) do Composto 44 (137,0 mg, 0,151 mmol), carbonato de potássio (15,8 mg, 0,113 mmol), à temperatura ambiente, e agitou-se a mistura durante 45 minutos à temperatura ambiente. Adicionou-se ácido clorídrico concentrado à mistura reaccional para a neutralizar, e em seguida extraiu-se o sistema por 3 vezes com cloreto de metileno. Lavou-se a fase orgânica com uma solução saturada de cloreto de sódio, e depois secou-se sobre sulfato de sódio. Separaram-se os solventes por destilação sob pressão reduzida, e purificou-se o produto resultante em bruto por cromatografia em coluna sobre silicagel (CHCl3-MeOH, 30:1) para se obter um pó branco, Composto 45 (83,4 mg, 0,097 mmol, 64%). p.f. 102-103°C (AcOEt-hexano) [a]D25 -2,00° (c = 0,40, CHC13) . IV vmax( KBr) : 3166, 2932, 1684, 1607 cm-1. 49 ΡΕ1013661 RMN de 1H (CDCI3) δ: 0, 90 ( 9H, s) , 1, 09 (3H, d , J = 7 Hz) , 1,13 (3H, d, J = 7 Hz), 2, , 30 (1H, , m ), 2,37 ( 3H, s) , 3, 71, 3,76 (2H, AB, J = = 11 Hz) , L 1,32, 4, 48 (2H, AB , J = 11 Hz) , 4 ,35 (1H, d , J = 6 Hz) , 4,63 , 4, 90 (2H , AB, J = 12 Hz) , 4 , 96 (1H, t, J = 6 H z) , 5,67 ( 1H, d, J = 7 Hz) , 7 ,17 - 7, 71 (21 OH, m) , 8, í 32 (1H, s) , 12,05 (1H, s Ig) • RMN de 13C (CDCI3) δ: 18,7, 19,0, , 21,6, 26, 5, 36 ,2, 63, 5 f 69, 1, 73,7, 74,3, 78,8 , 86,2 , 89,5, 127,7, 127 ,8, 128, 0, 12 : 8, 1, 128,. 5, 129, 7, 130,0, 132 '! 0, 132,6, 132 ,7, 135, 3, 135,4, 137,4, 138,2, 144 ,8, 146 5,9, 155 ,5, 178,5. (3) Síntese de 3'-O-benzil-5'-O-t-butildifenilsi-lil-2 ' -0,4 ' -C-metileno-N2-isobutirilguanosina (Composto 46)
Sob uma corrente de azoto, adicionou-se bis (tri-metilsilil) amideto de sódio (1,0 M em THF, 0,31 mL, 0,315 mmol) a uma solução em tetra-hidrofurano (3,0 mL) do Composto 45 (92,1 mg, 0,102 mmol), à temperatura ambiente, e agitou-se a mistura durante 3 horas à temperatura ambiente. Adicionou-se uma solução saturada de bicarbonato de sódio à mistura reaccional, e depois extraiu-se o sistema por 3 vezes com cloreto de metileno. Lavou-se a fase orgânica com uma solução saturada de cloreto de sódio, e depois secou-se sobre sulfato de sódio. Removeram-se os solventes por destilação sob pressão reduzida, e purificou-se o produto resultante em bruto por cromatografia em coluna sobre silicagel (CHCI3, MeOH, a 25:1) para se obter um pó branco, Composto 46 (31,4 mg, 0,160 mmol, 44%). 50 ΡΕ1013661 p.f. 99-100 °C. IV vmax (KBr) : 3162, 3068, 2932, 1683, 1610 cnf1. RMN de 3H (CDC13) δ: 1,0 6 (9H, s), 1,25 (3H , d , J = 7 Hz :) , 1,27 (3H, d, J = 7 Hz) , 2,64 (1H, m) , 3 , 83 , 4 ,01 (2H, AB, J = 8 Hz) , 3, 97 ( 2H, d, J = 7 Hz), 4,18 (1H, s) , 4,51 ( 1H, s) , 4,54 (2H , d, J = 2 Hz), 5,77 (1H, s) , 7, 17- 7,42 ( 5H, m) , 7, 64 - ' 7, 72 ( 10H , m) , 7,84 (1H, s) , 9,03 ( 1H, s) , 12 , 08 (1H, s lg) • RMN de 13( C ( :cdci 3) δ: 18,9, 19,0 , 19, a, 26 ,5, 26, 7 t 36, , 4, 59,1, 72, 4, 72, 5, 76, 8, 77,5 , 86, ,3, 88 ,3, 121, 7, 12 !7, 6, 127,7 , 127, 8, 127 ,9, 128,1, 128, 4, 129 ,6, 130, o, 132,36, 132,42, 134, 8, 135, 45, 135, 54, 135, 8, 136 ,8, 146, 8, 14 7,7, 155,4, 17 8, 6. (4) Síntese de 3'-O-benzil-2'-O,4'-C-metileno-N2-isobutirilguanosina (Composto 47)
Adicionou-se fluoreto de tetrabutilamónio (1,0 M em THF, 0,90 mL, 0,90 mmol), à temperatura ambiente, a uma solução em tetra-hidrofurano (3,0 mL) do Composto 46 (41,3 mg, 0,060 mmol), e agitou-se a mistura durante 1 hora à temperatura ambiente. Destilou-se a mistura reaccional sob pressão reduzida, e purificou-se o produto resultante em bruto por cromatografia em coluna sobre silicagel (AcOH-EtOH, a 20:1) para se obter um pó branco, Composto 47 (27,1 mg, 0,060 mmol, quant.). 51 ΡΕ1013661 P. f. 228 - 229°C (Et20) . [a] d25 +32,90° (c = 0, 875 , CHCls) . IR v max (KBr) : 3162 , 2934, 1683, 1608 cnT1. RMN de 1H (CDC13) δ: 1,24 (3H, d, J = 7 Hz), 1,26 (3H, d, J = 7 Hz), 2, 76 (1H, m) , 3, 83, 4,03 1 I2H, AB, J = 8 Hz) , 3,92, 4, 02 (2H, AB, J = 13 Hz), 4,33 (1H, s), 4,55 (1H, s), 4,62 (2H, s ), 5,80 (1H, s), 7,25 (5H, s), 7,91 (1H, s) , 9,85 (1H, s), . 12,05 (1H, s) . RMN de 13C (CDCI3) δ: 19,19, 19,25 , 36,4, 57,4, 72,5, 77, 0, 77,5, 86, 5, 88,8 , 121,0, 127,8, 128,1, 128,2, 128,3 , 128,4, 128,6, 137,1, 137,5, 147,5, 148,2, 155,7, 179,9.
[Exemplo de Referência 1] Síntese de um análogo de um oligonucleótido
CMTQ
J&, 'RÍ
1 Sinfetizader de AON
Diversos Anâiops Olqomdã駱s de P · "rM 21
$'-&asxrmT9CTx3' pera s^csrrxmscT^· rrsxrsj y^csrmsTFscT-y rrssní r-acGTTTmfQCT,3< ítss} s^csxxrmàcr^ ^ecsrnocrrscT-y h&aim s'-<jCsmTxxQCT-a’ í?mi «‘-scaxxtxxxscT-y im sN^TmTTTradc^ 'pes 52 ΡΕ1013661 (1) 3'-O-[2-cianoetoxi(di-isopropilamino)fosfi- no]-5'-O-(4,4'-dimetoxitritil)-2'-0,4'-metano-uridina (Composto 21)
Submeteram-se a uma destilação azeotrópica o Composto 8 (200 mg, 0,31 mmol) tetrazolido de di- isopropilamónio (39,6 mg, 0,23 mmol) com CH3CN anidro, três vezes, e depois transformou-se o sistema numa solução em CH3CN anidro-THF anidro (a 3:1, 4 mL) . Numa corrente de azoto, adicionou-se 2-cianoetil-N,N,Ν',Ν'-tetraisopropil-fosforodiamidito (0,12 mL, 0,37 mmol), e agitou-se a mistura durante 90 minutos à temperatura ambiente. Separaram-se os solventes por destilação sob pressão reduzida, e purificou-se o produto resultante em bruto por croma-tografia em coluna sobre silicagel (AcOEt:hexano:Et3N = 75:25:1). Em seguida, voltou a precipitar-se o produto purificado a partir de AcOEt-hexano para se obter um composto amidito, 21 (181 mg, 0,25 mmol, 81%). P.f. 71-74°C (AcOEt-hexano). RMN de 31P (CDC13) : δ 149, 6, 149, 5, 149, 4, 149, 3, 149,2. (2) Síntese geral de análogos de oligonucleótidos A síntese de um oligómero foi conduzida recorrendo ao sintetizador de ADN da Pharmacia, Gene Assembler 53 ΡΕ1013661
Plus, a uma escala de 0,2 pmol. As concentrações de solventes, reagentes, e fosforamidito eram as mesmas que se utilizaram para a síntese de ADN natural. Desprotegeu-se um grupo DMTr da 5'-O-DMTr-timidina (0,2 pmol) contendo um grupo 3'-hidroxilo ligado a um suporte CPG, com ácido tricloroacético. No seu grupo 5'-hidroxilo, repetiu-se a reacção de condensação utilizando um amidito que incluía quatro bases para síntese de ácido nucleico de ADN natural e Composto 21, para se sintetizarem análogos oligonucleo-tídicos das sequências respectivas. O ciclo sintético era como se segue:
Ciclo sintético (escala de 0,2 ymole) 1) Destritilação 2) Acoplamento 3) Terminação 4) Oxidação 1% de CCI3COOH em CH2C1CH2C1, 6 s fosforamidito 0,1 M (25 equiv.), lH-tetrazole 0,5 M (500 equiv.) em MeCN, 2 minutos 3% de 4-(dimetilamino)piridina, 10 % de Ac2Oi em MeCN, 18 s I2 0,01 M em 2,4,6-colidina/H20/ MeCN (1:5:11), 6 s
Clivou-se o oligómero sintetizado do suporte por tratamento com solução aquosa concentrada de amoníaco, do modo habitual. Ao mesmo tempo, clivou-se o grupo protector cianoetilo do átomo de fósforo, e também se removeram os grupos protectores das adenina, guanina e citosina. 54 ΡΕ1013661
Retirou-se ao análogo de oligonucleótido 5'-0-dimetoxitritilado o grupo DMTr usando 5 mL de ácido trifluoroacético numa coluna cromatográfica de fase reversa (Millipore, 01igo-Pak™SP) , e purificou-se mais para se obter o análogo de oligonucleótido pretendido.
De acordo com o método geral de síntese acima, sintetizaram-se os seguintes oligonucleótidos: (2) 5'-GCGXTTTTTGCT-3' (XT5)
Rendimento 0,06 pmole (rendimento de 30%) (3) 5'-GCGTTXTTTGCT-3' (T2XT3)
Rendimento 0,05 pmole (rendimento de 25%) (4) 5'-GCGTTTXTTGCT-3' (T3XT2)
Rendimento 0,03 pmole (rendimento de 15%) (5) 5'-GCGTTTTTXGCT-3' (T5X)
Rendimento 0,06 pmole (rendimento de 30%) (6) 5'-GCGXXTTTTGCT-3' (X2T4)
Rendimento 0,06 pmole (rendimento de 30%) (7) 5'-GCGTTXXTTGCT-3' (T2X2T2)
Rendimento 0,05 pmole (rendimento de 25%) (8) 5'-GCGTTTTXXGCT-3' (T4X2)
Rendimento 0,06 pmole (rendimento de 30%) (9) 5'-GCGXXXXXXGCT-3' (X6)
Rendimento 0,06 pmole (rendimento de 30%) (10) -5'-GTTTTTTTTXXC-3' (X2)
Rendimento 0,07 pmole (rendimento de 35%) 55 ΡΕ1013661 [Exemplo de Referência 2] Medição da temperatura de fusão (Tm)
Mediram-se as temperaturas de fusão (Tm) dos produtos de recozimento entre as estirpes de sentido reverso, que eram os diversos análogos de oligonucleótidos sintetizados no Exemplo 2, e cadeias baseadas em ADN ou ARN naturais de sentido directo, para se investigar a capacidade hibridizante doa análogos a oligonucleótidos da invenção presente para ADN e ARN complementares.
Cada solução de amostra (500 pL) com concentrações finais de 100 mM em NaCl, 10 mM em tampão de fosfato de sódio (pH 7,2), 4 μΜ em cadeia de sentido reverso, e 4 μΜ em cadeia de sentido directo, respectivamente, foi banhada em água a ferver, e lentamente arrefecida até à temperatura ambiente ao longo de 10 horas. Arrefeceu-se a solução de amostra gradualmente até 5°C, manteve-se a 5°C durante mais um período de 20 minutos, e depois começou a medir-se, passando-se uma corrente de azoto através da câmara com a célula de um espectrofotómetro (UV-2100PC, Shimadzu) para evitar a condensação de humidade. Aumentou-se a temperatura a uma taxa de 0,2°C/minuto até aos 90°C, e mediu-se a absorção no ultravioleta a 260 nm a intervalos de 0,1°C. Para evitar alterações da concentração das amostras com os aumentos de temperatura, a célula tinha uma tampa, e aplicou-se uma gota de óleo mineral sobre a superfície da solução de cada amostra durante a medição. ΡΕ1013661 56
Os resultados estão listados na tabela seguinte.
Tabela 1 Temperaturas de fusão (Tm) de Análogos de Oligonu-cleótidos de sentido reverso para ADN e ARN Complementares
Molécula de sentido reverso Tm para o ADNa> complementar (ATm/mod.) Tm para o ARNb) complementar (ATm/mod.) 5'-GCGTTTTTTGCT-3’ (natural) O O 45°C 5'-GCGXTTTTTGCT-3' (XT5) 50°C (+3°C) 49°C ( + 4 °C) 5'-GCGTTXTTTGCT-3' (T2XT3) 49°C ( + 2 °C) 49°C ( + 4 °C) 5’-GCGTTTXTTGCT-3' (T3XT2) 49°C ( + 2 °C) 50°C (+5°C) 5'-GCGTTTTTXGCT-3’ (T5X) 52 °C ( + 4 °C) 51°C (+6°C) 5'-GCGXXTTTTGCT-3' (X2T4) 51°C (+2 °C) 53°C (+4°C) 5'-GCGTTXXTTGCT-3’ (T2X2T2) 49°C (+1°C) 53°C ( + 4 °C) 5'-GCGTTTTXXGCT-3' (T4X2) 54 °C (+3,5°C) 55°C (+5°C) 5'-GCGXXXXXXGCT-3' (X6) 58 °C ( + 1,8 °C) 71.°C (+4,3°C) a): 3'-CGCAAAAAACGA-5' . b) : 3 ' -r(CGCAAAAAAC
Tal como se ilustra na tabela, no caso do oligómero contendo uma ou duas unidades (X) do análogo de nucleósido da invenção presente (fórmula geral (Ia)) introduzidas numa cadeia de ADN natural, a capacidade de se hibridizarem com o oligómero de ADN complementar, avaliada através da Tm, aumentou 2 a 7 graus (cerca de 2 graus por resíduo modificado) em comparação com a cadeia natural. Com o oligómero com todos os T substituídos por X (X6), o 57 ΡΕ1013661 aumento da capacidade foi tão elevado como 11 graus. Quando a capacidade de se hibridizar com o ARN complementar foi avaliada, o oligómero que incorporava um ou dois X apresentava um aumento em Tm de 4 - 10 graus (4 a 6 graus por resíduo modificado) ao longo da cadeia modificada. No caso de X6, a capacidade de se hibridizar com o ARN complementar era mais aumentada, mostrando um aumento de Tm de mais do que 25 graus (4 graus por resíduo modificado) . Não houve nenhum exemplo de análogos sofrendo estes aumentos em Tm em comparação com estirpes naturais, e a afinidade do oligómero era maior para o ARN do que para o ADN. Estes factos significam que o análogo de oligonucleótido constituído pelo análogo de biciclo-oligonucleósido da invenção presente tem um desempenho extremamente elevado a título de molécula de sentido reverso, e é útil como material para produtos farmacêuticos.
[Exemplo de Referência 3] Medição da resistência à nuclease
Misturou-se uma solução tampão (0,003 U/mL, 400 pL) de uma fosfodiesterase de um veneno de cobra com uma solução tampão (10 μΜ, 400 pL) do oligonucleótido mantendo-se a 37 °C durante 15 minutos. Colocou-se a mistura de soluções numa células em quartzo (800 pL) mantida a 37°C, e mediram-se os aumentos na absorção no ultravioleta (a 260 nm) devidos á decomposição do oligonucleótido ao longo do tempo usando um SHIMADZU UV-2100PC. O tampão utilizando incluía Tris-HCl 0,1 M (pH 8,6), NaClO,1 M, e MgCl2 14 mM, e foi suficientemente desgaseifiçado antes da medição. ΡΕ1013661 58
Medição da vida média (11/2) :
Calculou-se a média dos valores da absorção no UV medidos no inicio da medição (t=0) e a média medida na altura em que não se notou qualquer aumento deste parâmetro. 0 período correspondente a esta média foi designado como vida média (11/2) ·
Sequência de Oligonucleótido_ti/2 (segundos) 5’-GTTTTTTTTTTTC-3' (de tipo natural) 260 5’-GTTTTTTTTT-XX-C-3' (X2) 850
Apresentam-se a título de Fig. 1 gráficos mostrando o decurso temporal da absorção no ultravioleta (cadeia natural) e também na Fig. 2 (X2) . A absorção no ultravioleta atingiu um patamar em cerca de 30 minutos para a estirpe natural, e em cerca de 90 minutos para X2, após iniciação da reacção enzimática.
APLICABILIDADE INDUSTRIAL A utilização deste análogo proporciona um análogo de um oligonucleótido, molécula de sentido reverso, que é minimamente hidrolisável com um enzima em vivo, tem uma elevada capacidade para se ligar a uma cadeia de sentido directo, e se sintetiza facilmente. 59 ΡΕ1013661
Listagem de Sequências
Nome do requerente: Takeshi Imanishi
Titulo da invenção: Biciclonucleósido novo e análogo de oligonucleótido Referência N.°:
Pedido N.°:
Data do pedido: Março, 1998 Prioridade N.°: JPA 53409/97 Data de prioridade: 7 de Março, 1997 Número de sequências: 11 N.° ID Seq.: 1
Comprimento da sequência: 12 Tipo de sequência: Nucleótido Número de cadeias: Cadeia simples Topologia: Linear Sequência: 5'-GCGTTTTTTGCT-3' N.0 ID Seq.: 2
Comprimento da sequência: 12
Tipo de sequência: Nucleótido, análogo de nucleótido Número de cadeias: Cadeia simples Topologia: Linear Sequência: 5'-GCGXTTTTTGCT-3' N.° ID Seq.: 3
Comprimento da sequência: 12
Tipo de sequência: Nucleótido, análogo de nucleótido Número de cadeias: Cadeia simples 60 ΡΕ1013661
Topologia: Linear Sequência: 5'-GCGTTXTTTGCT-3' N.° ID Seq.: 4
Comprimento da sequência: 12
Tipo de sequência: Nucleótido, análogo de nucleótido Número de cadeias: Cadeia simples Topologia: Linear Sequência: 5'-GCGTTTXTTGCT-3' N.° ID Seq.: 5
Comprimento da sequência: 12
Tipo de sequência: Nucleótido, análogo de nucleótido Número de cadeias: Cadeia simples Topologia: Linear Sequência: 5'-GCGTTTTTXGCT-3' N.° ID Seq.: 6 Comprimento da sequência: 12
Tipo de sequência: Nucleótido, análogo de nucleótido Número de cadeias: Cadeia simples Topologia: Linear Sequência: 5'-GCGXXTTTTGCT-3' N.° ID Seq.: 7
Comprimento da sequência: 12
Tipo de sequência: Nucleótido, análogo de nucleótido Número de cadeias: Cadeia simples Topologia: Linear 61 ΡΕ1013661
Sequência: 5' 1-GCGTTXXTTGCT-3' N.0 ID Seq.: 8
Comprimento da sequência: 12
Tipo de sequência: Nucleótido, análogo de nucleótido Número de cadeias: Cadeia simples Topologia: Linear
Sequência: 5' 1-GCGTTTTXXGCT-3’ N.° ID Seq.: 9
Comprimento da sequência: 12
Tipo de sequência: Nucleótido, análogo de nucleótido Número de cadeias: Cadeia simples Topologia: Linear
Sequência: 5' 1-GCGXXXXXXGCT-3' N.° ID Seq.: 10
Comprimento da sequência: 13
Tipo de sequência: Nucleótido, análogo de nucleótido Número de cadeias: Cadeia simples Topologia: Linear
Sequência: 5' ,-gtttttttttttc-3' N.0 ID Seq.: 11
Comprimento da sequência: 13
Tipo de sequência: Nucleótido, análogo de nucleótido Número de cadeias: Cadeia simples Topologia: Linear Sequência: 5' -GTTTTTTTTXXTC-3' 62 ΡΕ1013661
Listagem de Sequências <110> <12 0> <130> Imanishi, Takeshi Biciclonucleósido inovador e análogo de oligonucleótido <14 0> <141> <150> <151> <160> 98905804.5 1998-03-09 JPA 53409/97 1997-03-07 11 <210> <211> 1 12
<212> ADN <213> <22 0> <221> <222> <223> Sequência Artificial Λ o o V gcgttttttgct <210> 2 <211> 12
<212> ADN <213> <22 0> Sequência Artificial <221> <222> <223> base modificada <400> gcgntttttgct <210> <211> 3 12
<212> ADN
<213> <22 0> Sequência Artificial <221> <222> <223> base modificada <400> gcgttntttgct <210> <211> 4 12 <212> <213> <22 0> <221> ADN Sequência Artificial <222> <223> base modificada <400> gcgtttnttgct <210> <211> 5 12 <212> ADN 63 ΡΕ1013661 <213> Sequência Artificial <22 0> <221> base modificada <222> <223> <400> gcgtttttngct
<210> 6 <211> 12 <212> ADN <213> Sequência Artificial <22 0> <221> <222> base modificada <223> <400> gcgnnttttgct
<210> 7 <211> 12 <212> ADN <213> Sequência Artificial <22 0> <221> <222> base modificada <223> <400> gcgttnnttgct
<210> 8 <211> 12 <212> ADN <213> Sequência Artificial <22 0> <221> <222> base modificada <223> <400> gcgttttnngct
<210> 9 <211> 12 <212> ADN <213> Sequência Artificial <22 0> <221> <222> base modificada <223> <400> gcgnnnnnngct
<210> 10 <211> 13 <212> ADN <213> Sequência Artificial <22 0> <221> <222> <223> 64 ΡΕ1013661 Λ o o V gtttttttttttc <210> 11 <211> 13 <212> ADN <213> Sequência Artificial <22 0> <221> <222> base modificada <223> Λ o o V gttttttttnntc
Lisboa, 15 de Março de 2012
Claims (16)
- ΡΕ1013661 1 REIVINDICAÇÕES 1. Um análogo do nucleósido com a fórmula geral (I) seguinte(D em que B seja uma base de ácido nucleico de pirimidina ou de purina, ou um seu análogo, e X e Y sejam idênticos ou diferentes, e cada um destes representa um átomo de hidrogénio, um grupo alquilo, um grupo alcenilo, um grupo alcinilo, um grupo cicloalquilo, um grupo aral-quilo, um grupo arilo, um grupo acilo, ou um grupo sililo, ou um seu derivado de amidito.
- 2. Um análogo de nucleósido de acordo com a reivindicação 1, em que a base de ácido nucleico de pirimidina ou de purina seja seleccionada de entre tiamina, uracilo, citosina, adenina, guanina, ou um seu derivado.
- 3. Um análogo de nucleósido de acordo com a reivindicação 1, em que a base de ácido nucleico de pirimidina ou de purina seja tiamina, ou um seu derivado.
- 4. Um análogo de nucleósido de acordo com a 2 ΡΕ1013661 reivindicação 1, em que a base de ácido nucleico de pirimidina ou de purina seja uracilo, ou um seu derivado.
- 5. Um análogo de nucleósido de acordo com a reivindicação 1, em que a base de ácido nucleico de pirimidina ou de purina seja citosina, ou um seu derivado.
- 6. Um análogo de nucleósido de acordo com a reivindicação 1, em que a base de ácido nucleico de pirimidina ou de purina seja adenina, ou um seu derivado.
- 7. Um análogo de nucleósido de acordo com a reivindicação 1, em que a base de ácido nucleico de pirimidina ou de purina seja guanina, ou um seu derivado.
- 8. Um análogo de nucleósido de acordo com qualquer uma das reivindicações 1-3 com a fórmula geral (li) seguinteem que B seja uma base de ácido nucleico de pirimidina ou de purina, ou um seu análogo, e X e Y sejam idênticos ou diferentes, e cada um destes representa um átomo de hidrogénio, um grupo alquilo, 3 ΡΕ1013661 um grupo alcenilo, um grupo alcinilo, um grupo cicloal-quilo, um grupo aralquilo, um grupo arilo, um grupo acilo, ou um grupo sililo, ou um seu derivado; em que a referida base de ácido nucleico de pirimidina ou de purina seja timina.
- 9. Um análogo de nucleósido de acordo com qualquer uma das reivindicações 1, 2 e 4 com a fórmula geral (Iii) seguinteem que B seja uma base de ácido nucleico de pirimidina ou de purina, ou um seu análogo, e X e Y sejam idênticos ou diferentes, e cada um destes representa um átomo de hidrogénio, um grupo alquilo, um grupo alcenilo, um grupo alcinilo, um grupo cicloalquilo, um grupo aralquilo, um grupo arilo, um grupo acilo, ou um grupo sililo, ou um seu derivado de amidito; em que a referida base de ácido nucleico de pirimidina ou de purina seja uracilo.
- 10. Um análogo de nucleósido de acordo com qualquer uma das reivindicações 1, 2 e 5 com a fórmula geral (Iiii) seguinte 4 ΡΕ1013661em que B seja uma base de ácido nucleico de pirimidina ou de purina, ou um seu derivado, e X e Y sejam idênticos ou diferentes, e cada um destes representa um átomo de hidrogénio, um grupo alquilo, um grupo alcenilo, um grupo alcinilo, um grupo ciclo-alquilo, um grupo aralquilo, um grupo arilo, um grupo acilo, ou um grupo sililo, ou um seu derivado de amidito; em que a referida base de ácido nucleico de pirimidina ou de purina seja citosina.
- 11. Um análogo de nucleósido de acordo com qualquer uma das reivindicações 1, 2 e 6 com a fórmula geral (Iiv) seguinteem que B seja uma base de ácido nucleico de pirimidina ou de purina, ou um seu derivado, e 5 ΡΕ1013661 X e Y sejam idênticos ou diferentes, e cada um destes representa um átomo de hidrogénio, um grupo alquilo, um grupo alcenilo, um grupo alcinilo, um grupo cicloal-quilo, um grupo aralquilo, um grupo arilo, um grupo acilo, ou um grupo sililo, ou um seu derivado de amidito; em que a referida base de ácido nucleico de pirimidina ou de purina seja adenina.
- 12. Um análogo de nucleósido de acordo com qualquer uma das reivindicações 1, 2 e 7 com a fórmula geral (Iv) seguinteem que B seja uma base de ácido nucleico de pirimidina ou de purina, ou um seu derivado, e X e Y sejam idênticos ou diferentes, e cada um destes representa um átomo de hidrogénio, um grupo alquilo, um grupo alcenilo, um grupo alcinilo, um grupo cicloal-quilo, um grupo aralquilo, um grupo arilo, um grupo acilo, ou um grupo sililo, ou um seu derivado de amidito; em que a referida base de ácido nucleico de pirimidina ou de purina seja guanina. 6 ΡΕ1013661
- 13. Um análogo de nucleósido tal como se reivindica em qualquer uma das reivindicações 1 a 12, em que X e Y representem cada qual um átomo de hidrogénio.
- 14. Um análogo de nucleósido tal como se reivindica em qualquer uma das reivindicações 1 a 12 que seja um derivado de amidito de mononucleósido, em que X seja 4,4-dimetoxitritilo (DMTr), e Y seja um grupo 2-cianoetoxi(di-isopropilamino)fosfino (grupo amidito).
- 15. Um análogo de nucleósido tal como se reivindica na reivindicação 1, em que o grupo aralquilo seja seleccionado de entre tritilo, benzilo, fenetilo, tritil-metilo, difenilmetilo, naftilmetilo e 4,4'-dimetoxitritilo (DMTr).
- 16. Um análogo de nucleósido de acordo com a reivindicação 1 que seja seleccionado de entre os seguintes :ΡΕ1013661 7 οTBDPSOv. . »Βη 37:Β-Τ 42:3mABx 4β: 8=G®U 38: Β=Τ 43: ΒβΑ®* 47: B-G10" 39a: Β«=Τ 39b: BaA02 39c: BaGíaj Lisboa, 15 de Março de 2012
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5340997 | 1997-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1013661E true PT1013661E (pt) | 2012-03-28 |
Family
ID=12942037
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT101729713T PT2295441E (pt) | 1997-03-07 | 1998-03-09 | Novo biciclonucleosido e análogo de oligonucleotido |
| PT98905804T PT1013661E (pt) | 1997-03-07 | 1998-03-09 | 2'-o,4'-c-metileno-biciclonucleósidos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT101729713T PT2295441E (pt) | 1997-03-07 | 1998-03-09 | Novo biciclonucleosido e análogo de oligonucleotido |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6268490B1 (pt) |
| EP (3) | EP1013661B2 (pt) |
| JP (1) | JP3756313B2 (pt) |
| AT (1) | ATE541576T2 (pt) |
| AU (1) | AU720472B2 (pt) |
| CA (1) | CA2283509C (pt) |
| DE (1) | DE98905804T1 (pt) |
| DK (3) | DK1013661T4 (pt) |
| ES (3) | ES2380354T5 (pt) |
| PT (2) | PT2295441E (pt) |
| WO (1) | WO1998039352A1 (pt) |
Families Citing this family (1208)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119184B2 (en) * | 1991-08-12 | 2006-10-10 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
| US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| USRE44779E1 (en) | 1997-03-07 | 2014-02-25 | Santaris Pharma A/S | Bicyclonucleoside and oligonucleotide analogues |
| JP3756313B2 (ja) † | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| CA2303299C (en) * | 1997-09-12 | 2016-02-23 | Exiqon A/S | Oligonucleotide analogues |
| RU2243231C2 (ru) * | 1997-09-12 | 2004-12-27 | Эксикон А/С | Бициклические аналоги нуклеозидов, нуклеотидов и олигонуклеотидов |
| US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
| US6583168B1 (en) | 1997-11-25 | 2003-06-24 | Applera Corporation | Sulfonated diarylrhodamine dyes |
| EP1082012A4 (en) * | 1998-05-26 | 2002-01-16 | Icn Pharmaceuticals | NEW NUCLEOSIDES WITH BICYCLICAL SUGAR PART |
| PT1152009E (pt) | 1999-02-12 | 2005-03-31 | Sankyo Co | Novos analogos de nucleosidos e oligonucleotidos |
| JP4148662B2 (ja) * | 2000-08-10 | 2008-09-10 | 第一三共株式会社 | ヌクレオシド及びオリゴヌクレオチド類縁体を含有する核酸試薬及び医薬 |
| JP5095888B2 (ja) | 1999-03-18 | 2012-12-12 | エクシコン エ／エス | 特異的ｌｎａプライマによる遺伝子内における突然変異の検出 |
| US7084125B2 (en) * | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
| US6436640B1 (en) * | 1999-03-18 | 2002-08-20 | Exiqon A/S | Use of LNA in mass spectrometry |
| JP4975905B2 (ja) | 1999-03-18 | 2012-07-11 | エクシコン エ／エス | 複合生物試料における核酸の単工程調製及び検出 |
| EP1161439B1 (en) * | 1999-03-18 | 2010-04-21 | Exiqon A/S | Xylo-lna analogues |
| US6734291B2 (en) * | 1999-03-24 | 2004-05-11 | Exiqon A/S | Synthesis of [2.2.1]bicyclo nucleosides |
| DK1163250T3 (da) * | 1999-03-24 | 2006-11-13 | Exiqon As | Forbedret syntese af [2.2.1]bicyclonukleosider |
| US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| NZ514348A (en) * | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
| JP4151751B2 (ja) * | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
| AU3041701A (en) * | 1999-12-23 | 2001-07-09 | Exiqon A/S | Therapeutic uses of lna-modified oligonucleotides |
| US6887664B2 (en) | 2000-06-06 | 2005-05-03 | Applera Corporation | Asynchronous primed PCR |
| AU2001271042A1 (en) * | 2000-07-19 | 2002-01-30 | Chugai Seiyaku Kabushiki Kaisha | Novel antisense oligonucleotide derivatives against wilms's tumor gene |
| JP2002322192A (ja) * | 2000-08-10 | 2002-11-08 | Sankyo Co Ltd | ２’−ｏ，４’−ｃ−架橋ヌクレオシドトリリン酸体 |
| US7053199B2 (en) * | 2000-08-29 | 2006-05-30 | Takeshi Imanishi | Nucleoside analogs and oligonucleotide derivatives containing these analogs |
| WO2002028875A2 (en) * | 2000-10-04 | 2002-04-11 | Cureon A/S | Improved synthesis of purine locked nucleic acid analogues |
| AU2002303176A1 (en) * | 2001-03-27 | 2002-10-15 | University Of Delaware | Genomics applications for modified oligonucleotides |
| EP1251183A3 (en) * | 2001-04-18 | 2003-12-10 | Exiqon A/S | Improved helper probes for detection of a target sequence by a capture oligonucleotide |
| KR100576674B1 (ko) | 2001-06-20 | 2006-05-10 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
| AU2002315393A1 (en) | 2001-06-21 | 2003-01-08 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
| US6822088B2 (en) | 2001-07-17 | 2004-11-23 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides on solid support |
| AU2002365115A1 (en) | 2001-07-20 | 2003-09-02 | North Carolina State University | Light addressable electrochemical detection of duplex structures |
| US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
| US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
| US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US20040096880A1 (en) * | 2001-08-07 | 2004-05-20 | Kmiec Eric B. | Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
| US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
| JPWO2003025173A1 (ja) * | 2001-09-17 | 2004-12-24 | 武 今西 | Ｃ型肝炎ウイルスに対する新規なアンチセンスオリゴヌクレオチド誘導体 |
| ES2431929T3 (es) | 2001-09-18 | 2013-11-28 | Genentech, Inc. | Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores |
| US7468244B2 (en) * | 2001-09-27 | 2008-12-23 | University Of Delaware | Polymorphism detection and separation |
| EP1448766A2 (en) * | 2001-09-27 | 2004-08-25 | University Of Delaware | Coisogenic eukaryotic cell collections |
| US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
| EP2270231A3 (en) | 2001-10-09 | 2011-04-27 | ISIS Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
| WO2003033696A1 (en) * | 2001-10-18 | 2003-04-24 | Sankyo Company, Limited | Vegf antisense compound |
| WO2003040395A2 (en) * | 2001-11-07 | 2003-05-15 | Applera Corporation | Universal nucleotides for nucleic acid analysis |
| AU2002362013B2 (en) | 2001-11-21 | 2008-04-24 | Applied Biosystems, Llc. | Digital assay |
| US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
| CA2471218A1 (en) * | 2001-12-21 | 2003-07-24 | Applera Corporation | Heteroconfigurational polynucleotide and methods of use |
| EP2067472A1 (en) | 2002-01-02 | 2009-06-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| EP3415625A1 (en) | 2002-02-01 | 2018-12-19 | Life Technologies Corporation | Double-stranded oligonucleotides |
| US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| WO2003064621A2 (en) | 2002-02-01 | 2003-08-07 | Ambion, Inc. | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| EP1481983A4 (en) * | 2002-02-13 | 2008-04-02 | Takeshi Imanishi | NUCLEOSIDE ANALOGUE AND OLIGONUCLEOTIDE DERIVATIVES CONTAINING A NUCLEOTIDE ANALOGON THEREOF |
| AU2003220119A1 (en) | 2002-03-07 | 2003-09-22 | University Of Delaware | Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea |
| US20030198960A1 (en) * | 2002-04-01 | 2003-10-23 | Wenhong Fan | Signal amplifying targeted reporters for biological and chemical sensor applications |
| US7211382B2 (en) * | 2002-04-09 | 2007-05-01 | Orchid Cellmark Inc. | Primer extension using modified nucleotides |
| CA2481507A1 (en) | 2002-04-16 | 2003-10-30 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
| US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
| US20040248094A1 (en) * | 2002-06-12 | 2004-12-09 | Ford Lance P. | Methods and compositions relating to labeled RNA molecules that reduce gene expression |
| AU2003276666A1 (en) * | 2002-06-12 | 2003-12-31 | Ambion, Inc. | Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference |
| US20100075423A1 (en) * | 2002-06-12 | 2010-03-25 | Life Technologies Corporation | Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference |
| US7005265B1 (en) | 2002-06-20 | 2006-02-28 | Wenhong Fan | Nonenzymatic catalytic signal amplification for nucleic acid hybridization assays |
| JP2005538186A (ja) | 2002-09-13 | 2005-12-15 | レプリコール インコーポレーティッド | 非配列相補性の抗ウイルス性オリゴヌクレオチド |
| AU2003278957A1 (en) | 2002-09-26 | 2004-04-23 | Amgen, Inc. | Modulation of forkhead box o1a expression |
| US20040175722A1 (en) * | 2002-10-07 | 2004-09-09 | Kmiec Eric B. | Methods and compositions for reducing screening in oligonucleotide-directed nucleic acid sequence alteration |
| US20040219565A1 (en) | 2002-10-21 | 2004-11-04 | Sakari Kauppinen | Oligonucleotides useful for detecting and analyzing nucleic acids of interest |
| WO2004043979A2 (en) * | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| WO2004041889A2 (en) | 2002-11-05 | 2004-05-21 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| EP2336318B1 (en) | 2002-11-13 | 2013-04-24 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
| ES2417879T3 (es) | 2002-11-13 | 2013-08-09 | Genzyme Corporation | Modulación antisentido de la expresión de la apolipoproteína B |
| US9045518B2 (en) | 2002-11-18 | 2015-06-02 | Santaris Pharma A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
| TWI347948B (en) * | 2002-11-19 | 2011-09-01 | Sankyo Co | Novel 2',5'-oligoadenylic acid compositions |
| JP5132025B2 (ja) * | 2002-11-19 | 2013-01-30 | 第一三共株式会社 | 新規２’，５’−オリゴアデニル酸類縁体 |
| US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
| US7468356B2 (en) | 2003-02-11 | 2008-12-23 | Antisense Therapeutics Ltd. | Modulation of insulin like growth factor I receptor expression |
| US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
| EP1608967A4 (en) | 2003-04-01 | 2006-08-09 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS |
| US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
| ATE542917T1 (de) | 2003-05-19 | 2012-02-15 | Gen Probe Inc | Zusammensetzungen, verfahren und kits zur bestimmung des vorhandenseins von trichomonas vaginalis in einer testprobe |
| CN1984921B (zh) | 2003-06-03 | 2010-06-16 | Isis药物公司 | 存活蛋白表达的调节 |
| ATE553216T1 (de) * | 2003-06-20 | 2012-04-15 | Exiqon As | Sonden, bibliotheken und kits zur analyse von nukleinsäuregemischen und verfahren zu deren konstruktion |
| EP2530157B1 (en) | 2003-07-31 | 2016-09-28 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of miRNAs |
| US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
| SG146682A1 (en) | 2003-09-18 | 2008-10-30 | Isis Pharmaceuticals Inc | Modulation of eif4e expression |
| US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
| ATE404697T1 (de) | 2003-11-07 | 2008-08-15 | Daiichi Sankyo Co Ltd | Verfahren zum nachweis von genetischem polymorphismus |
| PL2295073T3 (pl) | 2003-11-17 | 2014-09-30 | Genentech Inc | Przeciwciało przeciwko CD22 do leczenia nowotworu pochodzącego z układu krwiotwórczego |
| US7504495B2 (en) | 2003-11-20 | 2009-03-17 | Exiqon A/S | Quencher compositions comprising anthraquinone moieties |
| US7972783B2 (en) * | 2003-11-24 | 2011-07-05 | Branhaven LLC | Method and markers for determining the genotype of horned/polled cattle |
| WO2005071080A2 (en) | 2004-01-20 | 2005-08-04 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
| US7468431B2 (en) | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
| US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
| US8790919B2 (en) | 2004-03-15 | 2014-07-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for optimizing cleavage of RNA by RNase H |
| US8192937B2 (en) * | 2004-04-07 | 2012-06-05 | Exiqon A/S | Methods for quantification of microRNAs and small interfering RNAs |
| US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| EP2071031B1 (en) | 2004-08-27 | 2013-10-09 | Gen-Probe Incorporated | Single-primer nucleic acid amplification methods |
| US7713697B2 (en) * | 2004-08-27 | 2010-05-11 | Gen-Probe Incorporated | Methods and kits for amplifying DNA |
| US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
| US20060073506A1 (en) | 2004-09-17 | 2006-04-06 | Affymetrix, Inc. | Methods for identifying biological samples |
| EP1645640B1 (en) | 2004-10-05 | 2013-08-21 | Affymetrix, Inc. | Method for detecting chromosomal translocations |
| US7682782B2 (en) | 2004-10-29 | 2010-03-23 | Affymetrix, Inc. | System, method, and product for multiple wavelength detection using single source excitation |
| WO2006059507A1 (ja) * | 2004-11-30 | 2006-06-08 | Sankyo Company, Limited | 11β-HSD1アンチセンス化合物 |
| US20060166238A1 (en) * | 2004-12-22 | 2006-07-27 | Ramsing Niels B | Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same |
| US20060142228A1 (en) * | 2004-12-23 | 2006-06-29 | Ambion, Inc. | Methods and compositions concerning siRNA's as mediators of RNA interference |
| US20070099196A1 (en) * | 2004-12-29 | 2007-05-03 | Sakari Kauppinen | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs |
| US20060228726A1 (en) | 2005-01-06 | 2006-10-12 | Martin Patrick K | Polypeptides having nucleic acid binding activity and compositions and methods for nucleic acid amplification |
| EP2236628A3 (en) | 2005-02-01 | 2010-10-13 | AB Advanced Genetic Analysis Corporation | Reagents, methods and libraries for bead-based sequencing |
| EP2272983A1 (en) | 2005-02-01 | 2011-01-12 | AB Advanced Genetic Analysis Corporation | Reagents, methods and libraries for bead-based sequencing |
| EP1869076A2 (en) | 2005-03-10 | 2007-12-26 | Genentech, Inc. | Methods and compositions for modulating vascular integrity |
| US20070065840A1 (en) * | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
| WO2006138145A1 (en) | 2005-06-14 | 2006-12-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
| ATE489473T1 (de) | 2005-07-15 | 2010-12-15 | Life Technologies Corp | Analyse von boten-rna und mikro-rna im gleichen reaktionsansatz |
| WO2007011901A2 (en) | 2005-07-15 | 2007-01-25 | Applera Corporation | Hot start reverse transcription by primer design |
| US20100015604A1 (en) | 2005-08-17 | 2010-01-21 | Evriklia Lianidou | Composition and method for determination of ck19 expression |
| WO2007027775A2 (en) | 2005-08-29 | 2007-03-08 | Isis Pharmaceuticals, Inc. | Methods for use in modulating mir-122a |
| DK1931780T3 (en) | 2005-08-29 | 2016-01-25 | Regulus Therapeutics Inc | Antisense-forbindelser med forøget anti-microrna-aktivitet |
| JP4741328B2 (ja) * | 2005-09-08 | 2011-08-03 | クラリオン株式会社 | ナビゲーション装置 |
| US20070059713A1 (en) | 2005-09-09 | 2007-03-15 | Lee Jun E | SSB-DNA polymerase fusion proteins |
| WO2007041201A2 (en) | 2005-10-03 | 2007-04-12 | Applera Corporation | Compositions, methods, and kits for amplifying nucleic acids |
| EP1960536B1 (en) | 2005-11-30 | 2013-06-26 | St. Anna Kinderkrebsforschung | Detection of fungi |
| EP3000480A1 (en) | 2005-12-01 | 2016-03-30 | ProNAi Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
| WO2007073149A1 (en) | 2005-12-22 | 2007-06-28 | Keygene N.V. | Alternative nucleotides for improved targeted nucleotide exchange |
| JP5713377B2 (ja) | 2005-12-28 | 2015-05-07 | ザ スクリプス リサーチ インスティテュート | 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物 |
| EP1966390A1 (en) * | 2005-12-29 | 2008-09-10 | Exiqon A/S | Detection of tissue origin of cancer |
| SI2161038T1 (sl) | 2006-01-26 | 2014-05-30 | Isis Pharmaceuticals, Inc. | Sestavki in njihove uporabe, usmerjeni proti huntingtinu |
| US7569686B1 (en) | 2006-01-27 | 2009-08-04 | Isis Pharmaceuticals, Inc. | Compounds and methods for synthesis of bicyclic nucleic acid analogs |
| US8129515B2 (en) | 2006-01-27 | 2012-03-06 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
| ES2351674T3 (es) | 2006-01-27 | 2011-02-09 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en la posición 6. |
| US9677123B2 (en) | 2006-03-15 | 2017-06-13 | Siemens Healthcare Diagnostics Inc. | Degenerate nucleobase analogs |
| JP2009538123A (ja) * | 2006-04-19 | 2009-11-05 | アプライド バイオシステムズ， エルエルシー | ゲル非含有ビーズベースの配列決定のための試薬、方法およびライブラリー |
| US20090304704A1 (en) | 2006-05-03 | 2009-12-10 | Geisinger Clinic | Methods for diagnosing and predicting non-alcoholic steatohepatitis (nash) |
| DK2021472T3 (da) | 2006-05-05 | 2011-09-19 | Isis Pharmaceuticals Inc | Forbindelser og fremgangsmåder til modulering af genekspression |
| EP2505648A1 (en) | 2006-05-05 | 2012-10-03 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of PTP1B |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| US7666854B2 (en) * | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| US20090023221A1 (en) * | 2006-05-19 | 2009-01-22 | Exigon A/S | Oligonucleotide probes useful for detection and analysis of microrna precursors |
| WO2007146154A1 (en) | 2006-06-06 | 2007-12-21 | Gen-Probe Incorporated | Tagged oligonucleotides and their use in nucleic acid amplification methods |
| US20080076674A1 (en) * | 2006-07-06 | 2008-03-27 | Thomas Litman | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer |
| WO2008011473A2 (en) | 2006-07-19 | 2008-01-24 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hbxip |
| EP2484781B1 (en) | 2006-08-01 | 2017-08-23 | Applied Biosystems, LLC | Detection of analytes and nucleic acids |
| JP5244103B2 (ja) | 2006-08-09 | 2013-07-24 | ホームステッド クリニカル コーポレイション | 器官特異的蛋白質およびその使用方法 |
| JP5560039B2 (ja) | 2006-10-05 | 2014-07-23 | マサチューセッツ インスティテュート オブ テクノロジー | ハイスループット分析のための多機能のコード化された粒子 |
| CA2667055C (en) | 2006-10-18 | 2017-05-09 | Isis Pharmaceuticals, Inc. | Antisense compounds |
| AU2007310982A1 (en) * | 2006-10-18 | 2008-04-24 | Marina Biotech, Inc. | Nicked or gapped nucleic acid molecules and uses thereof |
| US8188255B2 (en) | 2006-10-20 | 2012-05-29 | Exiqon A/S | Human microRNAs associated with cancer |
| WO2008046911A2 (en) | 2006-10-20 | 2008-04-24 | Exiqon A/S | Novel human micrornas associated with cancer |
| US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| EP2455471A3 (en) | 2006-11-27 | 2012-09-12 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| US8293684B2 (en) * | 2006-11-29 | 2012-10-23 | Exiqon | Locked nucleic acid reagents for labelling nucleic acids |
| EP3536788A1 (en) | 2006-12-21 | 2019-09-11 | QIAGEN GmbH | Microrna target site blocking oligos and uses thereof |
| US8048998B2 (en) | 2007-01-19 | 2011-11-01 | Exiqon A/S | Mediated cellular delivery of LNA oligonucleotides |
| WO2009045469A2 (en) | 2007-10-02 | 2009-04-09 | Amgen Inc. | Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof |
| AU2008212820B2 (en) | 2007-02-09 | 2014-01-30 | Northwestern University | Particles for detecting intracellular targets |
| WO2008104978A2 (en) * | 2007-02-28 | 2008-09-04 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| US8183359B2 (en) * | 2007-03-01 | 2012-05-22 | Gen-Probe Incorporated | Kits for amplifying DNA |
| US20100112687A1 (en) * | 2007-03-02 | 2010-05-06 | Mdrna, Inc. | Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof |
| WO2009029293A2 (en) * | 2007-03-02 | 2009-03-05 | Mdrna, Inc. | Nucleic acid compounds for inhibiting myc gene expression and uses thereof |
| US20100105134A1 (en) * | 2007-03-02 | 2010-04-29 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
| WO2008109377A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof |
| EP2126081A2 (en) * | 2007-03-02 | 2009-12-02 | MDRNA, Inc. | Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof |
| US20080293136A1 (en) * | 2007-03-02 | 2008-11-27 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting akt gene expression and uses thereof |
| WO2008109518A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting wnt gene expression and uses thereof |
| WO2008109449A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna Inc. | Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof |
| WO2008109357A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting apob gene expression and uses thereof |
| WO2008109362A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting vegf gene expression and uses thereof |
| US20090041809A1 (en) * | 2007-03-07 | 2009-02-12 | Nventa Biopharmaceuticals Corporation | Double-stranded locked nucleic acid compositions |
| US8461124B2 (en) * | 2007-03-15 | 2013-06-11 | Jyoti Chattopadhyaya | Five- and six-membered conformationally locked 2′,4′-carbocyclic ribo-thymidines for the treatment of infections and cancer |
| EP1978111B1 (en) | 2007-04-02 | 2013-03-27 | Gen-Probe Incorporated | Compositions, kits and related methods for the detection and/or monitoring of Pseudomonas aeruginosa |
| FR2915208A1 (fr) | 2007-04-20 | 2008-10-24 | Millipore Corp | Composition comprenant l'association d'edta et de pei pour augmenter la permeabilite des parois des microorganismes et utilisations de ladite composition |
| US8999634B2 (en) | 2007-04-27 | 2015-04-07 | Quest Diagnostics Investments Incorporated | Nucleic acid detection combining amplification with fragmentation |
| EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| AU2008259907B2 (en) | 2007-05-30 | 2014-12-04 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
| US9598724B2 (en) | 2007-06-01 | 2017-03-21 | Ibis Biosciences, Inc. | Methods and compositions for multiple displacement amplification of nucleic acids |
| US7807372B2 (en) | 2007-06-04 | 2010-10-05 | Northwestern University | Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay |
| EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| WO2008151631A2 (en) * | 2007-06-15 | 2008-12-18 | Exiqon A/S | Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis |
| EP2176280B2 (en) * | 2007-07-05 | 2015-06-24 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| CN101849008A (zh) | 2007-09-19 | 2010-09-29 | 应用生物系统有限公司 | 用于减少RNAi中的脱靶表型效应的siRNA的不依赖于序列的修饰形式和其稳定形式 |
| CN103898110A (zh) * | 2007-10-03 | 2014-07-02 | 夸克制药公司 | 新siRNA结构 |
| WO2009059430A1 (en) * | 2007-11-07 | 2009-05-14 | The University Of British Columbia | Microfluidic device and method of using same |
| US8017338B2 (en) | 2007-11-20 | 2011-09-13 | Life Technologies Corporation | Reversible di-nucleotide terminator sequencing |
| WO2009067632A1 (en) * | 2007-11-20 | 2009-05-28 | Applied Biosystems Inc. | Method of sequencing nucleic acids using elaborated nucleotide phosphorothiolate compounds |
| WO2009067647A1 (en) * | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| US10365224B2 (en) | 2007-12-06 | 2019-07-30 | Genalyte, Inc. | Label-free optical sensors |
| US20110105584A1 (en) * | 2007-12-12 | 2011-05-05 | Elena Feinstein | Rtp80il sirna compounds and methods of use thereof |
| US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
| US8911946B2 (en) | 2007-12-21 | 2014-12-16 | Gen-Probe Incorporated | Detection of antibiotic-resistant microorganisms |
| EP2242854A4 (en) * | 2008-01-15 | 2012-08-15 | Quark Pharmaceuticals Inc | COMPOUNDS AND USES THEREOF |
| JPWO2009093384A1 (ja) * | 2008-01-24 | 2011-05-26 | 独立行政法人産業技術総合研究所 | ポリヌクレオチド及びポリヌクレオチド類似体並びにこれらを用いた遺伝子発現制御方法 |
| WO2009100320A2 (en) * | 2008-02-07 | 2009-08-13 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
| US20090215050A1 (en) * | 2008-02-22 | 2009-08-27 | Robert Delmar Jenison | Systems and methods for point-of-care amplification and detection of polynucleotides |
| CA2718765A1 (en) * | 2008-03-20 | 2009-09-24 | Quark Pharmaceuticals, Inc. | Novel sirna compounds for inhibiting rtp801 |
| US20100113284A1 (en) * | 2008-04-04 | 2010-05-06 | Alexander Aristarkhov | Small interfering rna (sirna) target site blocking oligos and uses thereof |
| WO2009124238A1 (en) * | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides |
| US20090326049A1 (en) * | 2008-04-04 | 2009-12-31 | Alexander Aristarkhov | Blocking oligos for inhibition of microrna and sirna activity and uses thereof |
| US8846639B2 (en) | 2008-04-04 | 2014-09-30 | Isis Pharmaceutical, Inc. | Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
| US8278287B2 (en) * | 2008-04-15 | 2012-10-02 | Quark Pharmaceuticals Inc. | siRNA compounds for inhibiting NRF2 |
| DK2281042T3 (en) | 2008-04-18 | 2015-11-09 | Baxter Int | Microsphere-based composition for preventing and / or deletion of starting autoimmune diabetes |
| WO2009140374A2 (en) | 2008-05-13 | 2009-11-19 | Gen-Probe Incorporated | Inactivatable target capture oligomers for use in the selective hybridization and capture of target nucleic acid sequences |
| EP2297358A2 (en) | 2008-05-30 | 2011-03-23 | Gen-Probe Incorporated | Compositions, kits and related methods for the detection and/or monitoring of salmonella |
| US8222221B2 (en) | 2008-06-04 | 2012-07-17 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small RNA targeting of gene promoters |
| WO2009147684A2 (en) | 2008-06-06 | 2009-12-10 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
| CA2732343C (en) | 2008-07-29 | 2017-05-09 | The Board Of Regents Of The University Of Texas System | Selective inhibition of polyglutamine protein expression |
| SG196769A1 (en) | 2008-08-25 | 2014-02-13 | Excaliard Pharmaceuticals Inc | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
| ES2657696T3 (es) | 2008-08-25 | 2018-03-06 | Excaliard Pharmaceuticals, Inc. | Método para reducir la cicatrización durante la curación de una herida utilizando compuestos antisentido dirigidos al CTGF |
| JP5221248B2 (ja) * | 2008-08-26 | 2013-06-26 | 株式会社日立ハイテクノロジーズ | 高発現遺伝子由来のｃＤＮＡクローンの含有率を低減させたｃＤＮＡライブラリーの作製方法 |
| US8476013B2 (en) | 2008-09-16 | 2013-07-02 | Sequenom, Inc. | Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
| US8962247B2 (en) | 2008-09-16 | 2015-02-24 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses |
| US8501805B2 (en) * | 2008-09-24 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Substituted alpha-L-bicyclic nucleosides |
| CA2739464C (en) | 2008-10-03 | 2020-03-31 | Curna, Inc. | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
| WO2010048585A2 (en) | 2008-10-24 | 2010-04-29 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| ES2939310T3 (es) | 2008-10-27 | 2023-04-20 | Genalyte Inc | Biosensores basados en sondeo y detección ópticos |
| DK2365803T3 (en) | 2008-11-24 | 2018-01-22 | Univ Northwestern | POLYVALENT RNA NANOPARTICLE COMPOSITIONS |
| KR101866152B1 (ko) | 2008-12-04 | 2018-06-08 | 큐알엔에이, 인크. | 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료 |
| KR101829469B1 (ko) | 2008-12-04 | 2018-03-30 | 큐알엔에이, 인크. | Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료 |
| MX2011005912A (es) | 2008-12-04 | 2011-06-17 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular. |
| US20110288155A1 (en) | 2008-12-18 | 2011-11-24 | Elena Feinstein | Sirna compounds and methods of use thereof |
| CN102257147A (zh) | 2008-12-22 | 2011-11-23 | 凯津公司 | 在植物原生质体中使用双链rna提高靶基因改变的效率 |
| US8748133B2 (en) | 2008-12-30 | 2014-06-10 | Gen-Probe Incorporated | Compositions, kits and related methods for the detection and/or monitoring of Listeria |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| DK2381965T3 (da) | 2009-01-14 | 2020-07-27 | Univ Drexel | Modulation af præ-mrna under anvendelse af splejsningsmodulerende oligonukleotider som terapeutiske midler til behandling af sygdom |
| JP5749656B2 (ja) | 2009-02-02 | 2015-07-15 | エクシコン エ／エス | 低分子ｒｎａ種の定量化のための方法 |
| US20120021515A1 (en) | 2009-02-06 | 2012-01-26 | Swayze Eric E | Oligomeric compounds and methods |
| WO2010093904A2 (en) | 2009-02-12 | 2010-08-19 | Curna, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
| EP3118208A1 (en) | 2009-02-26 | 2017-01-18 | Gen-Probe Incorporated | Assay for detection of human parvovirus nuleic acid |
| EP2408919B1 (en) | 2009-03-16 | 2017-10-18 | CuRNA, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
| EP2408920B1 (en) | 2009-03-17 | 2017-03-08 | CuRNA, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
| US8481698B2 (en) * | 2009-03-19 | 2013-07-09 | The President And Fellows Of Harvard College | Parallel proximity ligation event analysis |
| CN102449170A (zh) | 2009-04-15 | 2012-05-09 | 西北大学 | 寡核苷酸功能化的纳米颗粒的递送 |
| EP3248618A1 (en) | 2009-04-22 | 2017-11-29 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
| US8815586B2 (en) | 2009-04-24 | 2014-08-26 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression using oligomers that target gene regions downstream of 3′ untranslated regions |
| WO2010126913A1 (en) | 2009-04-27 | 2010-11-04 | Gen-Probe Incorporated | Methods and kits for use in the selective amplification of target sequences |
| WO2010129746A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
| CN102459596B (zh) | 2009-05-06 | 2016-09-07 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
| WO2010129861A2 (en) | 2009-05-08 | 2010-11-11 | Curna, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
| WO2010135329A2 (en) | 2009-05-18 | 2010-11-25 | Curna, Inc. | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
| US20120142004A1 (en) | 2009-05-21 | 2012-06-07 | Siemens Healthcare Diagnostics Inc. | Universal Tags With Non-Natural Nucleobases |
| CN102549158B (zh) | 2009-05-22 | 2017-09-26 | 库尔纳公司 | 通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病 |
| CA2764683A1 (en) | 2009-05-28 | 2010-12-02 | Joseph Collard | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
| EP2440214A4 (en) | 2009-06-08 | 2013-07-31 | Quark Pharmaceuticals Inc | METHOD FOR THE TREATMENT OF CHRONIC KIDNEY DISEASES |
| CN102612560B (zh) | 2009-06-16 | 2017-10-17 | 库尔纳公司 | 通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病 |
| JP5944311B2 (ja) | 2009-06-16 | 2016-07-05 | クルナ・インコーポレーテッド | コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療 |
| US8859515B2 (en) | 2009-06-24 | 2014-10-14 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2 |
| CA2765815A1 (en) | 2009-06-26 | 2010-12-29 | Opko Curna, Llc | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
| JP2011024434A (ja) | 2009-07-22 | 2011-02-10 | Galaxy Pharma Inc | オリゴヌクレオチドのスクリーニング方法及びオリゴヌクレオチドライブラリー |
| US20120252869A1 (en) | 2009-07-24 | 2012-10-04 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
| WO2011012136A1 (en) | 2009-07-28 | 2011-02-03 | Exiqon A/S | A method for classifying a human cell sample as cancerous |
| JP6128848B2 (ja) | 2009-08-05 | 2017-05-17 | クルナ・インコーポレーテッド | インスリン遺伝子（ｉｎｓ）に対する天然アンチセンス転写物の抑制によるインスリン遺伝子（ｉｎｓ）関連疾患の治療 |
| US9012421B2 (en) | 2009-08-06 | 2015-04-21 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| CA2770104C (en) | 2009-08-11 | 2019-03-19 | Opko Curna, Llc | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
| WO2011022606A2 (en) | 2009-08-21 | 2011-02-24 | Curna, Inc. | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
| KR101892760B1 (ko) | 2009-08-25 | 2018-08-28 | 큐알엔에이, 인크. | ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료 |
| DK2473522T3 (en) | 2009-09-02 | 2016-11-28 | Genentech Inc | Smoothened MUTANT AND METHODS OF USING THE SAME |
| US20110196141A1 (en) * | 2009-09-07 | 2011-08-11 | Council Of Scientific & Industrial Research | Locked and unlocked 2'-o phosphoramidite nucleosides, process of preparation thereof and oligomers comprising the nucleosides |
| KR101802540B1 (ko) | 2009-09-25 | 2017-11-28 | 큐알엔에이, 인크. | Ｆｌｇ의 발현 및 활성을 조절함으로써 필라그린(ｆｌｇ)에 관련된 질환의 치료 |
| US20150025122A1 (en) | 2009-10-12 | 2015-01-22 | Larry J. Smith | Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro |
| EP2957641B1 (en) | 2009-10-15 | 2017-05-17 | Ibis Biosciences, Inc. | Multiple displacement amplification |
| BR112012009409A2 (pt) | 2009-10-22 | 2017-02-21 | Genentech Inc | método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra |
| EP2494066B1 (en) | 2009-10-27 | 2017-04-05 | Swift Biosciences, Inc. | Bimolecular primers |
| US8541562B2 (en) | 2009-10-29 | 2013-09-24 | Osaka University | Bridged artificial nucleoside and nucleotide |
| JP5866119B2 (ja) | 2009-10-30 | 2016-02-17 | ノースウェスタン ユニバーシティ | 鋳型ナノ複合体 |
| WO2011053994A1 (en) | 2009-11-02 | 2011-05-05 | Alnylam Pharmaceuticals, Inc. | Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter |
| US20130084565A1 (en) | 2009-11-03 | 2013-04-04 | University Of Virginia Patent Foundation | Versatile, visible method for detecting polymeric analytes |
| EP2504450B1 (en) | 2009-11-23 | 2016-07-06 | Swift Biosciences, Inc. | Devices to extend single stranded target molecules |
| PE20121584A1 (es) | 2009-11-30 | 2012-11-29 | Genentech Inc | Composiciones y metodos para el diagnostico y el tratamiento de tumores |
| JP5685267B2 (ja) | 2009-12-09 | 2015-03-18 | 日東電工株式会社 | Ｈｓｐ４７発現の調節 |
| EP2510098B1 (en) | 2009-12-09 | 2015-02-11 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
| WO2011084455A2 (en) | 2009-12-16 | 2011-07-14 | Opko Curna, Llc. | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
| WO2011087789A2 (en) | 2009-12-22 | 2011-07-21 | Becton, Dickinson And Company | Methods for the detection of microorganisms |
| DK2516680T3 (en) | 2009-12-22 | 2016-05-02 | Sequenom Inc | Method and kits to identify aneuploidy |
| JP6031356B2 (ja) | 2009-12-23 | 2016-11-24 | カッパーアールエヌエー，インコーポレイテッド | Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療 |
| ES2661387T3 (es) | 2009-12-23 | 2018-03-28 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf |
| JP2011130725A (ja) * | 2009-12-25 | 2011-07-07 | Contig I:Kk | Ｌｎａオリゴヌクレオチドとそれを含有する化粧品 |
| KR101838305B1 (ko) | 2009-12-29 | 2018-03-13 | 큐알엔에이, 인크. | ＮＲＦ1(Ｎｕｃｌｅａｒ Ｒｅｓｐｉｒａｔｏｒｙ Ｆａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료 |
| US8962585B2 (en) | 2009-12-29 | 2015-02-24 | Curna, Inc. | Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63 |
| DK2519632T3 (en) | 2009-12-31 | 2018-07-23 | Curna Inc | TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2- (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3) |
| EP2521784B1 (en) | 2010-01-04 | 2017-12-06 | CuRNA, Inc. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
| CN102822342B (zh) | 2010-01-06 | 2017-05-10 | 库尔纳公司 | 通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病 |
| WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
| CN111700901A (zh) | 2010-01-08 | 2020-09-25 | Ionis制药公司 | 血管生成素样3表达的调节 |
| US9200277B2 (en) | 2010-01-11 | 2015-12-01 | Curna, Inc. | Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG |
| WO2011085102A1 (en) | 2010-01-11 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom |
| EP2524038A4 (en) * | 2010-01-12 | 2013-11-20 | Isis Pharmaceuticals Inc | MODULATION OF TRANSFORMING A GROWTH FACTOR BETA-1 EXPRESSION |
| CN102782135A (zh) | 2010-01-25 | 2012-11-14 | 库尔纳公司 | 通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病 |
| WO2011097388A1 (en) | 2010-02-03 | 2011-08-11 | Alnylam Pharmaceuticals, Inc. | Selective inhibition of polyglutamine protein expression |
| EP2534262B1 (en) | 2010-02-08 | 2016-12-14 | Ionis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| EP3561060A1 (en) | 2010-02-08 | 2019-10-30 | Ionis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| WO2011103528A2 (en) | 2010-02-22 | 2011-08-25 | Opko Curna Llc | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
| NZ601293A (en) | 2010-02-23 | 2014-10-31 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
| WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
| WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
| EP2539356A4 (en) * | 2010-02-26 | 2014-03-05 | Isis Pharmaceuticals Inc | MODULATION OF SMAD3 EXPRESSION |
| EP3214174B1 (en) | 2010-03-04 | 2019-10-16 | InteRNA Technologies B.V. | A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt |
| WO2011113054A2 (en) | 2010-03-12 | 2011-09-15 | Aurasense Llc | Crosslinked polynucleotide structure |
| WO2011112732A2 (en) | 2010-03-12 | 2011-09-15 | The Brigham And Women's Hospital, Inc. | Methods of treating vascular inflammatory disorders |
| WO2011115818A1 (en) | 2010-03-17 | 2011-09-22 | Isis Pharmaceuticals, Inc. | 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
| WO2011120023A1 (en) | 2010-03-26 | 2011-09-29 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting survivin gene expression uses thereof |
| WO2011120046A2 (en) | 2010-03-26 | 2011-09-29 | Swift Biosciences, Inc. | Methods and compositions for isolating polynucleotides |
| CA2795145C (en) | 2010-04-02 | 2019-01-22 | Curna, Inc. | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
| AU2011237630B2 (en) | 2010-04-06 | 2016-01-21 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of CD274/PD-L1 gene |
| KR101900962B1 (ko) | 2010-04-09 | 2018-09-20 | 큐알엔에이, 인크. | 섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료 |
| WO2011133584A2 (en) | 2010-04-19 | 2011-10-27 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting hras gene expression and uses thereof |
| WO2011133695A2 (en) | 2010-04-20 | 2011-10-27 | Swift Biosciences, Inc. | Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment |
| US8278049B2 (en) | 2010-04-26 | 2012-10-02 | Ann & Robert H. Lurie Children's Hospital of Chicago | Selective enrichment of CpG islands |
| WO2011139710A1 (en) | 2010-04-26 | 2011-11-10 | Marina Biotech, Inc. | Nucleic acid compounds with conformationally restricted monomers and uses thereof |
| WO2011139842A2 (en) | 2010-04-28 | 2011-11-10 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof |
| EP2601204B1 (en) | 2010-04-28 | 2016-09-07 | Ionis Pharmaceuticals, Inc. | Modified nucleosides and oligomeric compounds prepared therefrom |
| US9156873B2 (en) | 2010-04-28 | 2015-10-13 | Isis Pharmaceuticals, Inc. | Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom |
| EP3091027B1 (en) | 2010-04-28 | 2018-01-17 | Ionis Pharmaceuticals, Inc. | 5' modified nucleosides and oligomeric compounds prepared therefrom |
| US20130156845A1 (en) | 2010-04-29 | 2013-06-20 | Alnylam Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| HRP20170737T1 (hr) | 2010-04-29 | 2017-07-28 | Ionis Pharmaceuticals, Inc. | Modulacija ekspresije transtiretina |
| EP2563935B1 (en) | 2010-04-30 | 2014-04-16 | Exiqon A/S | In situ hybridization method and buffer. |
| CN102958941A (zh) | 2010-05-03 | 2013-03-06 | 霍夫曼-拉罗奇有限公司 | 用于肿瘤诊断和治疗的组合物和方法 |
| WO2011139387A1 (en) | 2010-05-03 | 2011-11-10 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
| TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病 |
| US20130203045A1 (en) | 2010-05-26 | 2013-08-08 | University Of Virginia Patent Foundation | Method for detecting nucleic acids based on aggregate formation |
| CA2799207C (en) | 2010-05-26 | 2019-03-26 | Curna, Inc. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
| RU2620978C2 (ru) | 2010-05-26 | 2017-05-30 | Курна, Инк. | Лечение заболеваний, связанных с метионинсульфоксидредуктазой а (msra), путем ингибирования природного антисмыслового транскрипта гена msra |
| US9944671B2 (en) | 2010-06-02 | 2018-04-17 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| US9476101B2 (en) | 2010-06-07 | 2016-10-25 | Firefly Bioworks, Inc. | Scanning multifunctional particles |
| WO2011156278A1 (en) | 2010-06-07 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
| WO2011156202A1 (en) | 2010-06-08 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| EP2582397A4 (en) | 2010-06-15 | 2014-10-29 | Isis Pharmaceuticals Inc | COMPOUNDS AND METHOD FOR MODULATING INTERACTION BETWEEN PROTEINS AND TARGET NUCLEIC ACIDS |
| KR101914309B1 (ko) | 2010-06-23 | 2018-11-02 | 큐알엔에이, 인크. | 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료 |
| EP2588629B1 (en) | 2010-06-30 | 2017-05-17 | Gen-Probe Incorporated | Method and apparatus for identifying analyte-containing samples using single-read determination of analyte and process control signals |
| NZ605420A (en) | 2010-07-06 | 2015-02-27 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
| WO2012006551A2 (en) | 2010-07-08 | 2012-01-12 | The Brigham And Women's Hospital, Inc. | Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules |
| NO2593547T3 (pt) | 2010-07-14 | 2018-04-14 | ||
| WO2012009711A2 (en) | 2010-07-16 | 2012-01-19 | Tocagen Inc. | Retrovirus detection |
| EP3489360A3 (en) | 2010-07-19 | 2019-08-28 | Ionis Pharmaceuticals, Inc. | Modulation of nuclear-retained rna |
| EP2412724A1 (en) | 2010-07-29 | 2012-02-01 | Centre National de la Recherche Scientifique (C.N.R.S) | Regulation of Glypican 4 activity to modulate the fate of stem cells and uses thereof |
| US9081737B2 (en) | 2010-08-02 | 2015-07-14 | Integrated Dna Technologies, Inc. | Methods for predicting stability and melting temperatures of nucleic acid duplexes |
| AU2011312205B2 (en) | 2010-10-05 | 2015-08-13 | Curis, Inc. | Mutant smoothened and methods of using the same |
| CA2813901C (en) | 2010-10-06 | 2019-11-12 | Curna, Inc. | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
| CN103517990A (zh) | 2010-10-07 | 2014-01-15 | 通用医疗公司 | 癌症生物标志物 |
| US8648053B2 (en) | 2010-10-20 | 2014-02-11 | Rosalind Franklin University Of Medicine And Science | Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome |
| JP6049623B2 (ja) | 2010-10-22 | 2016-12-21 | カッパーアールエヌエー，インコーポレイテッド | α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療 |
| EP3733866B1 (en) | 2010-11-05 | 2023-11-15 | Genalyte, Inc. | Optical analyte detection systems and methods of use |
| US9416360B2 (en) | 2010-11-05 | 2016-08-16 | MiRagen Therapeutics, Inc. | Base modified oligonucleotides |
| US9150864B2 (en) | 2010-11-08 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| AU2011325956B2 (en) | 2010-11-12 | 2016-07-14 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| WO2012068405A2 (en) | 2010-11-17 | 2012-05-24 | Isis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
| WO2012068519A2 (en) | 2010-11-19 | 2012-05-24 | Sirius Genomics Inc. | Markers associated with response to activated protein c administration, and uses thereof |
| WO2012071238A2 (en) | 2010-11-23 | 2012-05-31 | Opko Curna Llc | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
| CA2819423C (en) | 2010-12-02 | 2020-12-22 | Keygene N.V. | Targeted alteration of dna |
| JP5947309B2 (ja) | 2010-12-02 | 2016-07-06 | キージーン・エン・フェー | オリゴヌクレオチドを用いたｄｎａの標的改変 |
| EP2648763A4 (en) | 2010-12-10 | 2014-05-14 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A |
| US9193973B2 (en) | 2010-12-10 | 2015-11-24 | Alynylam Pharmaceuticals, Inc. | Compositions and methods for increasing erythropoietin (EPO) production |
| AR084319A1 (es) | 2010-12-15 | 2013-05-08 | Miragen Therapeutics | INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS |
| EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
| MX340258B (es) | 2011-01-11 | 2016-07-01 | Seegene Inc | Detección de secuencias de ácido nucleico objetivo mediante ensayo de escisión y extensión del pto. |
| EP2663323B1 (en) | 2011-01-14 | 2017-08-16 | The General Hospital Corporation | Methods targeting mir-128 for regulating cholesterol/lipid metabolism |
| SI2670411T1 (sl) | 2011-02-02 | 2019-06-28 | Excaliard Pharmaceuticals, Inc. | Protismiselne spojine, ki so usmerjene na rastni faktor veznega tkiva (CTGF), za uporabo v postopku zdravljenja keloidov ali hipertrofnih brazgotin |
| DK2670404T3 (en) | 2011-02-02 | 2018-11-19 | Univ Princeton | CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS |
| EP3067421B1 (en) | 2011-02-08 | 2018-10-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
| US9796979B2 (en) | 2011-03-03 | 2017-10-24 | Quark Pharmaceuticals Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| EP2681314B1 (en) | 2011-03-03 | 2017-11-01 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating lung disease and injury |
| WO2012118911A1 (en) | 2011-03-03 | 2012-09-07 | Quark Pharmaceuticals, Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| EP2691543B1 (en) | 2011-03-29 | 2017-11-01 | Seegene, Inc. | Detection of target nucleic acid sequence by pto cleavage and extension-dependent cleavage |
| MX360349B (es) | 2011-03-29 | 2018-10-30 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6). |
| RS58489B1 (sr) | 2011-04-01 | 2019-04-30 | Ionis Pharmaceuticals Inc | Modulacija eksprimiranja transduktora signala i aktivatora transkripcije 3 (stat3) |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| CN105886506A (zh) | 2011-04-13 | 2016-08-24 | Isis制药公司 | Ptp1b 表达的反义调节 |
| US8642752B2 (en) | 2011-04-21 | 2014-02-04 | Isis Pharmaceuticals, Inc. | Modulation of Hepatitis B virus (HBV) expression |
| WO2012149154A1 (en) | 2011-04-26 | 2012-11-01 | Swift Biosciences, Inc. | Polynucleotide primers and probes |
| US9157082B2 (en) | 2011-04-27 | 2015-10-13 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein CIII (ApoCIII) expression |
| EP2702168B1 (en) | 2011-04-29 | 2018-01-17 | Sequenom, Inc. | Quantification of a minority nucleic acid species |
| WO2012151289A2 (en) | 2011-05-02 | 2012-11-08 | University Of Virginia Patent Foundation | Method and system to detect aggregate formation on a substrate |
| WO2012151268A1 (en) | 2011-05-02 | 2012-11-08 | University Of Virginia Patent Foundation | Method and system for high throughput optical and label free detection of analytes |
| WO2012151324A1 (en) | 2011-05-02 | 2012-11-08 | Isis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with usher syndrome |
| MX342067B (es) | 2011-05-04 | 2016-09-09 | Seegene Inc | Detección de secuencias de ácido nucleico objetivo por desdoblamiento e hibridización de oligonucleótido de sonda. |
| TWI658830B (zh) | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Ｈｓｐ47表現調控強化用類視色素脂質體 |
| US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
| RU2620980C2 (ru) | 2011-06-09 | 2017-05-30 | Курна, Инк. | Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn |
| WO2012170347A1 (en) | 2011-06-09 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
| US9315811B2 (en) | 2011-06-10 | 2016-04-19 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
| US9187749B2 (en) | 2011-06-10 | 2015-11-17 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| CA2839437A1 (en) | 2011-06-16 | 2012-12-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
| EP3444348A1 (en) | 2011-06-21 | 2019-02-20 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| WO2012178033A2 (en) | 2011-06-23 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
| CN103765212A (zh) | 2011-06-27 | 2014-04-30 | 杰克逊实验室 | 治疗癌症和自体免疫性疾病的方法和组合物 |
| AU2012275096B2 (en) | 2011-06-29 | 2016-02-04 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
| WO2013019857A2 (en) | 2011-08-01 | 2013-02-07 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
| US10202599B2 (en) | 2011-08-11 | 2019-02-12 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| EP3640332A1 (en) | 2011-08-29 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| EP2751269B1 (en) | 2011-08-29 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| WO2013033658A1 (en) | 2011-09-02 | 2013-03-07 | Northwestern University | Self-assembled nanostructures |
| US10583128B2 (en) | 2011-09-06 | 2020-03-10 | Curna, Inc. | Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules |
| JP2014526517A (ja) | 2011-09-14 | 2014-10-06 | ノースウェスタン ユニバーシティ | 血液脳関門を通過することができるナノ抱合体 |
| JP6129844B2 (ja) | 2011-09-14 | 2017-05-17 | ラナ セラピューティクス インコーポレイテッド | 多量体オリゴヌクレオチド化合物 |
| EP2758533B1 (en) | 2011-09-20 | 2018-04-11 | Ionis Pharmaceuticals, Inc. | Antisense modulation of gcgr expression |
| WO2013044097A1 (en) | 2011-09-21 | 2013-03-28 | Gen-Probe Incorporated | Methods for amplifying nucleic acid using tag-mediated displacement |
| EP2766482B1 (en) | 2011-10-11 | 2016-12-07 | The Brigham and Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| WO2013063313A1 (en) | 2011-10-25 | 2013-05-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of gccr expression |
| EP2773777B1 (en) | 2011-10-31 | 2020-05-13 | University of Utah Research Foundation | Genetic alterations in glioblastoma |
| EP2773758B1 (en) | 2011-11-03 | 2017-06-07 | Quark Pharmaceuticals, Inc. | Compositions for use in neuroprotection |
| WO2013070786A1 (en) | 2011-11-07 | 2013-05-16 | Isis Pharmaceuticals, Inc. | Modulation of tmprss6 expression |
| US9243291B1 (en) | 2011-12-01 | 2016-01-26 | Isis Pharmaceuticals, Inc. | Methods of predicting toxicity |
| WO2013090457A2 (en) | 2011-12-12 | 2013-06-20 | Oncoimmunin Inc. | In vivo delivery of oligonucleotides |
| ES2707232T3 (es) | 2011-12-16 | 2019-04-03 | Univ Nat Corp Tokyo Medical & Dental | Acido nucleico bicatenario quimérico |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| ES2886147T3 (es) | 2011-12-22 | 2021-12-16 | Interna Tech B V | MiARN para el tratamiento del cáncer de cabeza y de cuello |
| JP6280045B2 (ja) | 2011-12-22 | 2018-02-14 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 肺腺癌内転移関連性転写物１（ｍｅｔａｓｔａｓｉｓ−ａｓｓｏｃｉａｔｅｄ−ｉｎ−ｌｕｎｇ−ａｄｅｎｏｃａｒｃｉｎｏｍａ−ｔｒａｎｓｃｒｉｐｔ−１：ｍａｌａｔ−１）の発現調節法 |
| WO2013106770A1 (en) | 2012-01-11 | 2013-07-18 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of ikbkap splicing |
| EP3330278A1 (en) | 2012-02-08 | 2018-06-06 | Ionis Pharmaceuticals, Inc. | Modulation of rna by repeat targeting |
| US9605313B2 (en) | 2012-03-02 | 2017-03-28 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| CA2864523C (en) | 2012-03-05 | 2019-02-05 | Seegene, Inc. | Detection of nucleotide variation on target nucleic acid sequence by pto cleavage and extension assay |
| EP2825885B1 (en) | 2012-03-12 | 2021-05-12 | The Board of Trustees of the University of Illinois | Optical analyte detection systems with magnetic enhancement |
| CN108300765B (zh) | 2012-03-13 | 2022-01-11 | 斯威夫特生物科学公司 | 用于通过核酸聚合酶对衬底多核苷酸进行大小受控的同聚物加尾的方法和组合物 |
| EP2825648B1 (en) | 2012-03-15 | 2018-09-05 | CuRNA, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
| WO2013138662A1 (en) | 2012-03-16 | 2013-09-19 | 4S3 Bioscience, Inc. | Antisense conjugates for decreasing expression of dmpk |
| WO2013142514A1 (en) | 2012-03-19 | 2013-09-26 | Isis Pharmaceuticals, Inc. | Methods and compositions for modulating alpha-1-antitrypsin expression |
| US9434779B2 (en) | 2012-03-19 | 2016-09-06 | The Brigham And Women's Hospital, Inc. | Growth differentiation factor 11 (GDF-11) for treatment of diastolic heart failure |
| WO2013148283A1 (en) | 2012-03-30 | 2013-10-03 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
| CN108949772A (zh) | 2012-04-02 | 2018-12-07 | 现代泰克斯公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| WO2013154799A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleosides and oligomeric compounds prepared therefrom |
| US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| EP2839006B1 (en) | 2012-04-20 | 2018-01-03 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
| US9574193B2 (en) | 2012-05-17 | 2017-02-21 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating apolipoprotein (a) expression |
| WO2013173789A2 (en) | 2012-05-17 | 2013-11-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
| US9920361B2 (en) | 2012-05-21 | 2018-03-20 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
| US10504613B2 (en) | 2012-12-20 | 2019-12-10 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| WO2013177248A2 (en) | 2012-05-22 | 2013-11-28 | Isis Pharmaceuticals, Inc. | Modulation of enhancer rna mediated gene expression |
| HUE051680T2 (hu) | 2012-05-24 | 2021-03-29 | Ionis Pharmaceuticals Inc | Apolipoprotein(a) expressziójának módosítására szolgáló eljárások és készítmények |
| LT3401400T (lt) | 2012-05-25 | 2019-06-10 | The Regents Of The University Of California | Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui |
| US9828602B2 (en) | 2012-06-01 | 2017-11-28 | Ionis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with fibronectin |
| US9487780B2 (en) | 2012-06-01 | 2016-11-08 | Ionis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with fibronectin |
| WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
| CN104685056A (zh) | 2012-06-21 | 2015-06-03 | 米拉根医疗股份有限公司 | 包含锁核酸基序的基于寡核苷酸的抑制剂 |
| JP6294876B2 (ja) | 2012-06-25 | 2018-03-14 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｕｂｅ３ａ−ａｔｓ発現の調節 |
| EP2872648B1 (en) | 2012-07-13 | 2019-09-04 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
| EP3354750A1 (en) | 2012-07-18 | 2018-08-01 | Siemens Healthcare Diagnostics Inc. | Kit of normalizing biological samples |
| ES2773489T3 (es) | 2012-07-27 | 2020-07-13 | Ionis Pharmaceuticals Inc | Modulación de enfermedades relacionadas con el sistema renina-angiotensina (RAS) mediante angiotensinógenos |
| AU2013202793B2 (en) | 2012-07-31 | 2014-09-18 | Gen-Probe Incorporated | System, method and apparatus for automated incubation |
| US9403865B2 (en) | 2012-08-15 | 2016-08-02 | Ionis Pharmaceuticals, Inc. | Method of preparing oligomeric compounds using modified capping protocols |
| EP2892617B1 (en) | 2012-09-06 | 2018-06-13 | The University of Chicago | Antisense polynucleotides to induce exon skipping and methods of treating dystrophies |
| WO2014045126A2 (en) | 2012-09-18 | 2014-03-27 | Uti Limited Partnership | Treatment of pain by inhibition of usp5 de-ubiquitinase |
| JP6048982B2 (ja) | 2012-09-21 | 2016-12-21 | 国立大学法人大阪大学 | グアニジン架橋を有する人工ヌクレオシドおよびオリゴヌクレオチド |
| CA2886334C (en) | 2012-09-28 | 2021-12-21 | Bna Inc. | Bna clamp method |
| WO2014059353A2 (en) | 2012-10-11 | 2014-04-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and uses thereof |
| AR092982A1 (es) | 2012-10-11 | 2015-05-13 | Isis Pharmaceuticals Inc | Modulacion de la expresion de receptores androgenicos |
| EP4052709A1 (en) | 2012-10-11 | 2022-09-07 | Ionis Pharmaceuticals, Inc. | Methods of treating kennedy's disease |
| US20150275208A1 (en) | 2012-10-12 | 2015-10-01 | Isis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| WO2014059341A2 (en) | 2012-10-12 | 2014-04-17 | Isis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
| RU2730677C2 (ru) | 2012-10-15 | 2020-08-24 | Ионис Фармасьютикалз, Инк. | Соединение для модуляции экспрессии гена c9orf72 и его применение |
| US9963699B2 (en) | 2012-10-15 | 2018-05-08 | Ionis Pharmaceuticals, Inc. | Methods for modulating C9ORF72 expression |
| WO2014062736A1 (en) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Methods for monitoring c9orf72 expression |
| US9029335B2 (en) | 2012-10-16 | 2015-05-12 | Isis Pharmaceuticals, Inc. | Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| EP2909222B1 (en) | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-bridged nucleosides for hcv infection |
| WO2014070868A1 (en) | 2012-10-31 | 2014-05-08 | Isis Pharmaceuticals Inc | Cancer treatment |
| WO2014071419A2 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| AU2013337277B2 (en) | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel NTRK1 fusion molecules and uses thereof |
| CN104884637A (zh) | 2012-11-05 | 2015-09-02 | 普隆奈治疗公司 | 利用生物标志物通过bcl2表达的调节治疗癌症的方法 |
| WO2014072357A1 (en) | 2012-11-06 | 2014-05-15 | Interna Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway |
| SG10201804331TA (en) | 2012-11-15 | 2018-07-30 | Roche Innovation Ct Copenhagen As | Oligonucleotide conjugates |
| CA2889993A1 (en) | 2012-11-26 | 2014-05-30 | Roche Innovation Center Copenhagen A/S | Compositions and methods for modulation of fgfr3 expression |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| WO2014093537A1 (en) | 2012-12-11 | 2014-06-19 | Isis Pharmaceuticals, Inc. | Competitive modulation of micrornas |
| WO2014113540A1 (en) | 2013-01-16 | 2014-07-24 | Iowa State University Research Foundation, Inc. | A deep intronic target for splicing correction on spinal muscular atrophy gene |
| JP2016504050A (ja) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド |
| WO2014113729A2 (en) | 2013-01-18 | 2014-07-24 | Foundation Mecicine, Inc. | Methods of treating cholangiocarcinoma |
| WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
| US20150368642A1 (en) | 2013-01-30 | 2015-12-24 | Hoffmann-La Roche Inc. | Lna oligonucleotide carbohydrate conjugates |
| US9701708B2 (en) | 2013-01-31 | 2017-07-11 | Ionis Pharmaceuticals, Inc. | Method of preparing oligomeric compounds using modified coupling protocols |
| US10260069B2 (en) | 2013-02-04 | 2019-04-16 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| KR102169899B1 (ko) | 2013-02-14 | 2020-10-26 | 아이오니스 파마수티컬즈, 인코포레이티드 | 지질단백질 리파제 결핍 (lpld) 모집단에서 아포지질단백질 c-iii (apociii) 발현의 조절 |
| EP2957567B1 (en) | 2013-02-18 | 2019-06-05 | Shionogi & Co., Ltd. | Nucleoside and nucleotide, having nitrogen-containing hetercycle structure |
| EP2770065B1 (en) | 2013-02-25 | 2017-12-13 | Seegene, Inc. | Detection of nucleotide variation on target nucleic acid sequence |
| US20150366890A1 (en) | 2013-02-25 | 2015-12-24 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
| EP2961853B1 (en) | 2013-02-28 | 2018-09-19 | The Board of Regents of The University of Texas System | Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers |
| WO2014134144A1 (en) | 2013-02-28 | 2014-09-04 | The General Hospital Corporation | Mirna profiling compositions and methods of use |
| WO2014132671A1 (en) | 2013-03-01 | 2014-09-04 | National University Corporation Tokyo Medical And Dental University | Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent |
| EP2971115B1 (en) | 2013-03-13 | 2022-07-27 | Seegene, Inc. | Quantification of target nucleic acid using melting peak analysis |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| WO2014168711A1 (en) | 2013-03-13 | 2014-10-16 | Sequenom, Inc. | Primers for dna methylation analysis |
| CN111254145A (zh) | 2013-03-14 | 2020-06-09 | Ionis制药公司 | 用于调节tau表达的组合物和方法 |
| US9273349B2 (en) | 2013-03-14 | 2016-03-01 | Affymetrix, Inc. | Detection of nucleic acids |
| ES2680595T3 (es) | 2013-03-14 | 2018-09-10 | Translate Bio, Inc. | Evaluación cuantitativa para eficacia de ARN mensajero para tapar |
| ME03043B (me) | 2013-03-14 | 2018-10-20 | Alnylam Pharmaceuticals Inc | Irnk sastavi komponente komplementa c5 i metode za njihovu upotrebu |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| EA201591286A1 (ru) | 2013-03-14 | 2016-02-29 | Шир Хьюман Дженетик Терапис, Инк. | Количественная оценка эффективности кэп матричной рнк |
| KR20150131365A (ko) | 2013-03-15 | 2015-11-24 | 미라젠 세러퓨틱스 인코포레이티드 | 브리지드 바이사이클릭 뉴클레오시드 |
| US9347095B2 (en) | 2013-03-15 | 2016-05-24 | Bio-Rad Laboratories, Inc. | Digital assays for mutation detection |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| CN105188715B (zh) | 2013-03-15 | 2018-12-25 | 米拉根医疗股份有限公司 | Mir-145的锁定核酸抑制剂及其用途 |
| US9983206B2 (en) | 2013-03-15 | 2018-05-29 | The Board Of Trustees Of The University Of Illinois | Methods and compositions for enhancing immunoassays |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| US10092627B2 (en) | 2013-04-08 | 2018-10-09 | President And Fellows Of Harvard College | Methods and compositions for rejuvenating skeletal muscle stem cells |
| US10590412B2 (en) | 2013-04-19 | 2020-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation nucleic acids through nonsense mediated decay |
| WO2014176259A1 (en) | 2013-04-22 | 2014-10-30 | Icahn School Of Medicine At Mount Sinai | Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis |
| ES2982836T3 (es) | 2013-04-29 | 2024-10-17 | Memorial Sloan Kettering Cancer Center | Composiciones y métodos para alterar la señalización de segundos mensajeros |
| CA2921162A1 (en) | 2013-05-01 | 2014-11-06 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| KR102463973B1 (ko) | 2013-05-22 | 2022-11-07 | 알닐람 파마슈티칼스 인코포레이티드 | ＳＥＲＰＩＮＡ1 ｉＲＮＡ 조성물 및 이의 사용 방법 |
| EA201592225A1 (ru) | 2013-05-22 | 2016-04-29 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ НА ОСНОВЕ iRNA TMPRSS6 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| EP3004347B1 (en) | 2013-05-30 | 2018-09-26 | National University Corporation Tokyo Medical and Dental University | Double-stranded agents for delivering therapeutic oligonucleotides |
| WO2014197835A2 (en) | 2013-06-06 | 2014-12-11 | The General Hospital Corporation | Methods and compositions for the treatment of cancer |
| EP3007719B1 (en) | 2013-06-11 | 2021-03-17 | President and Fellows of Harvard College | Methods and compositions for increasing neurogenesis and angiogenesis |
| EP3007704B1 (en) | 2013-06-13 | 2021-01-06 | Antisense Therapeutics Ltd | Combination therapy for acromegaly |
| EP3010514B1 (en) | 2013-06-16 | 2021-01-20 | National University Corporation Tokyo Medical and Dental University | Double-stranded antisense nucleic acid with exon-skipping effect |
| JP6694382B2 (ja) | 2013-06-21 | 2020-05-13 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 標的核酸を調節するための組成物および方法 |
| EP3011026B1 (en) | 2013-06-21 | 2019-12-18 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile |
| AU2014300981B2 (en) | 2013-06-27 | 2017-08-10 | Ricc A/S | Antisense oligomers and conjugates targeting PCSK9 |
| ES2787600T3 (es) | 2013-07-02 | 2020-10-16 | Ionis Pharmaceuticals Inc | Moduladores del receptor de la hormona del crecimiento |
| HUE056760T2 (hu) | 2013-07-11 | 2022-03-28 | Modernatx Inc | A CRISPR-hez kapcsolódó fehérjéket és a szintetikus SGRNS-ket kódoló szintetikus polinukleotidokat tartalmazó készítmények és felhasználási módjaik |
| JP6617702B2 (ja) | 2013-07-15 | 2019-12-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｆｔｙ７２０のアザサイクリック拘束アナログ |
| WO2015008985A1 (en) | 2013-07-15 | 2015-01-22 | Seegene, Inc. | Detection of target nucleic acid sequence by pto cleavage and extension-dependent immobilized oligonucleotide hybridization |
| TWI657819B (zh) | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| WO2015017675A2 (en) | 2013-07-31 | 2015-02-05 | Isis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| RS59991B1 (sr) | 2013-08-08 | 2020-04-30 | Scripps Research Inst | Metoda enzimskog in vitro obeležavanja specifičnog za položaj nukleinskih kiselina uvođenjem neprirodnih nukleotida |
| TW201536329A (zh) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
| WO2015023503A2 (en) | 2013-08-14 | 2015-02-19 | Primeradx, Inc. | Compositions and methods for multimodal analysis of cmet nucleic acids |
| BR112016003058A2 (pt) | 2013-08-14 | 2017-11-21 | Qiagen Mansfield Inc | composições e métodos para análise multiplex de ácidos nucleicos nras e braf |
| KR102365486B1 (ko) | 2013-08-28 | 2022-02-18 | 아이오니스 파마수티컬즈, 인코포레이티드 | 프리칼리크레인 (pkk) 발현의 조절 |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| JP6666250B2 (ja) | 2013-09-13 | 2020-03-13 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 補体ｂ因子の調節薬 |
| US9943604B2 (en) | 2013-09-20 | 2018-04-17 | Ionis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
| CA2925107A1 (en) | 2013-10-02 | 2015-04-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| SG11201602631XA (en) | 2013-10-04 | 2016-05-30 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of the alas1 gene |
| SG10201808903UA (en) | 2013-10-11 | 2018-11-29 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
| US11162096B2 (en) | 2013-10-14 | 2021-11-02 | Ionis Pharmaceuticals, Inc | Methods for modulating expression of C9ORF72 antisense transcript |
| JP6640079B2 (ja) | 2013-10-16 | 2020-02-05 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 小容積の粒子を調製するためのデバイス及び方法 |
| EP3058105B1 (en) | 2013-10-18 | 2019-05-22 | Seegene, Inc. | Detection of target nucleic acid sequence on solid phase by pto cleavage and extension using hcto assay |
| WO2015061246A1 (en) | 2013-10-21 | 2015-04-30 | Isis Pharmaceuticals, Inc. | Method for solution phase detritylation of oligomeric compounds |
| EP3060680B1 (en) | 2013-10-21 | 2019-02-27 | The General Hospital Corporation | Methods relating to circulating tumor cell clusters and the treatment of cancer |
| WO2015066708A1 (en) | 2013-11-04 | 2015-05-07 | Northwestern University | Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna) |
| CA2930877A1 (en) | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
| WO2015075166A1 (en) | 2013-11-22 | 2015-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of a bacterial infection |
| EP3077510B1 (en) | 2013-12-02 | 2020-05-06 | Ionis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
| JP6527516B2 (ja) | 2013-12-03 | 2019-06-05 | ノースウェスタン ユニバーシティ | リポソーム粒子、前述のものを作製する方法及びその使用 |
| CA2844640A1 (en) | 2013-12-06 | 2015-06-06 | The University Of British Columbia | Method for treatment of castration-resistant prostate cancer |
| WO2015085183A2 (en) | 2013-12-06 | 2015-06-11 | Swift Biosciences, Inc. | Cleavable competitor polynucleotides |
| CA2931090A1 (en) | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
| EP3835419A1 (en) | 2013-12-12 | 2021-06-16 | The Regents of The University of California | Methods and compositions for modifying a single stranded target nucleic acid |
| AU2014364520B2 (en) | 2013-12-20 | 2020-01-02 | The General Hospital Corporation | Methods and assays relating to circulating tumor cells |
| HUE052243T2 (hu) | 2013-12-24 | 2021-04-28 | Ionis Pharmaceuticals Inc | Az angiopoietin-szerû 3 expressziójának modulációja |
| US9765332B2 (en) | 2014-01-29 | 2017-09-19 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Oligonucleotides and methods for inhibiting or reducing bacterial biofilms |
| ES2694857T3 (es) | 2014-02-04 | 2018-12-27 | Genentech, Inc. | Smoothened mutante y métodos de uso de la misma |
| AU2015217301A1 (en) | 2014-02-11 | 2016-08-25 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (KHK) iRNA compositions and methods of use thereof |
| CA2939822C (en) * | 2014-02-18 | 2018-09-25 | Osaka University | Crosslinked nucleoside and nucleotide |
| US11365447B2 (en) | 2014-03-13 | 2022-06-21 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| WO2015142910A1 (en) | 2014-03-17 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom |
| CN116970607A (zh) | 2014-03-19 | 2023-10-31 | Ionis制药公司 | 用于调节共济失调蛋白2表达的组合物 |
| MY192634A (en) | 2014-04-01 | 2022-08-29 | Biogen Ma Inc | Compositions for modulating sod-1 expression |
| TWI638047B (zh) | 2014-04-09 | 2018-10-11 | 史基普研究協會 | 藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中 |
| US10221416B2 (en) | 2014-04-24 | 2019-03-05 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising alpha-beta-constrained nucleic acid |
| WO2015168172A1 (en) | 2014-04-28 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
| US10280423B2 (en) | 2014-05-01 | 2019-05-07 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating complement factor B expression |
| JP6665111B2 (ja) | 2014-05-01 | 2020-03-13 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｐｋｋ発現を調節するための組成物及び方法 |
| AU2015252841B2 (en) | 2014-05-01 | 2020-03-19 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
| MX382230B (es) | 2014-05-01 | 2025-03-13 | Ionis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3. |
| WO2015168514A1 (en) | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Method for synthesis of reactive conjugate clusters |
| WO2015175510A1 (en) | 2014-05-12 | 2015-11-19 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a serpinc1-associated disorder |
| BR122020023687B1 (pt) | 2014-05-22 | 2023-03-07 | Alnylam Pharmaceuticals, Inc | Agente de ácido ribonucleico (rnai) de fita dupla, seus usos e composição farmacêutica |
| US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| CN106659758A (zh) | 2014-06-02 | 2017-05-10 | 儿童医疗中心有限公司 | 用于免疫调节的组合物和方法 |
| EP3164113B1 (en) | 2014-06-04 | 2019-03-27 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| WO2015190922A1 (en) | 2014-06-10 | 2015-12-17 | Erasmus University Medical Center Rotterdam | Antisense oligonucleotides useful in treatment of pompe disease |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| TW201620526A (zh) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法 |
| EP3760208B1 (en) | 2014-06-25 | 2024-05-29 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| US20170211073A1 (en) * | 2014-07-10 | 2017-07-27 | Kenji Nakano | Antisense antineoplastic agent |
| EP3169693B1 (en) | 2014-07-16 | 2022-03-09 | ModernaTX, Inc. | Chimeric polynucleotides |
| WO2016014846A1 (en) | 2014-07-23 | 2016-01-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of intrabodies |
| WO2016017422A1 (ja) * | 2014-07-31 | 2016-02-04 | 国立大学法人大阪大学 | 架橋型ヌクレオシドおよびヌクレオチド |
| WO2016028940A1 (en) | 2014-08-19 | 2016-02-25 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
| WO2016027168A2 (en) | 2014-08-20 | 2016-02-25 | Lifesplice Pharma Llc | Splice modulating oligonucleotides and methods of use thereof |
| IL234246A0 (en) | 2014-08-21 | 2014-11-30 | Omrix Biopharmaceuticals Ltd | Stabilized thrombin |
| ES2985036T3 (es) | 2014-08-29 | 2024-11-04 | Childrens Medical Ct Corp | Métodos y composiciones para el tratamiento del cáncer |
| WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
| US10731163B2 (en) | 2014-09-02 | 2020-08-04 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Oligonucleotide targeted to the A20-3′ untranslated region |
| WO2016040748A1 (en) | 2014-09-12 | 2016-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for detection of smn protein in a subject and treatment of a subject |
| EP3191591A1 (en) | 2014-09-12 | 2017-07-19 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| CA2960728C (en) | 2014-09-18 | 2023-06-06 | The University Of British Columbia | Allele-specific therapy for huntington disease haplotypes |
| SG10201902811TA (en) | 2014-09-29 | 2019-04-29 | Jackson Lab | High efficiency, high throughput generation of genetically modified mammals by electroporation |
| EP3201339A4 (en) | 2014-10-03 | 2018-09-19 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| TWI864340B (zh) | 2014-10-10 | 2024-12-01 | 美商艾爾妮蘭製藥公司 | 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法 |
| WO2016061131A1 (en) | 2014-10-14 | 2016-04-21 | The J. David Gladstone Institutes | Compositions and methods for reactivating latent immunodeficiency virus |
| EP3207138B1 (en) | 2014-10-17 | 2020-07-15 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
| EP3904519A1 (en) | 2014-10-30 | 2021-11-03 | Genzyme Corporation | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
| SG11201703646SA (en) | 2014-11-10 | 2017-06-29 | Glaxosmithkline Intellectual Property (No 2) Ltd | Combination long acting compositions and methods for hepatitis c |
| EP3218485A1 (en) | 2014-11-10 | 2017-09-20 | Glaxosmithkline Intellectual Property (No. 2) Limited | Long acting pharmaceutical compositions for hepatitis c |
| SG11201703638XA (en) | 2014-11-10 | 2017-06-29 | Alnylam Pharmaceuticals Inc | Hepatitis b virus (hbv) irna compositions and methods of use thereof |
| AU2015346042A1 (en) | 2014-11-14 | 2017-04-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of proteins |
| WO2016077704A1 (en) | 2014-11-14 | 2016-05-19 | The Regents Of The University Of California | Modulation of agpat5 expression |
| CA2968114A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| US10400243B2 (en) | 2014-11-25 | 2019-09-03 | Ionis Pharmaceuticals, Inc. | Modulation of UBE3A-ATS expression |
| EP3229842B1 (en) | 2014-12-08 | 2022-07-06 | The Board of Regents of The University of Texas System | Lipocationic polymers and uses thereof |
| EP3234141A4 (en) | 2014-12-18 | 2018-06-20 | Alnylam Pharmaceuticals, Inc. | Reversir tm compounds |
| US9688707B2 (en) | 2014-12-30 | 2017-06-27 | Ionis Pharmaceuticals, Inc. | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom |
| WO2016112132A1 (en) | 2015-01-06 | 2016-07-14 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
| WO2016118476A1 (en) | 2015-01-20 | 2016-07-28 | The Children's Medical Center Corporation | Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing |
| CN107636003A (zh) | 2015-01-20 | 2018-01-26 | 米拉根医疗股份有限公司 | miR‑92抑制剂及其用途 |
| WO2016126972A1 (en) | 2015-02-04 | 2016-08-11 | Genentech, Inc. | Mutant smoothened and methods of using the same |
| JP6929791B2 (ja) | 2015-02-09 | 2021-09-01 | デューク ユニバーシティ | エピゲノム編集のための組成物および方法 |
| WO2016130806A2 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| KR102626448B1 (ko) | 2015-02-24 | 2024-01-19 | 더 유니버시티 오브 브리티시 콜롬비아 | 연속 흐름 미세유체 시스템 |
| US10426789B2 (en) | 2015-02-26 | 2019-10-01 | Ionis Pharmaceuticals, Inc. | Allele specific modulators of P23H rhodopsin |
| EP4636085A3 (en) | 2015-03-03 | 2026-01-07 | Ionis Pharmaceuticals, Inc. | Compositions for modulating mecp2 expression |
| WO2016141145A1 (en) | 2015-03-03 | 2016-09-09 | Ionis Pharmaceuticals, Inc. | Methods for modulating mecp2 expression |
| HK1249140A1 (zh) | 2015-04-03 | 2018-10-26 | Ionis Pharmaceuticals, Inc. | 用於调节tmprss6表达的化合物和方法 |
| US10961532B2 (en) | 2015-04-07 | 2021-03-30 | The General Hospital Corporation | Methods for reactivating genes on the inactive X chromosome |
| MX2017012610A (es) | 2015-04-08 | 2018-03-16 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion del gen lect2. |
| PT3283500T (pt) | 2015-04-08 | 2021-01-28 | Univ Chicago | Composições e métodos para corrigir distrofia muscular das cinturas tipo 2c com utilização de salto do exão |
| WO2016167780A1 (en) | 2015-04-16 | 2016-10-20 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
| SI3283080T1 (sl) | 2015-04-16 | 2020-06-30 | Ionis Pharmaceuticals, Inc. | Sestavki za moduliranje izražanja C9ORF72 |
| ES2961374T3 (es) | 2015-04-24 | 2024-03-11 | Atila Biosystems Incorporated | Amplificación con cebadores de composición de nucleótidos limitada |
| EP3303634B1 (en) | 2015-06-03 | 2023-08-30 | The Regents of The University of California | Cas9 variants and methods of use thereof |
| WO2016201301A1 (en) | 2015-06-12 | 2016-12-15 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| EP3310918B1 (en) | 2015-06-18 | 2020-08-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
| WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
| CA2990852A1 (en) | 2015-06-26 | 2016-12-29 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
| CA2990699A1 (en) | 2015-06-29 | 2017-01-05 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and modified single crispr rna and uses thereof |
| US10494632B2 (en) | 2015-07-10 | 2019-12-03 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof |
| PE20180800A1 (es) | 2015-07-10 | 2018-05-09 | Ionis Pharmaceuticals Inc | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) |
| DK3324980T3 (da) | 2015-07-17 | 2022-02-14 | Alnylam Pharmaceuticals Inc | Multimålrettede enkeltenhedskonjugater |
| JP2018140938A (ja) * | 2015-07-24 | 2018-09-13 | 日産化学株式会社 | 人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド |
| WO2017023861A1 (en) | 2015-08-03 | 2017-02-09 | The Regents Of The University Of California | Compositions and methods for modulating abhd2 activity |
| HK1252479A1 (zh) | 2015-08-24 | 2019-05-24 | Roche Innovation Center Copenhagen A/S | Lna-g方法 |
| CN108368507B (zh) | 2015-09-02 | 2022-03-22 | 阿尔尼拉姆医药品有限公司 | 程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法 |
| CN108271360B (zh) | 2015-09-14 | 2023-01-24 | 得克萨斯州大学系统董事会 | 亲脂阳离子树枝状聚合物及其用途 |
| TW201718618A (zh) * | 2015-09-18 | 2017-06-01 | 田邊三菱製藥股份有限公司 | 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物 |
| HK1255699A1 (zh) | 2015-09-24 | 2019-08-23 | Ionis Pharmaceuticals, Inc. | Kras表达的调节剂 |
| CN108366990B (zh) | 2015-09-24 | 2021-09-03 | 加利福尼亚大学董事会 | 合成的鞘脂类分子、药物、它们的合成方法及治疗方法 |
| CA2998287A1 (en) | 2015-09-24 | 2017-04-20 | Crispr Therapeutics Ag | Novel family of rna-programmable endonucleases and their uses in genome editing and other applications |
| US10533175B2 (en) | 2015-09-25 | 2020-01-14 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating Ataxin 3 expression |
| EP4474389A3 (en) | 2015-10-08 | 2025-03-19 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating angiotensinogen expression |
| AU2016334804B2 (en) | 2015-10-09 | 2022-03-31 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| WO2017068087A1 (en) | 2015-10-22 | 2017-04-27 | Roche Innovation Center Copenhagen A/S | Oligonucleotide detection method |
| EP3368692B1 (en) | 2015-10-29 | 2021-07-21 | Temple University Of The Commonwealth System Of Higher Education | Modification of 3' terminal ends of nucleic acids by dna polymerase theta |
| US11260073B2 (en) | 2015-11-02 | 2022-03-01 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating C90RF72 |
| EP3371211B1 (en) | 2015-11-04 | 2025-01-01 | Icahn School of Medicine at Mount Sinai | Rho-associated protein kinase ("rock") inhibitor for treating tumors and cancer, and identifying candidate subjects for such treatment |
| EP3370708A4 (en) | 2015-11-06 | 2019-06-26 | Ionis Pharmaceuticals, Inc. | MODULATION OF APOLIPOPROTEIN (A) EXPRESSION |
| SI4119569T1 (sl) | 2015-11-06 | 2024-10-30 | Ionis Pharmaceuticals, Inc. | Konjugirane protismiselne spojine za uporabo v terapiji |
| UA125963C2 (uk) | 2015-11-12 | 2022-07-20 | Ф. Хоффманн-Ля Рош Аг | Олігонуклеотид для індукції батьківської експресії ube3a |
| WO2017091630A1 (en) | 2015-11-23 | 2017-06-01 | The Regents Of The University Of California | Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 |
| WO2017095967A2 (en) | 2015-11-30 | 2017-06-08 | Duke University | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use |
| US11058709B1 (en) | 2015-12-04 | 2021-07-13 | Ionis Pharmaceuticals, Inc. | Methods of treating breast cancer |
| SG11201804729RA (en) | 2015-12-07 | 2018-07-30 | Genzyme Corp | Methods and compositions for treating a serpinc1-associated disorder |
| CA3007152A1 (en) | 2015-12-07 | 2017-06-15 | Erasmus University Medical Center Rotterdam | Enzymatic replacement therapy and antisense therapy for pompe disease |
| WO2017098468A1 (en) | 2015-12-09 | 2017-06-15 | Novartis Ag | Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry |
| ES2882500T3 (es) | 2015-12-14 | 2021-12-02 | Cold Spring Harbor Laboratory | Oligómeros antisentido para el tratamiento del síndrome de Dravet |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| WO2017106767A1 (en) | 2015-12-18 | 2017-06-22 | The Scripps Research Institute | Production of unnatural nucleotides using a crispr/cas9 system |
| EP4678748A2 (en) | 2015-12-21 | 2026-01-14 | Novartis AG | Compositions and methods for decreasing tau expression |
| AU2017205462A1 (en) | 2016-01-05 | 2018-06-07 | Ionis Pharmaceuticals, Inc. | Methods for reducing LRRK2 expression |
| ES3047482T3 (en) | 2016-01-06 | 2025-12-03 | Univ British Columbia | Bifurcating mixers and methods of their use and manufacture |
| AU2017208086A1 (en) | 2016-01-15 | 2018-08-09 | The Jackson Laboratory | Genetically modified non-human mammals by multi-cycle electroporation of Cas9 protein |
| CN116064544A (zh) | 2016-01-26 | 2023-05-05 | 日产化学株式会社 | 单链寡核苷酸 |
| AU2017213826A1 (en) | 2016-02-04 | 2018-08-23 | Curis, Inc. | Mutant smoothened and methods of using the same |
| JP6853537B2 (ja) | 2016-02-17 | 2021-03-31 | 国立大学法人東京工業大学 | 人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド |
| JP7033072B2 (ja) | 2016-02-25 | 2022-03-09 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | Ｓｍｏｃ２を標的化する線維症のための治療方法 |
| EP3420110B1 (en) | 2016-02-26 | 2021-09-22 | The Board of Trustees of the Leland Stanford Junior University | Multiplexed single molecule rna visualization with a two-probe proximity ligation system |
| WO2023150553A1 (en) | 2022-02-01 | 2023-08-10 | University Of Rochester | Gpr17 promoter-based targeting and transduction of glial progenitor cells |
| US11136577B2 (en) | 2016-03-09 | 2021-10-05 | Ionis Pharmaceuticals, Inc. | Methods and compositions for inhibiting PMP22 expression |
| TWI794662B (zh) | 2016-03-14 | 2023-03-01 | 瑞士商赫孚孟拉羅股份公司 | 用於降低pd-l1表現之寡核苷酸 |
| EP3429690A4 (en) | 2016-03-16 | 2019-10-23 | Ionis Pharmaceuticals, Inc. | METHOD FOR MODULATING KEAP1 |
| WO2017161168A1 (en) | 2016-03-16 | 2017-09-21 | Ionis Pharmaceuticals, Inc. | Modulation of dyrk1b expression |
| EP3443081A4 (en) | 2016-04-13 | 2019-10-30 | Duke University | CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE |
| ES2933435T3 (es) | 2016-04-13 | 2023-02-08 | Ionis Pharmaceuticals Inc | Métodos para reducir la expresión de C9ORF72 |
| EP3442983A1 (en) | 2016-04-14 | 2019-02-20 | H. Hoffnabb-La Roche Ag | TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE |
| WO2017184689A1 (en) | 2016-04-19 | 2017-10-26 | Alnylam Pharmaceuticals, Inc. | High density lipoprotein binding protein (hdlbp/vigilin) irna compositions and methods of use thereof |
| WO2017189730A1 (en) | 2016-04-26 | 2017-11-02 | Icahn School Of Medicine At Mount Sinai | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment |
| KR102706686B1 (ko) | 2016-05-06 | 2024-09-19 | 아이오니스 파마수티컬즈, 인코포레이티드 | Glp-1 수용체 리간드 모이어티 컨쥬게이트된 올리고뉴클레오티드 및 이의 용도 |
| AU2017267634C1 (en) | 2016-05-16 | 2022-05-26 | The Board Of Regents Of The University Of Texas System | Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids |
| WO2017214518A1 (en) | 2016-06-10 | 2017-12-14 | Alnylam Pharmaceuticals, Inc. | COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
| EP3472350B1 (en) | 2016-06-15 | 2022-08-17 | Streck, Inc. | Assays and methods for determining microbial resistance |
| US10337051B2 (en) | 2016-06-16 | 2019-07-02 | The Regents Of The University Of California | Methods and compositions for detecting a target RNA |
| CA3023514A1 (en) | 2016-06-17 | 2017-12-21 | Ionis Pharmaceuticals, Inc. | Modulation of gys1 expression |
| AU2017285350A1 (en) | 2016-06-17 | 2018-12-20 | F. Hoffmann-La Roche Ag | Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection |
| EP4163293A1 (en) | 2016-06-24 | 2023-04-12 | The Scripps Research Institute | Novel nucleoside triphosphate transporter and uses thereof |
| EP3478839A1 (en) | 2016-07-01 | 2019-05-08 | H. Hoffnabb-La Roche Ag | Antisense oligonucleotides for modulating htra1 expression |
| ES2935658T3 (es) | 2016-07-15 | 2023-03-09 | Ionis Pharmaceuticals Inc | Compuestos y métodos para la modulación de SMN2 |
| EP4275747A3 (en) | 2016-07-19 | 2024-01-24 | Duke University | Therapeutic applications of cpf1-based genome editing |
| NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
| NL2017295B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Antisense oligomeric compound for Pompe disease |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| SG10201607303YA (en) | 2016-09-01 | 2018-04-27 | Agency Science Tech & Res | Antisense oligonucleotides to induce exon skipping |
| TWI769177B (zh) | 2016-09-14 | 2022-07-01 | 美商艾洛斯生物製藥公司 | 經修飾之寡核苷酸及使用方法 |
| KR102468633B1 (ko) | 2016-09-15 | 2022-11-18 | 에프. 호프만-라 로슈 아게 | 멀티플렉스 실시간 pcr 수행 방법 |
| ES2963428T3 (es) | 2016-09-29 | 2024-03-27 | Biogen Ma Inc | Compuestos y métodos para reducir la expresión de Tau |
| KR20190065341A (ko) | 2016-10-06 | 2019-06-11 | 아이오니스 파마수티컬즈, 인코포레이티드 | 올리고머 화합물들의 접합 방법 |
| SG10201609048RA (en) | 2016-10-28 | 2018-05-30 | Agency Science Tech & Res | Antisense oligonucleotides |
| CA3037046A1 (en) | 2016-10-31 | 2018-05-03 | University Of Massachusetts | Targeting microrna-101-3p in cancer therapy |
| JOP20190104A1 (ar) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن atxn3 |
| WO2018087200A1 (en) | 2016-11-11 | 2018-05-17 | Roche Innovation Center Copenhagen A/S | Therapeutic oligonucleotides capture and detection |
| TW202313978A (zh) | 2016-11-23 | 2023-04-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| US11033570B2 (en) | 2016-12-02 | 2021-06-15 | Cold Spring Harbor Laboratory | Modulation of Lnc05 expression |
| AU2017376950B2 (en) | 2016-12-16 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing TTR-associated diseases using transthyretin (TTR) iRNA compositions |
| UY37565A (es) | 2017-01-10 | 2018-07-31 | Arrowhead Pharmaceuticals Inc | Agentes de iarn alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y métodos de uso |
| US20190338286A1 (en) | 2017-01-13 | 2019-11-07 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating rel expression |
| WO2018130583A1 (en) | 2017-01-13 | 2018-07-19 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating nfkb1 expression |
| WO2018130585A1 (en) | 2017-01-13 | 2018-07-19 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating relb expression |
| WO2018130581A1 (en) | 2017-01-13 | 2018-07-19 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating rela expression |
| EP3568480A1 (en) | 2017-01-13 | 2019-11-20 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating nfkb2 expression |
| US11572558B2 (en) | 2017-02-06 | 2023-02-07 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
| US11180756B2 (en) | 2017-03-09 | 2021-11-23 | Ionis Pharmaceuticals | Morpholino modified oligomeric compounds |
| US11479769B2 (en) | 2017-03-17 | 2022-10-25 | National University Corporation Chiba University | Technique for treating cancer using structurally-reinforced S-TuD |
| JOP20190215A1 (ar) | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | مُعدّلات التعبير الوراثي عن pcsk9 |
| JP7190794B2 (ja) | 2017-03-29 | 2022-12-16 | 塩野義製薬株式会社 | 核酸医薬及び多分岐脂質の複合体 |
| WO2018191603A1 (en) | 2017-04-14 | 2018-10-18 | University Of Massachusetts | Targeting cell tropism receptors to inhibit cytomegalovirus infection |
| SG11201909572QA (en) | 2017-04-18 | 2019-11-28 | Alnylam Pharmaceuticals Inc | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection |
| CA3062595A1 (en) | 2017-05-10 | 2018-11-15 | The Regents Of The University Of California | Directed editing of cellular rna via nuclear delivery of crispr/cas9 |
| US20190055564A1 (en) | 2017-06-01 | 2019-02-21 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides for modulating htra1 expression |
| JP2020530442A (ja) | 2017-07-10 | 2020-10-22 | ジェンザイム・コーポレーション | 血友病を有する対象の出血事象を処置するための方法および組成物 |
| SG11202000167SA (en) | 2017-07-11 | 2020-02-27 | Synthorx Inc | Incorporation of unnatural nucleotides and methods thereof |
| MA49716A (fr) | 2017-07-11 | 2021-04-07 | Scripps Research Inst | Incorporation de nucléotides non naturels et procédés d'utilisationin vivo |
| JP2020526558A (ja) | 2017-07-13 | 2020-08-31 | ノースウェスタン ユニバーシティ | オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法 |
| TWI902655B (zh) | 2017-07-26 | 2025-11-01 | 日商日產化學股份有限公司 | 單股寡核苷酸 |
| KR20250145137A (ko) | 2017-08-03 | 2025-10-13 | 신톡스, 인크. | 자가면역 질환의 치료를 위한 사이토카인 접합체 |
| WO2019030313A2 (en) | 2017-08-11 | 2019-02-14 | Roche Innovation Center Copenhagen A/S | OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION |
| AU2018318231A1 (en) | 2017-08-18 | 2020-02-13 | Ionis Pharmaceuticals, Inc. | Modulation of the notch signaling pathway for treatment of respiratory disorders |
| WO2019038228A1 (en) | 2017-08-22 | 2019-02-28 | Roche Innovation Center Copenhagen A/S | OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION |
| SI3673080T1 (sl) | 2017-08-25 | 2024-03-29 | Stoke Therapeutics, Inc. | Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni |
| KR102380264B1 (ko) | 2017-08-31 | 2022-03-29 | 주식회사 씨젠 | 다이머-형성 프라이머 쌍을 이용한 구성요소의 성능 평가 |
| AU2018325645C1 (en) | 2017-08-31 | 2025-01-30 | Hyogo College Of Medicine | IL-33 antagonist-containing therapeutic agent for endometriosis |
| US10517889B2 (en) | 2017-09-08 | 2019-12-31 | Ionis Pharmaceuticals, Inc. | Modulators of SMAD7 expression |
| SG11202002149XA (en) | 2017-09-14 | 2020-04-29 | Janssen Biopharma Inc | Galnac derivatives |
| WO2019066461A2 (en) | 2017-09-29 | 2019-04-04 | Seegene, Inc. | DETECTION OF TARGET NUCLEIC ACID SEQUENCES BY CLEAVAGE ANALYSIS AND EXTENSION OF PTO |
| CN111226114A (zh) | 2017-10-13 | 2020-06-02 | 罗氏创新中心哥本哈根有限公司 | 用部分立体限定的寡核苷酸子文库鉴定反义寡核苷酸改进的立体限定硫代磷酸酯寡核苷酸变体的方法 |
| CN111511914B (zh) | 2017-10-16 | 2023-11-17 | 豪夫迈·罗氏有限公司 | 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染 |
| US11261445B2 (en) | 2017-10-17 | 2022-03-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combination treatment for cystic fibrosis |
| US11866701B2 (en) | 2017-11-01 | 2024-01-09 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
| EP3704250A1 (en) | 2017-11-03 | 2020-09-09 | InteRNA Technologies B.V. | Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
| TWI809004B (zh) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
| US20200385719A1 (en) | 2017-11-16 | 2020-12-10 | Alnylam Pharmaceuticals, Inc. | Kisspeptin 1 (kiss1) irna compositions and methods of use thereof |
| EP3714054A1 (en) | 2017-11-20 | 2020-09-30 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
| US20200385714A1 (en) | 2017-12-11 | 2020-12-10 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating fndc3b expression |
| WO2019115417A2 (en) | 2017-12-12 | 2019-06-20 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating rb1 expression |
| EP3724206B1 (en) | 2017-12-14 | 2023-06-28 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| CN111801417B (zh) | 2017-12-14 | 2024-10-29 | 克里斯珀医疗股份公司 | 新的rna-可编程的内切核酸酶系统及其在基因组编辑和其他应用中的用途 |
| EP3724355A1 (en) | 2017-12-15 | 2020-10-21 | Novartis AG | Polya tail length analysis of rna by mass spectrometry |
| WO2019126097A1 (en) | 2017-12-18 | 2019-06-27 | Alnylam Pharmaceuticals, Inc. | High mobility group box-1 (hmgb1) irna compositions and methods of use thereof |
| JP2021507253A (ja) | 2017-12-21 | 2021-02-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｈｔｒａ１ ｒｎａアンタゴニストについてのコンパニオン診断 |
| TW201929870A (zh) | 2017-12-22 | 2019-08-01 | 丹麥商羅氏創新中心哥本哈根有限公司 | 包含二硫代磷酸酯核苷間連結之寡核苷酸 |
| CA3084170A1 (en) | 2017-12-22 | 2019-06-27 | Roche Innovation Center Copenhagen A/S | Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage |
| JP2021508327A (ja) | 2017-12-22 | 2021-03-04 | ロシュ イノベーション センター コペンハーゲン エーエス | 新規のチオホスホラミダイト |
| IL275694B2 (en) | 2017-12-29 | 2025-08-01 | Scripps Research Inst | Unnatural base pair compositions and methods of use |
| WO2019137883A1 (en) | 2018-01-10 | 2019-07-18 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating pias4 expression |
| CN120310791A (zh) | 2018-01-12 | 2025-07-15 | 百时美施贵宝公司 | 靶向α-突触核蛋白的反义寡核苷酸及其用途 |
| MA51634A (fr) | 2018-01-12 | 2020-11-18 | Roche Innovation Ct Copenhagen As | Oligonucléotides antisens d'alpha-synucléine et leurs utilisations |
| US20210095275A1 (en) | 2018-01-12 | 2021-04-01 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating gsk3b expression |
| US12241065B2 (en) | 2018-01-12 | 2025-03-04 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| US20200392510A1 (en) | 2018-01-15 | 2020-12-17 | Ionis Pharmaceuticals, Inc. | Modulators of dnm2 expression |
| EP3740574A1 (en) | 2018-01-17 | 2020-11-25 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating erc1 expression |
| WO2019141723A1 (en) | 2018-01-18 | 2019-07-25 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting srebp1 |
| US12509492B2 (en) | 2018-01-19 | 2025-12-30 | Duke University | Genome engineering with CRISPR-Cas systems in eukaryotes |
| WO2019145386A1 (en) | 2018-01-26 | 2019-08-01 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating csnk1d expression |
| RU2020125769A (ru) | 2018-02-09 | 2022-03-10 | Дженентек, Инк. | Олигонуклеотиды для модуляции экспрессии tmem106b |
| CA3090901A1 (en) | 2018-02-12 | 2019-08-15 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| WO2019155094A1 (en) | 2018-02-12 | 2019-08-15 | Interna Technologies B.V. | Anticancer microrna and lipid formulations thereof |
| CA3091789A1 (en) | 2018-02-21 | 2019-08-29 | Bristol-Myers Squibb Company | Camk2d antisense oligonucleotides and uses thereof |
| WO2019165453A1 (en) | 2018-02-26 | 2019-08-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
| BR112020018365A2 (pt) | 2018-03-13 | 2020-12-29 | Janssen Pharmaceutica Nv | Oligonucleotídeos modificados e métodos para uso em tauopatias |
| JP7550648B2 (ja) | 2018-03-19 | 2024-09-13 | クリスパー セラピューティクス アーゲー | 新規ｒｎａプログラム可能エンドヌクレアーゼ系およびその使用 |
| CN111868244A (zh) | 2018-03-20 | 2020-10-30 | 国立大学法人东京工业大学 | 降低了毒性的反义寡核苷酸 |
| EP3775208A1 (en) | 2018-04-05 | 2021-02-17 | F. Hoffmann-La Roche AG | Use of fubp1 inhibitors for treating hepatitis b virus infection |
| US12263205B2 (en) | 2018-04-30 | 2025-04-01 | The Children's Hospital Of Philadelphia | Methods of improving anemias by combining agents |
| WO2019213525A1 (en) | 2018-05-04 | 2019-11-07 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| JP2021522816A (ja) | 2018-05-07 | 2021-09-02 | ロシュ イノベーション センター コペンハーゲン エーエス | オリゴヌクレオチド治療のための超並列的探索方法 |
| EP3790970A1 (en) | 2018-05-07 | 2021-03-17 | Alnylam Pharmaceuticals Inc. | Extrahepatic delivery |
| WO2019215175A1 (en) | 2018-05-08 | 2019-11-14 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating myh7 expression |
| SG11202010215TA (en) | 2018-05-09 | 2020-11-27 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing atxn3 expression |
| JP7438135B2 (ja) | 2018-05-09 | 2024-02-26 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | Ｆｘｉの発現を低下させるための化合物及び方法 |
| CA3099963A1 (en) | 2018-05-11 | 2019-11-14 | University Of Massachusetts | Methods for improving leptin sensitivity for the treatment of obesity and diabetes |
| TWI851574B (zh) | 2018-05-14 | 2024-08-11 | 美商阿尼拉製藥公司 | 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法 |
| JP2021524450A (ja) | 2018-05-18 | 2021-09-13 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | マイクロｒｎａ関連疾患の処置のための薬学的組成物 |
| US11578325B2 (en) | 2018-05-24 | 2023-02-14 | David Berz | Methods and formulations for the treatment of obesity and obesity-related metabolic diseases |
| WO2019224172A1 (en) | 2018-05-25 | 2019-11-28 | Roche Innovation Center Copenhagen A/S | Novel process for making allofuranose from glucofuranose |
| CN112912500A (zh) | 2018-06-05 | 2021-06-04 | 豪夫迈·罗氏有限公司 | 用于调节atxn2表达的寡核苷酸 |
| CA3103663A1 (en) | 2018-06-18 | 2019-12-26 | University Of Rochester | Inhibition of re1-silencing transcription factor in the treatment of schizophrenia and other neuropsychiatric disorders |
| WO2019246450A1 (en) | 2018-06-20 | 2019-12-26 | Yale University | Rig-i agonists and treatments using same |
| KR20210054502A (ko) | 2018-06-21 | 2021-05-13 | 유니버시티 오브 로체스터 | 헌팅턴병을 치료하거나 이의 발병을 저해하는 방법 |
| JP7595464B2 (ja) | 2018-06-21 | 2024-12-06 | エフ． ホフマン－ラ ロシュ アーゲー | 全ｌｎａオリゴヌクレオチドのハイブリダイズ |
| WO2020007700A1 (en) | 2018-07-02 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting spi1 |
| WO2020007702A1 (en) | 2018-07-02 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting bcl2l11 |
| WO2020007772A1 (en) | 2018-07-02 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting gbp-1 |
| WO2020007892A1 (en) | 2018-07-03 | 2020-01-09 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating tau expression |
| WO2020007826A1 (en) | 2018-07-05 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting mbtps1 |
| WO2020007889A1 (en) | 2018-07-05 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting stat1 |
| WO2020011743A1 (en) | 2018-07-09 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting mafb |
| WO2020011653A1 (en) | 2018-07-09 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting kynu |
| WO2020011869A2 (en) | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting tlr2 |
| WO2020011745A2 (en) | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting cers6 |
| WO2020011744A2 (en) | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting cers5 |
| JP7616987B2 (ja) | 2018-07-13 | 2025-01-17 | エフ． ホフマン－ラ ロシュ アーゲー | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド |
| EP3823725A4 (en) | 2018-07-17 | 2023-05-10 | Aronora, Inc. | METHODS FOR SAFELY REDUCING THROMBOPOIETIN |
| CA3106986A1 (en) | 2018-07-25 | 2020-01-30 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing atxn2 expression |
| CN112512584A (zh) | 2018-07-27 | 2021-03-16 | 国立大学法人大阪大学 | 用于抑制衰老、预防、改善或治疗衰老相关疾病或症状、或者延长寿命的组合物 |
| KR20210041537A (ko) | 2018-07-31 | 2021-04-15 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 포스포로트리티오에이트 뉴클레오사이드간 연결을 포함하는 올리고뉴클레오타이드 |
| JP7470097B2 (ja) | 2018-07-31 | 2024-04-17 | ロシュ イノベーション センター コペンハーゲン エーエス | ホスホロトリチオアートヌクレオシド間結合を含むオリゴヌクレオチド |
| WO2020028729A1 (en) | 2018-08-01 | 2020-02-06 | Mammoth Biosciences, Inc. | Programmable nuclease compositions and methods of use thereof |
| US20210317461A1 (en) | 2018-08-09 | 2021-10-14 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| MA70658B1 (fr) | 2018-08-13 | 2026-04-30 | Alnylam Pharmaceuticals, Inc. | Compositions d'agent d'arndb du virus de l'hépatite b (vhb) et leurs méthodes d'utilisation |
| US11987792B2 (en) | 2018-08-16 | 2024-05-21 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
| CA3110211A1 (en) | 2018-08-20 | 2020-02-27 | Rogcon, Inc. | Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathies |
| EP3841205A4 (en) | 2018-08-22 | 2022-08-17 | The Regents of The University of California | Variant type v crispr/cas effector polypeptides and methods of use thereof |
| WO2020038968A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Microrna-134 biomarker |
| WO2020038971A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting vcan |
| WO2020038976A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting usp8 |
| WO2020038973A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting sptlc1 |
| WO2020046809A1 (en) | 2018-08-27 | 2020-03-05 | The Regents Of The University Of California | Reporter nucleic acids for type v crispr-mediated detection |
| EP3844274A1 (en) | 2018-08-28 | 2021-07-07 | Roche Innovation Center Copenhagen A/S | Neoantigen engineering using splice modulating compounds |
| US12281308B2 (en) | 2018-08-29 | 2025-04-22 | University Of Massachusetts | Inhibition of protein kinases to treat Friedreich ataxia |
| EP3620519A1 (en) | 2018-09-04 | 2020-03-11 | F. Hoffmann-La Roche AG | Use of isolated milk extracellular vesicles for delivering oligonucleotides orally |
| EP3846824B1 (en) | 2018-09-07 | 2025-06-18 | The General Hospital Corporation | Compositions and methods for immune checkpoint inhibition |
| EP3620520A1 (en) | 2018-09-10 | 2020-03-11 | Universidad del Pais Vasco | Novel target to treat a metabolic disease in an individual |
| CA3112793A1 (en) | 2018-09-14 | 2020-03-19 | Northwestern University | Programming protein polymerization with dna |
| WO2020060986A1 (en) | 2018-09-18 | 2020-03-26 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
| TWI869213B (zh) | 2018-09-19 | 2025-01-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
| WO2020068983A1 (en) | 2018-09-25 | 2020-04-02 | Co-Diagnostics, Inc. | Allele-specific design of cooperative primers for improved nucleic acid variant genotyping |
| JP7470107B2 (ja) | 2018-09-28 | 2024-04-17 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | トランスサイレチン（ＴＴＲ）ｉＲＮＡ組成物及びＴＴＲ関連眼疾患を治療又は予防するためのその使用方法 |
| WO2020086701A1 (en) | 2018-10-24 | 2020-04-30 | Codiak Biosciences, Inc. | Methods to improve potency of electroporation |
| US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
| WO2020089260A1 (en) | 2018-11-01 | 2020-05-07 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting tia1 |
| BR112021005401A2 (pt) | 2018-11-08 | 2021-06-29 | Synthorx, Inc. | conjugados de interleucina 10 e usos dos mesmos |
| EP3877517A4 (en) | 2018-11-09 | 2022-09-07 | Inari Agriculture, Inc. | RNA-DRIVEN NUCLEASES AND DNA-BINDING PROTEINS |
| TW202028222A (zh) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
| EA202191342A1 (ru) | 2018-11-15 | 2021-08-10 | Айонис Фармасьютикалз, Инк. | Модуляторы экспрессии irf5 |
| KR102624804B1 (ko) | 2018-11-16 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | 결합 쌍의 부재를 갖는 스트렙타비딘 코팅된 고체상 |
| US12281305B2 (en) | 2018-11-21 | 2025-04-22 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing prion expression |
| CN113166185A (zh) | 2018-11-22 | 2021-07-23 | 罗氏创新中心哥本哈根有限公司 | 作为立体限定的寡核苷酸合成中的活化剂的吡啶鎓盐 |
| CA3121191A1 (en) | 2018-11-28 | 2020-06-04 | Crispr Therapeutics Ag | Optimized mrna encoding cas9 for use in lnps |
| WO2020109343A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Combination therapy for treatment of macular degeneration |
| WO2020109344A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Occular administration device for antisense oligonucleotides |
| WO2020117706A1 (en) | 2018-12-03 | 2020-06-11 | Triplet Therapeutics, Inc. | Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity |
| WO2020118259A1 (en) | 2018-12-06 | 2020-06-11 | Northwestern University | Protein crystal engineering through dna hybridization interactions |
| CA3122289A1 (en) | 2018-12-11 | 2020-06-18 | University Of Rochester | Methods of treating schizophrenia and other neuropsychiatric disorders |
| JP7562424B2 (ja) | 2018-12-17 | 2024-10-07 | イルミナ ケンブリッジ リミテッド | シーケンシング用プライマーオリゴヌクレオチド |
| LT4285929T (lt) | 2018-12-20 | 2026-01-12 | Humabs Biomed Sa | Kompleksinė hbv terapija |
| CN113631709A (zh) | 2018-12-20 | 2021-11-09 | 普拉克西斯精密药物股份有限公司 | 用于治疗kcnt1相关病症的组合物和方法 |
| EP3899035B1 (en) | 2018-12-20 | 2025-04-16 | F. Hoffmann-La Roche AG | Detection of target nucleic acid by solid-phase molography |
| US20220273691A1 (en) | 2018-12-21 | 2022-09-01 | Ionis Pharmaceuticals, Inc. | Modulators of hsd17b13 expression |
| EP3898975A2 (en) | 2018-12-21 | 2021-10-27 | Boehringer Ingelheim International GmbH | Antisense oligonucleotides targeting card9 |
| EP3931313A2 (en) | 2019-01-04 | 2022-01-05 | Mammoth Biosciences, Inc. | Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection |
| CN113557023A (zh) | 2019-01-16 | 2021-10-26 | 建新公司 | Serpinc1 iRNA组合物及其使用方法 |
| EP3914232A1 (en) | 2019-01-25 | 2021-12-01 | F. Hoffmann-La Roche AG | Lipid vesicle for oral drug delivery |
| MX2021008918A (es) | 2019-01-31 | 2021-08-24 | Ionis Pharmaceuticals Inc | Moduladores de expresion yap1. |
| US20200246467A1 (en) | 2019-02-06 | 2020-08-06 | Synthorx, Inc. | Il-2 conjugates and methods of use thereof |
| WO2020167822A2 (en) | 2019-02-13 | 2020-08-20 | University Of Rochester | Gene networks that mediate remyelination of the human brain |
| CA3129646A1 (en) | 2019-02-20 | 2020-08-27 | Roche Innovation Center Copenhagen A/S | Novel phosphoramidites |
| CA3130431A1 (en) | 2019-02-20 | 2020-08-27 | Roche Innovation Center Copenhagen A/S | Phosphonoacetate gapmer oligonucleotides |
| JP7503072B2 (ja) | 2019-02-26 | 2024-06-19 | ロシュ イノベーション センター コペンハーゲン エーエス | オリゴヌクレオチドの製剤化方法 |
| WO2020176771A1 (en) | 2019-02-27 | 2020-09-03 | Ionis Pharmaceuticals, Inc. | Modulators of malat1 expression |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| US12215382B2 (en) | 2019-03-01 | 2025-02-04 | The General Hospital Corporation | Liver protective MARC variants and uses thereof |
| EP3934695A1 (en) | 2019-03-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Intracellular targeting of molecules |
| EP4219700A1 (en) | 2019-03-07 | 2023-08-02 | The Regents of the University of California | Crispr-cas effector polypeptides and methods of use thereof |
| US20220145274A1 (en) | 2019-03-12 | 2022-05-12 | Crispr Therapeutics Ag | Novel high fidelity rna-programmable endonuclease systems and uses thereof |
| EP3981431A4 (en) | 2019-03-14 | 2023-06-28 | Rena Therapeutics Inc. | Nucleic acid complex for modulating ihh expression |
| CA3133314A1 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Extracellular vesicle conjugates and uses thereof |
| WO2020191177A1 (en) | 2019-03-21 | 2020-09-24 | Sudhir Agrawal | Antisense oligonucleotides for allele specificity |
| BR112021018793A2 (pt) | 2019-03-29 | 2021-11-23 | Mitsubishi Tanabe Pharma Corp | Oligonucleotídeo modificado, composição farmacêutica compreendendo o mesmo composto para modular a expressão de dux4 e uso |
| CA3135180A1 (en) | 2019-03-29 | 2020-10-08 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating ube3a-ats |
| WO2020206115A2 (en) | 2019-04-03 | 2020-10-08 | Bristol-Myers Squibb Company | Angptl2 antisense oligonucleotides and uses thereof |
| EP3947677A1 (en) | 2019-04-04 | 2022-02-09 | F. Hoffmann-La Roche AG | Oligonucleotides for modulating atxn2 expression |
| US11286485B2 (en) | 2019-04-04 | 2022-03-29 | Hoffmann-La Roche Inc. | Oligonucleotides for modulating ATXN2 expression |
| CN113661168A (zh) | 2019-04-16 | 2021-11-16 | 罗氏创新中心哥本哈根有限公司 | 用于制备核苷酸p(v)单体的新方法 |
| WO2020221705A1 (en) | 2019-04-30 | 2020-11-05 | Roche Innovation Center Copenhagen A/S | Novel process for preparing rhenium chelated mag3 oligonucleotides |
| AU2020268798A1 (en) | 2019-05-03 | 2021-11-04 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules with shortened sense strands |
| TWI902693B (zh) | 2019-05-13 | 2025-11-01 | 美商維爾生物科技公司 | 用於治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物及方法 |
| US20220211743A1 (en) | 2019-05-17 | 2022-07-07 | Alnylam Pharmaceuticals, Inc. | Oral delivery of oligonucleotides |
| SI3976791T1 (sl) | 2019-05-28 | 2025-06-30 | Ionis Pharmaceuticals, Inc. | Spojine in postopki za zmanjševanje izražanja fus |
| WO2020243644A1 (en) | 2019-05-31 | 2020-12-03 | Streck, Inc. | Detection of antibiotic resistance genes |
| EP3980540A4 (en) | 2019-06-06 | 2023-11-01 | Arrowhead Pharmaceuticals, Inc. | METHOD FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) |
| CN113950529A (zh) | 2019-06-06 | 2022-01-18 | 豪夫迈·罗氏有限公司 | 靶向atxn3的反义寡核苷酸 |
| WO2020245377A1 (en) | 2019-06-07 | 2020-12-10 | F. Hoffmann-La Roche Ag | Hybridizing all-lna oligonucleotides |
| BR112021025130A2 (pt) | 2019-06-14 | 2022-03-15 | Scripps Research Inst | Reagentes e métodos para replicação, transcrição e tradução em organismos semissintéticos |
| CA3142593C (en) * | 2019-06-19 | 2025-05-20 | Yamasa Corporation | Crosslinked nucleoside intermediate crystal and method for producing same, and method for producing crosslinked nucleoside amidite |
| EP3997225A1 (en) | 2019-07-10 | 2022-05-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of epilepsy |
| JP7708737B2 (ja) | 2019-07-18 | 2025-07-15 | ユニバーシティー オブ ロチェスター | 細胞の細胞型選択的免疫保護 |
| ES3048358T3 (en) | 2019-07-26 | 2025-12-10 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating gfap |
| WO2021020412A1 (ja) | 2019-07-30 | 2021-02-04 | 塩野義製薬株式会社 | Ｍｕｒｆ１を標的とする核酸医薬 |
| EP4007811A2 (en) | 2019-08-01 | 2022-06-08 | Alnylam Pharmaceuticals, Inc. | Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof |
| EP4007812A1 (en) | 2019-08-01 | 2022-06-08 | Alnylam Pharmaceuticals, Inc. | Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof |
| WO2021030522A1 (en) | 2019-08-13 | 2021-02-18 | Alnylam Pharmaceuticals, Inc. | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2021030769A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with nras antisense oligonucleotides |
| KR20220078565A (ko) | 2019-08-14 | 2022-06-10 | 코디악 바이오사이언시즈, 인크. | 분자에 연결된 세포외 소포 및 이의 용도 |
| JP2022544289A (ja) | 2019-08-14 | 2022-10-17 | コディアック バイオサイエンシーズ， インコーポレイテッド | Ｓｔａｔ６を標的とする細胞外小胞－ａｓｏ構築物 |
| BR112022002690A2 (pt) | 2019-08-14 | 2022-08-23 | Codiak Biosciences Inc | Construtos de vesícula-aso extracelular tendo como alvo cebp/beta |
| CN114641570A (zh) | 2019-08-14 | 2022-06-17 | 科迪亚克生物科学公司 | 具有靶向kras的反义寡核苷酸的细胞外囊泡 |
| WO2021030773A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicle-nlrp3 antagonist |
| TW202543680A (zh) | 2019-08-15 | 2025-11-16 | 美商欣爍克斯公司 | 使用il-2接合物之免疫腫瘤學組合療法 |
| KR20220062517A (ko) | 2019-08-15 | 2022-05-17 | 아이오니스 파마수티컬즈, 인코포레이티드 | 결합 변형된 올리고머 화합물 및 이의 용도 |
| PH12022500004A1 (en) | 2019-08-23 | 2023-04-03 | Synthorx Inc | Il-15 conjugates and uses thereof |
| US20220290152A1 (en) | 2019-09-03 | 2022-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
| MX2022002740A (es) | 2019-09-10 | 2022-03-25 | Synthorx Inc | Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes. |
| US12319711B2 (en) | 2019-09-20 | 2025-06-03 | Northwestern University | Spherical nucleic acids with tailored and active protein coronae |
| US12616712B2 (en) | 2019-09-25 | 2026-05-05 | Lonza Sales Ag | Sting agonist comprising exosomes for treating neuroimmunological disorders |
| WO2021067747A1 (en) | 2019-10-04 | 2021-04-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
| JP7757277B2 (ja) | 2019-10-14 | 2025-10-21 | アストラゼネカ・アクチエボラーグ | Ｐｎｐｌａ３発現のモジュレーター |
| WO2021074657A1 (en) | 2019-10-17 | 2021-04-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination treatment for cystic fibrosis |
| IL292286A (en) | 2019-10-18 | 2022-06-01 | Daiichi Sankyo Co Ltd | Production method for bicyclic phosphoramidite |
| WO2021076828A1 (en) | 2019-10-18 | 2021-04-22 | Alnylam Pharmaceuticals, Inc. | Solute carrier family member irna compositions and methods of use thereof |
| BR112022007540A2 (pt) | 2019-10-22 | 2022-07-12 | Alnylam Pharmaceuticals Inc | Composições de irna de componente complementar c3 e métodos de uso das mesmas |
| US12378560B2 (en) | 2019-10-29 | 2025-08-05 | Northwestern University | Sequence multiplicity within spherical nucleic acids |
| CN114728018B (zh) | 2019-11-01 | 2024-07-19 | 阿尔尼拉姆医药品有限公司 | 亨廷顿(HTT)iRNA药剂组合物及其使用方法 |
| WO2021087325A1 (en) | 2019-11-01 | 2021-05-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
| AU2020380275A1 (en) | 2019-11-04 | 2022-04-14 | Synthorx, Inc. | Interleukin 10 conjugates and uses thereof |
| EP4055165A1 (en) | 2019-11-06 | 2022-09-14 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
| AU2020378414A1 (en) | 2019-11-06 | 2022-05-26 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| TW202526019A (zh) | 2019-11-13 | 2025-07-01 | 美商阿尼拉製藥公司 | 用於治療血管收縮素原相關病症之方法及組成物 |
| WO2021099394A1 (en) | 2019-11-19 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antisense oligonucleotides and their use for the treatment of cancer |
| EP4061945A1 (en) | 2019-11-22 | 2022-09-28 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3) rnai agent compositions and methods of use thereof |
| CA3159501A1 (en) | 2019-11-27 | 2021-06-03 | Brian Joseph CAFFERTY | Methods of synthesizing rna molecules |
| EP3831843A1 (en) | 2019-12-08 | 2021-06-09 | Royal College Of Surgeons In Ireland | A hemostatic agent and uses thereof |
| BR112022011214A2 (pt) | 2019-12-11 | 2022-08-23 | Intellia Therapeutics Inc | Rnas-guia modificados para edição de gene |
| TWI897902B (zh) | 2019-12-13 | 2025-09-21 | 美商阿尼拉製藥公司 | 人類染色體9開讀框72 (C9ORF72) iRNA劑組成物及其使用方法 |
| WO2021126734A1 (en) | 2019-12-16 | 2021-06-24 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| CA3164781A1 (en) | 2019-12-18 | 2021-06-24 | F. Hoffmann-La Roche Ag | Methods of sequencing by synthesis using a consecutive labeling scheme |
| WO2021122921A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of cops3 inhibitors for treating hepatitis b virus infection |
| EP4706689A2 (en) | 2019-12-19 | 2026-03-11 | Entrada Therapeutics, Inc. | Compositions for delivery of antisense compounds |
| EP4077671A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of saraf inhibitors for treating hepatitis b virus infection |
| WO2021122735A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of sept9 inhibitors for treating hepatitis b virus infection |
| WO2021122869A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of scamp3 inhibitors for treating hepatitis b virus infection |
| CN114829601A (zh) | 2019-12-19 | 2022-07-29 | 豪夫迈·罗氏有限公司 | Sbds抑制剂用于治疗乙型肝炎病毒感染的用途 |
| TW202136510A (zh) | 2019-12-20 | 2021-10-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制ｓｃｎ９ａ表現之增強型寡核苷酸 |
| CN114828852A (zh) | 2019-12-24 | 2022-07-29 | 豪夫迈·罗氏有限公司 | 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合 |
| AU2020410993A1 (en) | 2019-12-24 | 2022-06-16 | F. Hoffmann-La Roche Ag | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |
| WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
| US20230127437A1 (en) | 2020-01-31 | 2023-04-27 | Sanwa Kagaku Kenkyusho Co., Ltd. | Antisense oligonucleotide of atn1 |
| WO2021158810A1 (en) | 2020-02-05 | 2021-08-12 | Bristol-Myers Squibb Company | Oligonucleotides for splice modulation of camk2d |
| MX2022009763A (es) | 2020-02-10 | 2022-09-09 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para silenciar la expresion del factor de crecimiento endotelial vascular a (vegf-a). |
| WO2021167841A1 (en) | 2020-02-18 | 2021-08-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| CN115176010A (zh) | 2020-02-28 | 2022-10-11 | 豪夫迈·罗氏有限公司 | 用于调节cd73外显子7剪接的寡核苷酸 |
| PH12022552258A1 (en) | 2020-02-28 | 2023-11-20 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating smn2 |
| JPWO2021177418A1 (pt) | 2020-03-04 | 2021-09-10 | ||
| EP4114947A1 (en) | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
| JP7802676B2 (ja) | 2020-03-06 | 2026-01-20 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | トランスサイレチン（ｔｔｒ）の発現を阻害するための組成物および方法 |
| WO2021178736A1 (en) | 2020-03-06 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2021184020A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Methods of treating neuroinflammation |
| WO2021184021A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting pmp22 |
| EP4121534A1 (en) | 2020-03-18 | 2023-01-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
| WO2021195307A1 (en) | 2020-03-26 | 2021-09-30 | Alnylam Pharmaceuticals, Inc. | Coronavirus irna compositions and methods of use thereof |
| EP4127171A2 (en) | 2020-03-30 | 2023-02-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
| CN115843299A (zh) | 2020-03-31 | 2023-03-24 | 詹森生物制药有限公司 | 寡核苷酸的合成和相关化合物 |
| US12534731B2 (en) | 2020-04-01 | 2026-01-27 | Alnylam Pharmaceuticals, Inc. | Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof |
| CA3179411A1 (en) | 2020-04-06 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing myoc expression |
| IL297130A (en) | 2020-04-07 | 2022-12-01 | Alnylam Pharmaceuticals Inc | Compositions and methods for silencing scn9a expression |
| WO2021206917A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2021206922A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
| CA3176196A1 (en) | 2020-04-21 | 2021-10-28 | Flagship Pioneering, Inc. | Bifunctional molecules and methods of using thereof |
| WO2021222065A1 (en) | 2020-04-27 | 2021-11-04 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein e (apoe) irna agent compositions and methods of use thereof |
| EP4142738A1 (en) | 2020-04-30 | 2023-03-08 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
| WO2021231204A1 (en) | 2020-05-11 | 2021-11-18 | Genentech, Inc. | Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same |
| EP4150085A1 (en) | 2020-05-11 | 2023-03-22 | Genentech, Inc. | Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same |
| BR112022022889A2 (pt) | 2020-05-11 | 2023-04-04 | Stoke Therapeutics Inc | Oligômeros antissentido de opa1 para tratamento de condições e doenças |
| CN115551519A (zh) | 2020-05-11 | 2022-12-30 | 基因泰克公司 | 用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法 |
| CN115667513A (zh) | 2020-05-12 | 2023-01-31 | 田边三菱制药株式会社 | 用于调节Ataxin 3表达的化合物、方法和药物组合物 |
| TW202208628A (zh) | 2020-05-13 | 2022-03-01 | 瑞士商赫孚孟拉羅股份公司 | 靶向顆粒蛋白前體之寡核苷酸促效劑 |
| WO2021231680A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2) |
| WO2021231692A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
| WO2021231673A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2) |
| WO2021231679A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
| WO2021231691A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi) |
| EP4150077A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1) |
| WO2021231698A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
| EP4150088A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
| EP4153746A1 (en) | 2020-05-21 | 2023-03-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
| WO2021233551A1 (en) | 2020-05-22 | 2021-11-25 | F.Hoffmann-La Roche Ag | Oligonucleotides for splice modulation of card9 |
| US11408000B2 (en) | 2020-06-03 | 2022-08-09 | Triplet Therapeutics, Inc. | Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity |
| US20230212572A1 (en) | 2020-06-09 | 2023-07-06 | Roche Innovation Center Copenhagen A/S | Guanosine Analogues for Use in Therapeutics Polynucleotides |
| EP4162050A1 (en) | 2020-06-09 | 2023-04-12 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
| US20230203496A1 (en) | 2020-06-09 | 2023-06-29 | Alnylam Pharmaceuticals, Inc. | Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression |
| AU2021292296A1 (en) | 2020-06-18 | 2023-01-19 | Alnylam Pharmaceuticals, Inc. | Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof |
| AR122722A1 (es) | 2020-06-24 | 2022-09-28 | Vir Biotechnology Inc | Anticuerpos que neutralizan el virus de la hepatitis b y sus usos |
| JP2023531509A (ja) | 2020-06-25 | 2023-07-24 | シンソークス， インコーポレイテッド | Ｉｌ－２コンジュゲートおよび抗ｅｇｆｒ抗体を用いる免疫腫瘍学併用療法 |
| AR122731A1 (es) | 2020-06-26 | 2022-10-05 | Hoffmann La Roche | Oligonucleótidos mejorados para modular la expresión de fubp1 |
| WO2022011214A1 (en) | 2020-07-10 | 2022-01-13 | Alnylam Pharmaceuticals, Inc. | Circular sirnas |
| IL299771A (en) | 2020-07-10 | 2023-03-01 | Inst Nat Sante Rech Med | Methods and compounds for the treatment of epilepsy |
| WO2022008935A1 (en) | 2020-07-10 | 2022-01-13 | Horizon Discovery Limited | Method for producing genetically modified cells |
| WO2022018155A1 (en) | 2020-07-23 | 2022-01-27 | F. Hoffmann-La Roche Ag | Lna oligonucleotides for splice modulation of stmn2 |
| WO2022018187A1 (en) | 2020-07-23 | 2022-01-27 | F. Hoffmann-La Roche Ag | Oligonucleotides targeting rna binding protein sites |
| EP4200419A2 (en) | 2020-08-21 | 2023-06-28 | F. Hoffmann-La Roche AG | Use of a1cf inhibitors for treating hepatitis b virus infection |
| TW202227102A (zh) | 2020-09-22 | 2022-07-16 | 瑞典商阿斯特捷利康公司 | 治療脂肪肝病之方法 |
| EP4217489A1 (en) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
| TW202229552A (zh) | 2020-10-05 | 2022-08-01 | 美商艾拉倫製藥股份有限公司 | Ｇ蛋白－偶合受體７５（ＧＰＲ７５）ｉＲＮＡ組成物及其使用方法 |
| WO2022076596A1 (en) | 2020-10-06 | 2022-04-14 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
| JP2023546010A (ja) | 2020-10-09 | 2023-11-01 | シンソークス， インコーポレイテッド | Ｉｌ－２コンジュゲートを用いた免疫腫瘍療法 |
| IL301611A (en) | 2020-10-09 | 2023-05-01 | Synthorx Inc | Immuno oncology combination therapy with il-2 conjugates and pembrolizumab |
| AU2021365822A1 (en) | 2020-10-21 | 2023-06-08 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
| CN116761885A (zh) | 2020-10-23 | 2023-09-15 | 斯克利普斯研究所 | 包含非天然核苷酸的多核苷酸的逆转录 |
| WO2022087329A1 (en) | 2020-10-23 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
| WO2022103999A1 (en) | 2020-11-13 | 2022-05-19 | Alnylam Pharmaceuticals, Inc. | COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| JP7820374B2 (ja) | 2020-11-18 | 2026-02-25 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | アンジオテンシノーゲン発現を調節するための化合物及び方法 |
| KR20230110293A (ko) | 2020-11-18 | 2023-07-21 | 렘바 비브이 | Umlilo 안티센스 전사 억제제 |
| CA3202708A1 (en) | 2020-11-23 | 2022-05-27 | Alpha Anomeric Sas | Nucleic acid duplexes |
| EP4256053A1 (en) | 2020-12-01 | 2023-10-11 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
| AR124229A1 (es) | 2020-12-03 | 2023-03-01 | Hoffmann La Roche | Oligonucleótidos antisentido que actúan sobre atxn3 |
| WO2022117747A2 (en) | 2020-12-03 | 2022-06-09 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting atxn3 |
| JP2023553069A (ja) | 2020-12-08 | 2023-12-20 | エフ． ホフマン－ラ ロシュ アーゲー | ホスホロジチオエートオリゴヌクレオチドの新規合成 |
| WO2022125490A1 (en) | 2020-12-08 | 2022-06-16 | Alnylam Pharmaceuticals, Inc. | Coagulation factor x (f10) irna compositions and methods of use thereof |
| GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
| WO2022124410A1 (ja) | 2020-12-11 | 2022-06-16 | ヤマサ醤油株式会社 | シトシン型架橋型ヌクレオシドアミダイト結晶及びその製造方法 |
| CR20230308A (es) | 2020-12-11 | 2023-09-08 | Civi Biopharma Inc | Entrega oral de conjugados antisentido que tienen por blanco a pcsk9 |
| US12018261B2 (en) | 2020-12-18 | 2024-06-25 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating factor XII |
| JP2023553710A (ja) | 2020-12-18 | 2023-12-25 | エフ． ホフマン－ラ ロシュ アーゲー | プログラニュリンを標的とするためのアンチセンスオリゴヌクレオチド |
| CN116670282A (zh) | 2020-12-22 | 2023-08-29 | 豪夫迈·罗氏有限公司 | 靶向xbp1的寡核苷酸 |
| WO2022136477A1 (en) | 2020-12-22 | 2022-06-30 | F. Hoffmann-La Roche Ag | Methods for performing multiplexed real-time pcr with the use of large stokes shift fluorescent dyes |
| EP4271695A2 (en) | 2020-12-31 | 2023-11-08 | Alnylam Pharmaceuticals, Inc. | 2'-modified nucleoside based oligonucleotide prodrugs |
| WO2022147214A2 (en) | 2020-12-31 | 2022-07-07 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
| EP4274896A1 (en) | 2021-01-05 | 2023-11-15 | Alnylam Pharmaceuticals, Inc. | Complement component 9 (c9) irna compositions and methods of use thereof |
| WO2022155500A1 (en) | 2021-01-14 | 2022-07-21 | Senti Biosciences, Inc. | Secretable payload regulation |
| TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| TW202245843A (zh) | 2021-02-12 | 2022-12-01 | 美商欣爍克斯公司 | Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法 |
| EP4291654A2 (en) | 2021-02-12 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
| TW202302148A (zh) | 2021-02-12 | 2023-01-16 | 美商欣爍克斯公司 | 使用ｉｌ－２接合物和抗ｐｄ－１抗體或其抗原結合片段的肺癌組合療法 |
| EP4294456A1 (en) | 2021-02-17 | 2023-12-27 | Lonza Sales AG | Extracellular vesicle linked to a biologically active molecule via an optimized linker and an anchoring moiety |
| US20240167036A1 (en) | 2021-02-17 | 2024-05-23 | Lonza Sales Ag | Extracellular vesicle-nlrp3 antagonist |
| WO2022182864A1 (en) | 2021-02-25 | 2022-09-01 | Alnylam Pharmaceuticals, Inc. | Prion protein (prnp) irna compositions and methods and methods of use thereof |
| JP2024515423A (ja) | 2021-02-26 | 2024-04-10 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ケトヘキソキナーゼ（ＫＨＫ）ｉＲＮＡ組成物およびその使用方法 |
| AU2022231003A1 (en) | 2021-03-04 | 2023-09-14 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| EP4305169A1 (en) | 2021-03-12 | 2024-01-17 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
| US20220288181A1 (en) | 2021-03-12 | 2022-09-15 | Northwestern University | Antiviral vaccines using spherical nucleic acids |
| US20220290221A1 (en) | 2021-03-15 | 2022-09-15 | Roche Molecular Systems, Inc. | Compositions and methods for detecting severe acute respiratory syndrome coronavirus 2 (sars-cov-2) variants having spike protein mutations |
| IL307239A (en) | 2021-03-29 | 2023-11-01 | Alnylam Pharmaceuticals Inc | Preparations containing Huntingtin IRNA factor (HTT) and methods of using them |
| US20250243244A1 (en) | 2021-03-31 | 2025-07-31 | Entrada Therapeutics, Inc. | Cyclic cell penetrating peptides |
| KR20230166101A (ko) | 2021-04-01 | 2023-12-06 | 론자 세일즈 아게 | 세포외 소포 조성물 |
| WO2022212153A1 (en) | 2021-04-01 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof |
| BR112023022284A2 (pt) | 2021-04-26 | 2023-12-26 | Alnylam Pharmaceuticals Inc | Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma |
| EP4330396A1 (en) | 2021-04-29 | 2024-03-06 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
| EP4337261A2 (en) | 2021-05-10 | 2024-03-20 | Entrada Therapeutics, Inc. | Compositions and methods for modulating mrna splicing |
| AU2022271873A1 (en) | 2021-05-10 | 2024-01-04 | Entrada Therapeutics, Inc. | Compositions and methods for intracellular therapeutics |
| WO2022240721A1 (en) | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity |
| EP4341401A1 (en) | 2021-05-18 | 2024-03-27 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
| EP4341405A1 (en) | 2021-05-20 | 2024-03-27 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
| WO2022255273A1 (ja) | 2021-05-31 | 2022-12-08 | レナセラピューティクス株式会社 | リガンド結合核酸複合体 |
| WO2022256283A2 (en) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
| JP2024522996A (ja) | 2021-06-02 | 2024-06-25 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法 |
| TW202313679A (zh) | 2021-06-03 | 2023-04-01 | 美商欣爍克斯公司 | 包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法 |
| BR112023025224A2 (pt) | 2021-06-04 | 2024-02-27 | Alnylam Pharmaceuticals Inc | Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos |
| WO2022256597A1 (en) | 2021-06-04 | 2022-12-08 | Translate Bio, Inc. | Assay for quantitative assessment of mrna capping efficiency |
| EP4351541A2 (en) | 2021-06-08 | 2024-04-17 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders |
| JP2024524874A (ja) | 2021-06-08 | 2024-07-09 | エフ． ホフマン－ラ ロシュ アーゲー | オリゴヌクレオチドプログラニュリンアゴニスト |
| EP4352225A1 (en) | 2021-06-10 | 2024-04-17 | Intellia Therapeutics, Inc. | Modified guide rnas comprising an internal linker for gene editing |
| IL308896A (en) | 2021-06-11 | 2024-01-01 | Bayer Ag | Type v rna programmable endonuclease systems |
| EP4101928A1 (en) | 2021-06-11 | 2022-12-14 | Bayer AG | Type v rna programmable endonuclease systems |
| AU2022297448A1 (en) | 2021-06-22 | 2024-01-04 | AcuraStem Incorporated | Pikfyve antisense oligonucleotides |
| GEAP202416440A (en) | 2021-06-23 | 2024-04-25 | Entrada Therapeutics Inc | Antisense compounds and methods for targeting cug repeats |
| US20250034564A1 (en) | 2021-06-29 | 2025-01-30 | Korro Bio, Inc. | Methods and Compositions for ADAR-Mediated Editing |
| US20230194709A9 (en) | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
| MX2023015489A (es) | 2021-06-30 | 2024-01-19 | Alnylam Pharmaceuticals Inc | Metodos y composiciones para tratar un trastorno asociado al angiotensinogeno (agt). |
| WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
| WO2023003805A1 (en) | 2021-07-19 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
| KR20240036041A (ko) | 2021-07-21 | 2024-03-19 | 알닐람 파마슈티칼스 인코포레이티드 | 대사 장애-연관 표적 유전자 iRNA 조성물 및 이의 사용 방법 |
| MX2024000996A (es) | 2021-07-21 | 2024-06-28 | AcuraStem Incorporated | Oligonucleótido antisentido unc13a. |
| JP2024528701A (ja) | 2021-07-23 | 2024-07-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ベータカテニン（ＣＴＮＮＢ１）ｉＲＮＡ組成物およびその使用方法 |
| JP2024529437A (ja) | 2021-07-29 | 2024-08-06 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ３－ヒドロキシ－３－メチルグリタル－ＣＯＡレダクターゼ（ＨＭＧＣＲ）ｉＲＮＡ組成物およびその使用方法 |
| TW202328445A (zh) | 2021-08-03 | 2023-07-16 | 美商艾拉倫製藥股份有限公司 | 甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物及其使用方法 |
| PE20241132A1 (es) | 2021-08-04 | 2024-05-24 | Alnylam Pharmaceuticals Inc | Composiciones de arni y metodos para silenciar el angiotensinogeno (agt) |
| IL310407A (en) | 2021-08-13 | 2024-03-01 | Alnylam Pharmaceuticals Inc | Factor XII (F12) IRNA compositions and methods of using them |
| WO2023021046A1 (en) | 2021-08-16 | 2023-02-23 | Vib Vzw | Oligonucleotides for modulating synaptogyrin-3 expression |
| MX2024002440A (es) | 2021-08-31 | 2024-03-08 | Alnylam Pharmaceuticals Inc | Composiciones de acido ribonucleico de interferencia (arni) del efector b similar al factor de fragmentacion de adn subunidad alfa (dffa) que induce la muerte celular (cideb) y metodos de uso de estas. |
| EP4395829A1 (en) | 2021-09-01 | 2024-07-10 | Entrada Therapeutics, Inc. | Compounds and methods for skipping exon 44 in duchenne muscular dystrophy |
| US11833221B2 (en) | 2021-09-01 | 2023-12-05 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds for reducing DMPK expression |
| EP4144841A1 (en) | 2021-09-07 | 2023-03-08 | Bayer AG | Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof |
| KR20240058112A (ko) | 2021-09-17 | 2024-05-03 | 주식회사 씨젠 | 합성 비자연 염기를 포함하는 태그 올리고뉴클레오타이드를 이용한 타겟 핵산 서열의 검출 |
| JP2024535850A (ja) | 2021-09-17 | 2024-10-02 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法 |
| EP4405478A1 (en) | 2021-09-20 | 2024-07-31 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
| MX2024003519A (es) | 2021-09-24 | 2024-04-01 | Alnylam Pharmaceuticals Inc | Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso. |
| EP4408999A1 (en) | 2021-09-29 | 2024-08-07 | F. Hoffmann-La Roche AG | Rna editing |
| CA3233755A1 (en) | 2021-10-01 | 2023-04-06 | Adarx Pharmaceuticals, Inc. | Prekallikrein-modulating compositions and methods of use thereof |
| IL311864A (en) | 2021-10-15 | 2024-06-01 | Alnylam Pharmaceuticals Inc | IRNA compositions for extrahepatic administration and methods of using them |
| AU2022370009A1 (en) | 2021-10-22 | 2024-05-16 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
| CA3234636A1 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
| TW202334418A (zh) | 2021-10-29 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | 杭丁頓（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法 |
| WO2023078883A1 (en) | 2021-11-03 | 2023-05-11 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating apolipoprotein e4 expression |
| US20250066790A1 (en) | 2021-11-10 | 2025-02-27 | University Of Rochester | Antisense oligonucleotides for modifying protein expression |
| CA3237769A1 (en) | 2021-11-10 | 2023-05-19 | University Of Rochester | Gata4-targeted therapeutics for treatment of cardiac hypertrophy |
| IL312635A (en) | 2021-11-11 | 2024-07-01 | Hoffmann La Roche | Pharmaceutical combinations for treatment of hbv |
| JP2025501682A (ja) | 2021-12-03 | 2025-01-23 | クラリス コーポレーション | 改変された骨格化学を有するギャップマーアンチセンスオリゴヌクレオチド |
| CN118434858A (zh) | 2021-12-07 | 2024-08-02 | 豪夫迈·罗氏有限公司 | 靶向actl6b的反义寡核苷酸 |
| GB202117758D0 (en) | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
| EP4446435A4 (en) | 2021-12-10 | 2025-04-02 | Nitto Boseki Co., Ltd. | Method for detecting mutations in the target base sequence of nucleic acid, method for selectively inhibiting nucleic acid amplification, and kit for implementing the same |
| EP4446434A4 (en) | 2021-12-10 | 2025-04-02 | Nitto Boseki Co., Ltd. | Methods for detecting mutations in the target base sequence of nucleic acids, methods for selectively inhibiting the amplification of nucleic acids, and kits for carrying them out |
| WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
| JP2024546887A (ja) | 2021-12-17 | 2024-12-26 | ジェネンテック， インコーポレイテッド | オリゴヌクレオチドｇｂａアゴニスト |
| WO2023122573A1 (en) | 2021-12-20 | 2023-06-29 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
| EP4453206A1 (en) | 2021-12-20 | 2024-10-30 | F. Hoffmann-La Roche AG | Threose nucleic acid antisense oligonucleotides and methods thereof |
| US20250066436A1 (en) | 2021-12-22 | 2025-02-27 | Royal College Of Surgeons In Ireland | A conjugate for use in localising a molecule to the vascular endothelium |
| KR20240126870A (ko) | 2021-12-22 | 2024-08-21 | 캠프4 테라퓨틱스 코포레이션 | 조절 rna들을 표적으로 하는 안티센스 올리고뉴클레오티드를 사용한 유전자 전사의 조절 |
| CA3243301A1 (en) | 2021-12-23 | 2023-06-29 | Bayer Aktiengesellschaft | NEW SMALL PROGRAMMABLE TYPE V RNA ENDONUCLEASE SYSTEMS |
| WO2023122750A1 (en) | 2021-12-23 | 2023-06-29 | Synthorx, Inc. | Cancer combination therapy with il-2 conjugates and cetuximab |
| CN119095963A (zh) | 2022-01-10 | 2024-12-06 | 杭州浩博医药有限公司 | 乙型肝炎病毒(hbv)表达的调节 |
| WO2023141507A1 (en) | 2022-01-20 | 2023-07-27 | Genentech, Inc. | Antisense oligonucleotides for modulating tmem106b expression |
| EP4469575A2 (en) | 2022-01-24 | 2024-12-04 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
| WO2023152369A1 (en) | 2022-02-14 | 2023-08-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis |
| US20240167040A1 (en) | 2022-02-21 | 2024-05-23 | Hoffmann-La Roche Inc. | Antisense oligonucleotide |
| EP4514968A1 (en) | 2022-04-28 | 2025-03-05 | AcuraStem Incorporated | Syf2 antisense oligonucleotides |
| CN119173632A (zh) | 2022-05-10 | 2024-12-20 | 豪夫迈·罗氏有限公司 | 靶向cfp-elk1基因间区域的反义寡核苷酸 |
| JP2025516680A (ja) | 2022-05-13 | 2025-05-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 一本鎖ループオリゴヌクレオチド |
| KR20250011958A (ko) | 2022-05-18 | 2025-01-22 | 에프. 호프만-라 로슈 아게 | Rna 결합 단백질 부위를 표적으로 하는 개선된 올리고뉴클레오티드 |
| AU2023283551A1 (en) | 2022-06-10 | 2024-12-19 | Camp4 Therapeutics Corporation | Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas |
| WO2023237587A1 (en) | 2022-06-10 | 2023-12-14 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
| CN119365600A (zh) | 2022-06-17 | 2025-01-24 | 豪夫迈·罗氏有限公司 | 靶向颗粒蛋白前体的反义寡核苷酸 |
| EP4547683A2 (en) | 2022-06-30 | 2025-05-07 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
| WO2024010841A2 (en) | 2022-07-06 | 2024-01-11 | Molecular Axiom, Llc | Compositions and methods for treating pancreatic cancer |
| WO2024017990A1 (en) | 2022-07-21 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating chronic pain disorders |
| WO2024040041A1 (en) | 2022-08-15 | 2024-02-22 | Dicerna Pharmaceuticals, Inc. | Regulation of activity of rnai molecules |
| JP2025527531A (ja) | 2022-08-18 | 2025-08-22 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ユニバーサル非標的ｓｉｒｎａ組成物およびその使用方法 |
| JP2025530741A (ja) | 2022-08-29 | 2025-09-17 | ユニヴァーシティ オヴ ロチェスター | アンチセンスオリゴヌクレオチドベースの抗線維化治療剤 |
| EP4332221A1 (en) | 2022-08-29 | 2024-03-06 | Roche Innovation Center Copenhagen A/S | Threose nucleic acid antisense oligonucleotides and methods thereof |
| IL318655A (en) | 2022-09-06 | 2025-03-01 | Hoffmann La Roche | Double RNA molecule for ocular administration |
| TW202424193A (zh) | 2022-09-15 | 2024-06-16 | 美商艾拉倫製藥股份有限公司 | 第１３型１７β－羥基類固醇去氫酶（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物及其使用方法 |
| WO2024073042A1 (en) | 2022-09-30 | 2024-04-04 | Entrada Therapeutics, Inc. | Ocular delivery of therapeutic agents |
| JP2025532985A (ja) | 2022-09-30 | 2025-10-03 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 修飾二本鎖ｒｎａ剤 |
| WO2024098061A2 (en) | 2022-11-04 | 2024-05-10 | Genkardia Inc. | Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure |
| KR20250108634A (ko) | 2022-11-10 | 2025-07-15 | 룩스나 바이오테크 가부시키가이샤 | 가교부에 구아니디노 구조를 갖는 수식 뉴클레오시드 및 그것을 이용한 올리고뉴클레오티드의 제조 방법 |
| JP2025539043A (ja) | 2022-11-14 | 2025-12-03 | バイオンテック・エスイー | Ｒｎａキャッピング効率アッセイ |
| JP2025540101A (ja) | 2022-12-01 | 2025-12-11 | キャンプ４ セラピューティクス コーポレイション | 調節ｒｎａを標的とするアンチセンスオリゴヌクレオチドを用いたｓｙｎｇａｐ１遺伝子転写の調節 |
| WO2024126654A1 (en) | 2022-12-14 | 2024-06-20 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting actl6b |
| WO2024136899A1 (en) | 2022-12-21 | 2024-06-27 | Synthorx, Inc. | Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies |
| CN120752339A (zh) | 2023-01-06 | 2025-10-03 | 国家医疗保健研究所 | 静脉内施用用于治疗疼痛的反义寡核苷酸 |
| WO2024155986A2 (en) | 2023-01-20 | 2024-07-25 | AcuraStem Incorporated | Unc13a antisense oligonucleotides |
| WO2024160756A1 (en) | 2023-01-30 | 2024-08-08 | Vib Vzw | Suppressors of tauopathies |
| AU2024215901A1 (en) | 2023-01-31 | 2025-07-24 | AcuraStem Incorporated | Syf2 antisense oligonucleotides |
| AU2024213258A1 (en) | 2023-01-31 | 2025-06-26 | Seqirus Inc. | Capping assay |
| IL322380A (en) | 2023-02-06 | 2025-09-01 | AcuraStem Incorporated | PIKFYVE Antisense Oligonucleotides |
| AU2024217843A1 (en) | 2023-02-09 | 2025-07-31 | Alnylam Pharmaceuticals, Inc. | Reversir molecules and methods of use thereof |
| WO2024175586A2 (en) | 2023-02-21 | 2024-08-29 | Vib Vzw | Inhibitors of synaptogyrin-3 expression |
| JP2026507051A (ja) | 2023-02-21 | 2026-02-27 | ブイアイビー ブイゼットダブリュ | シナプトギリン－３発現を調節するためのオリゴヌクレオチド |
| WO2024175707A1 (en) | 2023-02-22 | 2024-08-29 | Helmholtz-Zentrum für Infektionsforschung GmbH | A synthetic oligonucleotide for treating nidovirales infections |
| TW202444349A (zh) | 2023-03-20 | 2024-11-16 | 美商欣爍克斯公司 | 使用ｉｌ－２綴合物之癌症療法 |
| UY40699A (es) | 2023-04-05 | 2024-08-30 | Ionis Pharmaceuticals Inc | Compuestos y métodos para reducir la expresión de pln |
| CN121816199A (zh) | 2023-04-12 | 2026-04-07 | 阿尔尼拉姆制药公司 | 双链rna药剂的肝外递送 |
| CN121285630A (zh) | 2023-04-20 | 2026-01-06 | 阿达尔克斯制药有限公司 | Mapt调节组合物及其使用方法 |
| WO2024220746A2 (en) | 2023-04-21 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting fatty acid synthase and related methods |
| CN121079412A (zh) | 2023-04-28 | 2025-12-05 | 比姆医疗股份有限公司 | 经修饰的指导rna |
| WO2024227765A2 (en) | 2023-05-04 | 2024-11-07 | F. Hoffmann-La Roche Ag | Oligonucleotides capable of upregulating glucocerebrosidase expression |
| GB202306715D0 (en) | 2023-05-05 | 2023-06-21 | Univ Dublin | Microfluidic nucleic acid extraction |
| WO2024231285A1 (en) | 2023-05-05 | 2024-11-14 | BioNTech SE | Method of analysing contaminants in rna products by ion-pair chromatography |
| WO2024233864A2 (en) | 2023-05-10 | 2024-11-14 | Dicerna Pharmaceuticals, Inc. | Galnac-conjugated rnai oligonucleotides |
| KR20260021635A (ko) | 2023-05-12 | 2026-02-13 | 아다르엑스 파마슈티컬스, 인크. | Nmda 리간드 접합 화합물 및 이의 용도 |
| CN121729491A (zh) | 2023-05-12 | 2026-03-24 | 阿尔尼拉姆制药公司 | 单链环寡核苷酸 |
| WO2024243062A1 (en) | 2023-05-19 | 2024-11-28 | Streck Llc | Detection of antibiotic resistance genes |
| IL324720A (en) | 2023-05-26 | 2026-01-01 | Adarx Pharmaceuticals Inc | SOD1 modulators and methods of using them |
| IL325280A (en) | 2023-06-14 | 2026-02-01 | Sanofi Pasteur Inc | Methods for simultaneous detection or quantification of messenger coverage and residual modification |
| KR20260026070A (ko) | 2023-06-16 | 2026-02-25 | 에프. 호프만-라 로슈 아게 | Jak1 발현 조절을 위한 이중 가닥 올리고뉴클레오티드 |
| CN121712891A (zh) | 2023-06-20 | 2026-03-20 | 阿达尔克斯制药有限公司 | Lrrk2调节组合物及其使用方法 |
| JPWO2025005265A1 (pt) * | 2023-06-30 | 2025-01-02 | ||
| WO2025008406A1 (en) | 2023-07-04 | 2025-01-09 | Institut National de la Santé et de la Recherche Médicale | Antisense oligonucleotides and their use for the treatment of cancer |
| AU2024287308A1 (en) | 2023-07-13 | 2025-12-18 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
| AU2024297923A1 (en) | 2023-07-25 | 2026-01-22 | Flagship Pioneering Innovations Vii, Llc | Cas endonucleases and related methods |
| US20250092426A1 (en) | 2023-07-25 | 2025-03-20 | Flagship Pioneering Innovations Vii, Llc | Cas endonucleases and related methods |
| IL326321A (en) | 2023-08-04 | 2026-04-01 | Alnylam Pharmaceuticals Inc | Methods and compositions for treating CTNNB1-related disorders |
| WO2025038901A1 (en) | 2023-08-17 | 2025-02-20 | Entrada Therapeutics, Inc. | Cyclic peptides for delivering therapeutics |
| KR20260056195A (ko) | 2023-08-17 | 2026-04-24 | 엔트라다 테라퓨틱스, 인크. | 올리고뉴클레오타이드의 세포내 표적화 |
| TW202516006A (zh) | 2023-08-30 | 2025-04-16 | 日商Ｓｔｒａｔｏｉｍｍｕｎｅ股份有限公司 | ＲａｓＧＲＰ４的反義寡核苷酸 |
| WO2025054459A1 (en) | 2023-09-08 | 2025-03-13 | Dicerna Pharmaceuticals, Inc. | Rnai oligonucleotide conjugates |
| WO2025061842A1 (en) | 2023-09-19 | 2025-03-27 | Charité - Universitätsmedizin Berlin | Gene editing tgm1 mutations for treating autosomal recessive congenital ichthyosis (arci) |
| IL326940A (en) | 2023-09-21 | 2026-05-01 | Alnylam Pharmaceuticals Inc | Activin A Receptor Type 1C (ACVR1C) IRNA Compositions and Methods of Using Them |
| WO2025072331A1 (en) | 2023-09-26 | 2025-04-03 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| IL327379A (en) | 2023-09-26 | 2026-05-01 | Entrada Therapeutics Inc | Compounds and methods for skipping exon 50 in Duchenne muscular dystrophy |
| WO2025076031A2 (en) | 2023-10-03 | 2025-04-10 | Alnylam Pharmaceuticals, Inc. | Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof |
| WO2025074331A1 (en) | 2023-10-04 | 2025-04-10 | Lemba Bv | Compounds for inhibiting amanzi |
| US20250115914A1 (en) | 2023-10-04 | 2025-04-10 | Lemba Bv | Compounds for inhibition of il-1beta expression |
| WO2025080939A1 (en) | 2023-10-13 | 2025-04-17 | Ultragenyx Pharmaceutical, Inc. | Compositions and methods for treating conditions associated with cartilage oligomeric matrix protein (comp) mutations |
| WO2025096809A1 (en) | 2023-10-31 | 2025-05-08 | Korro Bio, Inc. | Oligonucleotides comprising phosphoramidate internucleotide linkages |
| TW202540417A (zh) | 2023-11-10 | 2025-10-16 | 美商英特利亞醫療公司 | 用於基因體編輯之組合物、方法及系統 |
| WO2025117877A2 (en) | 2023-12-01 | 2025-06-05 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| WO2025128799A1 (en) | 2023-12-12 | 2025-06-19 | Korro Bio, Inc. | Double-stranded rna-editing oligonucleotides and uses thereof |
| WO2025128853A2 (en) | 2023-12-13 | 2025-06-19 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating conditions associated with ube3a overexpression |
| TW202535425A (zh) | 2023-12-21 | 2025-09-16 | 瑞士商赫孚孟拉羅股份公司 | 反義寡核苷酸 |
| GB202400711D0 (en) | 2024-01-18 | 2024-03-06 | Univ Dublin | A method for determining the risk of, or prognosis of, lung, pancreatic, and ovarian cancer, and cutaneous and uveal melanoma. |
| WO2025158385A1 (en) | 2024-01-25 | 2025-07-31 | Genzyme Corporation | Pegylated il-2 for suppressing adaptive immune response to gene therapy |
| WO2025178854A2 (en) | 2024-02-19 | 2025-08-28 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting cideb and related methods |
| WO2025199231A2 (en) | 2024-03-20 | 2025-09-25 | Vertex Pharmaceuticals Incorporated | Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof |
| WO2025207517A2 (en) | 2024-03-25 | 2025-10-02 | Synthorx, Inc. | Synthetic trna synthetases and cells comprising synthetic molecules for production of polypeptides |
| GB202404290D0 (en) | 2024-03-26 | 2024-05-08 | Senisca Ltd | Novel oligoncleotides |
| WO2025217275A2 (en) | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Immune cell targeted compositions and related methods |
| WO2025237990A1 (en) | 2024-05-14 | 2025-11-20 | Institut National de la Santé et de la Recherche Médicale | Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis |
| WO2025252669A1 (en) | 2024-06-03 | 2025-12-11 | Evotec International Gmbh | Modified oligonucleotides for reducing atxn3 expression |
| WO2025255388A1 (en) | 2024-06-05 | 2025-12-11 | Camp4 Therapeutics Corporation | Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas |
| WO2025259747A2 (en) | 2024-06-12 | 2025-12-18 | Alnylam Pharmaceuticals, Inc. | Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof |
| WO2025259743A1 (en) | 2024-06-12 | 2025-12-18 | Alnylam Pharmaceuticals, Inc. | Dual conjugate compounds for extrahepatic delivery |
| WO2026006436A1 (en) | 2024-06-25 | 2026-01-02 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43) |
| WO2026006390A2 (en) | 2024-06-26 | 2026-01-02 | Intellia Therapeutics, Inc. | Modified guide rnas for genome editing |
| WO2026041784A1 (en) | 2024-08-23 | 2026-02-26 | Vib Vzw | Oligonucleotides for modulating synaptogyrin-3 expression |
| WO2026050243A1 (en) | 2024-08-26 | 2026-03-05 | Korro Bio, Inc. | Galnac conjugated oligonucleotides for rna editing |
| WO2026055461A1 (en) | 2024-09-05 | 2026-03-12 | Aperture Therapeutics, Inc. | Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof |
| WO2026052826A1 (en) | 2024-09-09 | 2026-03-12 | Roche Diagnostics Gmbh | Methods for producing fluorescent dyes |
| EP4711455A1 (en) | 2024-09-11 | 2026-03-18 | Aarhus Universitet | Small artificial rna (smartrna) oligonucleotide for modulating protein expression |
| WO2026057749A1 (en) | 2024-09-11 | 2026-03-19 | Sixfold Bioscience Ltd. | Method and product |
| WO2026061986A1 (en) | 2024-09-17 | 2026-03-26 | Institut National de la Santé et de la Recherche Médicale | Antisense oligonucleotide (aso)-mediated down-regulation of cd33 to safely enrich for genetically modified cells |
| WO2026062247A1 (en) | 2024-09-20 | 2026-03-26 | Astrazeneca Ab | Liquid-phase oligonucleotide synthesis using 2-(2-nitrophenyl)propyloxycarbonyl (nppoc) as a protecting group |
| WO2026080323A1 (en) | 2024-10-09 | 2026-04-16 | Quralis Corporation | Treatment of neurological diseases using modulators of unc13a gene transcripts |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859221A (en) * | 1990-01-11 | 1999-01-12 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
| JPH0953409A (ja) † | 1995-08-15 | 1997-02-25 | Mitsubishi Heavy Ind Ltd | ガスタービン用セラミック静翼 |
| GB9612600D0 (en) * | 1996-06-13 | 1996-08-21 | Ciba Geigy Ag | Chemical compounds |
| JP3756313B2 (ja) † | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| CA2303299C (en) † | 1997-09-12 | 2016-02-23 | Exiqon A/S | Oligonucleotide analogues |
-
1998
- 1998-03-06 JP JP05511498A patent/JP3756313B2/ja not_active Expired - Lifetime
- 1998-03-09 WO PCT/JP1998/000945 patent/WO1998039352A1/ja not_active Ceased
- 1998-03-09 US US09/380,638 patent/US6268490B1/en not_active Ceased
- 1998-03-09 DK DK98905804.5T patent/DK1013661T4/en active
- 1998-03-09 AT AT98905804T patent/ATE541576T2/de active
- 1998-03-09 DE DE98905804T patent/DE98905804T1/de active Pending
- 1998-03-09 DK DK10011863.7T patent/DK2361921T3/en active
- 1998-03-09 PT PT101729713T patent/PT2295441E/pt unknown
- 1998-03-09 EP EP98905804.5A patent/EP1013661B2/en not_active Expired - Lifetime
- 1998-03-09 EP EP10172971.3A patent/EP2295441B1/en not_active Expired - Lifetime
- 1998-03-09 CA CA002283509A patent/CA2283509C/en not_active Expired - Lifetime
- 1998-03-09 ES ES98905804T patent/ES2380354T5/es not_active Expired - Lifetime
- 1998-03-09 DK DK10172971.3T patent/DK2295441T3/da active
- 1998-03-09 AU AU61209/98A patent/AU720472B2/en not_active Expired
- 1998-03-09 EP EP10011863.7A patent/EP2361921B1/en not_active Expired - Lifetime
- 1998-03-09 PT PT98905804T patent/PT1013661E/pt unknown
- 1998-03-09 ES ES10172971.3T patent/ES2485716T3/es not_active Expired - Lifetime
- 1998-03-09 ES ES10011863.7T patent/ES2545211T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE98905804T1 (de) | 2010-08-26 |
| ES2545211T3 (es) | 2015-09-09 |
| EP1013661B2 (en) | 2018-10-24 |
| AU720472B2 (en) | 2000-06-01 |
| DK2361921T3 (en) | 2015-09-14 |
| HK1154590A1 (en) | 2012-04-27 |
| JP3756313B2 (ja) | 2006-03-15 |
| EP2295441A3 (en) | 2011-10-26 |
| US6268490B1 (en) | 2001-07-31 |
| EP2361921A2 (en) | 2011-08-31 |
| PT2295441E (pt) | 2014-07-25 |
| EP1013661A1 (en) | 2000-06-28 |
| ATE541576T2 (de) | 2012-02-15 |
| EP1013661B1 (en) | 2012-01-18 |
| EP2295441A2 (en) | 2011-03-16 |
| ES2380354T3 (es) | 2012-05-10 |
| DK2295441T3 (da) | 2014-07-21 |
| EP2361921B1 (en) | 2015-06-03 |
| ES2380354T5 (es) | 2019-04-02 |
| EP1013661A4 (en) | 2000-11-22 |
| AU6120998A (en) | 1998-09-22 |
| EP2361921A3 (en) | 2012-06-27 |
| DK1013661T3 (da) | 2012-03-19 |
| ES2485716T3 (es) | 2014-08-14 |
| WO1998039352A1 (en) | 1998-09-11 |
| EP2295441B1 (en) | 2014-05-07 |
| CA2283509A1 (en) | 1998-09-11 |
| JPH10304889A (ja) | 1998-11-17 |
| DK1013661T4 (en) | 2019-01-21 |
| CA2283509C (en) | 2005-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2295441B1 (en) | Bicyclonucleoside Oligonucleotide Analogue | |
| US6770748B2 (en) | Bicyclonucleoside and oligonucleotide analogue | |
| USRE44779E1 (en) | Bicyclonucleoside and oligonucleotide analogues | |
| US6043060A (en) | Nucleotide analogues | |
| RU2145964C1 (ru) | Нуклеозиды с модифицированными сахарами и олигонуклеотиды | |
| US7053199B2 (en) | Nucleoside analogs and oligonucleotide derivatives containing these analogs | |
| JP3781879B2 (ja) | 新規ヌクレオチド類縁体 | |
| IL135000A (en) | Locked nucleoside analogues contain nucleic acid compounds that contain them | |
| US6329346B1 (en) | Oligo-2′-deoxynucleotides and their use as pharmaceutical agents with antiviral activity | |
| US5807837A (en) | Composition and method for the treatment or prophylaxis of viral infections using modified oligodeoxyribonucleotides | |
| WO1990012022A1 (en) | Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections | |
| US20040033967A1 (en) | Alkylated hexitol nucleoside analogues and oligomers thereof | |
| AU742476B2 (en) | Novel bicyclonucleoside and oligonucleotide analogue | |
| AU659078B2 (en) | Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections | |
| WO1995031470A2 (en) | Antisense inhibitors of gene expression | |
| HK1154590B (en) | Bicyclonucleoside oligonucleotide analogue | |
| HK1160473A (en) | Novel bicyclonucleoside and oligonnucleotide analogue | |
| JP2683296B2 (ja) | オリゴ−２’−デオキシヌクレオチドおよび抗ウイルス活性を有する医薬物質としてのそれらの使用 | |
| JPH08119945A (ja) | 新規ヌクレオチド類縁体 | |
| JPWO2002018388A1 (ja) | 新規なヌクレオシド類縁体及びその類縁体を含むオリゴヌクレオチド誘導体 |